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Abstract 
Aberrant  methylation  of  CpG  islands  (CGIs)  is  associated  with  transcriptional  silencing  of 
key  tumour  suppressor  genes  in  cancer  and  is  a  frequent  epigenetic  event  in  epithelial 
ovarian  cancer  (EOC).  It  has  been  shown  to  be  involved  in  many  aspects  of  tumour 
progression  including  chemoresistance.  Methylation  of  CGIs  can  be  detected  in  tumour 
DNA  released  into  plasma,  which  means  it  has  potential  clinical  use  both  as  an  early 
diagnostic  and  prognostic/predictive  marker  in  EOC.  The  methylation  status  of  24  CGIs  in 
a  retrospective  group  of  142  EOCs  and  16  non-turnour  adjacent  tissues  were  analysed 
using  methylation-specific  PCR  (MSP)  and  Combined  Bisulphite  Restriction  Analysis 
(COBRA)  methods.  CGI  methylation  of  at  least  one  of  these  loci  was  a  frequent  event  in 
both  early  (78%)  and  late  stage  (60%)  disease.  A  group  of  loci  were  identified  as  being 
methylated  in  64%  of  early  stage  turnours;  (CGIs  linked  to  the  OPCAM,  RASSFIA  and 
HICI  genes).  The  HICI  CGI  was  frequently  methylated  in  matched  non-tumour  adjacent 
tissues,  but  not  in  normal  ovarian  surface  epithelium,  potentially  representing  an  early 
epigenetic  event  in  the  carcinogenic  process  present  even  before  apparent  morphological 
change. 
Differential  methylation  hybridisation  (DMH)  of  a  12K  CGI  microarray  using  ovarian  cell 
lines  identified  methylation  of  a  CGI  located  at  the  LAMIA  gene.  This  CGI  was  shown  by 
MSP  to  be  a  potential  early  epigenetic  marker  methylated  in  75%  of  early  stage  ovarian 
tumours.  87.5%  of  the  early  stage  turnours  examined  were  methylated  in  at  least  one  of 
four  loci  (LAMA,  OPCML,  RASSFIA  or  HICI).  The  clinical  application  of  this  group  of 
methylated  CGIs  was  examined  in  matched  plasma  from  chemonaive  patients  with  EOC 
for  similar  methylation  changes.  Methylation  of  LAMIA  was  detected  in  43.3%  of  all 
plasma  samples  and  in  48.2%  of  those  patients  with  methylated  LAMA  in  their  tumour. 
When  methylation  was  detected  in  plasma,  it  was  always  detectable  in  the  corresponding 
tumour.  Therefore,  detection  of  LAMIA  methylation  in  plasma  has  a  sensitivity  of  48.2% 
and  a  specificity  of  100%. 
In  late  stage  chemonaive  ovarian  turnours,  methylation  in  tumour  of  CGIs  associated  with 
BRCA1,  GSTPI  or  MGMT  correlated  with  an  improved  response  to  chemotherapy 
(p=0.013).  In  addition,  a  non-random  pattern  of  methylation  was  observed  which 
demonstrated  that  there  is  an  underlying  biological  mechanism  leading  to  co-methylation 
of  specific  genes,  but  the  cause  of  this  remains  unidentified. 4 
In  addition  to  identifying  methylation  of  the  LAMIA  CGI  as  a  potentially  early  epigenetic 
event  DMH  of  ovarian  cell  lines  also  identified  both  the  LAMA  CGI  and  a  CGI  at  the 
NR2EI  gene,  within  a  group  of  ranked  sequences,  whose  methylation  status  optimally 
discriminate  between  cisplatin  sensitive  and  resistant  cell  lines.  CGI  methylation  of  these 
genes  was  associated  with  a  transcriptionally  repressed  state.  Methylation  of  these  CGIs 
was  observed  in  61.8%  and  12.6%  of  chemonaive,  ovarian  turnours  respectively,  but  not  in 
normal  ovarian  surface  epithelium.  Comparison  of  matched  pairs  of  chemonaive,  ovarian 
turnours  and  post-chemotherapy  residual  samples  showed  that  methylation  of  NR2EI  and 
LAMA  increased  in  33%  and  25%  respectively  following  chemotherapy,  which  is  in 
keeping  with  selection  of  methylation  of  these  genes  during  platinum  based  chemotherapy 
and  a  potential  role  for  these  genes  in  platinum  resistance  mechanisms. Table  of  Contents 
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1  Introduction 
1.1  Clinical  diagnosis  and  first-line  treatment  of  ovarian 
cancer 
Ovarian  cancer  is  a  heterogeneous  disease  in  its  biological  nature,  aggressive 
characteristics  and  response  to  chemotherapeutic  agents.  Epithelial  ovarian  cancer  (EOQ 
is  considered  to  be  the  most  aggressive  neoplasm  of  the  female  genital  tract  and  remains 
the  cause  of  more  cancer-related  deaths  than  a  combination  of  both  cervical  and 
endometrial  cancers  (Ozols  et  al.,  2004).  EOC  is  the  most  common  WHO  (World  Health 
Organisation)  histological  type  and  multiple  subtypes  of  this  exist  which  are  based  on  cell 
type  and  architecture  of  the  tumour.  At  least  80%  of  EOCs  arise  from  the  coelomic 
epithelium  of  which  75%  are  serous  cystadenocarcinomas.  These  are  predominantly  found 
in  advanced  ovarian  malignancy.  Less  common  types  include  mucinous,  endometrioid, 
transitional  cell  (Brenner),  carcinosarcoma,  clear  cell  and  unclassified  carcinomas. 
Approximately  20%  are  germ-cell  and  sex  cord-stromal  cell  tumours  (Kaku  et  al.,  2003). 
Despite  the  many  advances  in  diagnosis  and  treatment  of  ovarian  cancer  over  the  last  four 
decades,  approximately  7000  women  develop  this  disease  in  the  United  Kingdom,  with 
more  than  4600  women  dying  annually  (www.  info.  cancerresearchuk.  orwcancerstatý).  The 
most  important  determinant  of  survival  from  ovarian  cancer  is  turnour  stage  at  diagnosis. 
Early  stage  ovarian  cancer,  which  is  limited  to  the  ovary,  can  be  treated  successfully  with 
surgery  alone  in  90%  of  patients,  but  due  to  its  insidious  onset  the  majority  (approximately 
80%)  present  with  incurative  disseminated  late  stage  disease  (FIGO  Stage  III/IV) 
(International  Federation  of  Gynaecology  and  Obstetrics)  (Agarwal  and  Kaye,  2003).  The 
five  year  survival  rates  for  these  advanced  turnours  dramatically  decrease  to  17-35% 
(Angioli  et  al.,  2006).  Ovarian  turnours  are  known  to  spread  via  the  lymphatic  system  and 
through  seedling  implantations  on  the  peritoneum.  Development  of  this  disease  is  not 
associated  with  any  specific  clinical  symptoms  or  signs.  A  diagnosis  is  therefore  very 
difficult  to  make  based  on  non-specific  symptoms  as  these  will  often  mimic  upper 
gastrointestinal  disease  with  abdominal  fullness,  dyspepsia  and  bloating  (Cannistra,  2004). 
Over  the  last  four  decades,  surgical  debulking  has  been  the  accepted  initial  management  of 
patients  with  advanced  ovarian  cancer  (Griffiths,  1975).  One  of  the  most  important 
prognostic  factors  in  the  treatment  of  advanced  ovarian  malignancy  is  a  crude 
measurement  of  the  extent  to  which  the  tumour  is  optimally  debulked.  Patients  with Catriona  Hardie,  2007  18 
residual  tumour  mass  of  greater  than  2cm  have  a  median  survival  of  12-16  months 
compared  to  4045  months  if  residual  disease  is  less  than  2cm  (Mutch,  2002).  However, 
the  evidence  for  debulking  surgery  has  previously  mainly  been  based  on  small, 
retrospective  studies  (Allen  et  al.,  1995;  Hunter  et  al.,  1992;  Voest  et  al.,  1989),  but  there  is 
recent  evidence  to  suggest  that  increased  progression-free  survival  (PFS)  may  be 
associated  with  patients  who  are  optimally  debulked  with  less  advanced  disease  (Crawford 
et  al.,  2005).  Some  authors  have  suggested  that  the  underlying  heterogeneous  biological 
nature  of  ovarian  turnours  may  dictate  its  potential  surgical  resectibility  (Hogberg,  1995; 
Zanaboni  et  al.,  1988).  This  has  lead  to  some  debate  over  whether  or  not  neoadjuvant 
chemotherapy  would  improve  survival  (Inciura  et  al.,  2006;  Schwartz  et  al.,  1999;  Vergote 
et  al.,  2000).  There  are  now  randomised  prospective  studies  examining  this  which  are 
being  undertaken  by  the  European  Organisation  for  Research  and  Treatment  of  Cancýr 
55971  (EORTC)  and  Chemotherapy  or  Up-Front  Surgery  studies.  These  studies  are 
comparing  neoadjuvant  chemotherapy  followed  by  surgery  versus  primary  surgery 
followed  by  chemotherapy.  Until  conclusions  are  drawn  from  these  studies  and  other 
future  prospective  trials,  cytoreductive  surgery  will  remain  the  recommendation  for  the 
first-line  treatment  of  FIGO  Stage  III/IV  disease. 
The  majority  of  patients  present  too  late  for  curative  removal  of  the  tumour,  hence, 
chemotherapeutic  agents  remain  a  key  part  of  treatment  for  most  women.  Historically, 
women  were  treated  with  alkylating  agents  such  as  cyclophosphamide.  However,  adjuvant 
chemotherapy  has  advanced  significantly  over  the  last  four  decades  with  the  introduction 
of  platinum,  and  more  recently,  taxane-based  chemotherapy  (McGuire  and  Markman, 
2003).  Platinum  analogues,  such  as  cisplatin  or  carboplatin,  are  DNA  damaging  agents 
which  mediate  their  effects  by  inducing  intra-  and  interstrand  crosslinks  within  DNA 
(Kartalou  and  Essigmann,  2001).  In  contrast,  taxanes  such  as  paclitaxel  and  docetaxel  exert 
their  cytotoxic  effects  by  binding  to  and  stabilising  the  tubulin  polymer  (Rowinsky  and 
Donehower,  1995).  For  patients  with  early-stage  turnours  with  an  increased  risk  of  relapse, 
i.  e.  those  with  Stage  Ia/b  high  grade,  Stage  Ic  and  Stage  II  disease,  the  use  of  platinum- 
based  chemotherapy  can  result  in  a5  year  disease-free  survival  of  approximately  80% 
compared  to  approximately  65%  in  those  patients  who  do  not  receive  platinum  adjuvant 
therapy  (Young,  2003;  Young  et  al.,  2003).  In  advanced  ovarian  malignancy,  two 
randomised-controlled  trials  (RCTs)  in  the  1990s  established  paclitaxel  combined  with  a 
platinum  agent  as  standard  first-line  chemotherapy  (McGuire  et  al.,  1996;  Piccart  et  al., 
2000),  showing  a  particular  increase  in  overall  survival  when  compared  to  treatment  with 
cyclophosphamide.  Meta-analysis  results  showed  that  carboplatin  has  a  lower  toxicity 
profile  than  cisplatin  in  patients  (Aabo  et  al.,  1998),  and  this  is  now  routinely  used Catriona  Hardie,  2007  19 
following  two  larger  RCTs  (du  Bois  et  al.,  2003;  Ozols  et  al.,  2003).  There  remain  many 
controversies  surrounding  the  current  first-line  chernotherapeutics  used  in  this  disease. 
Firstly,  there  are  differing  opinions  over  whether  combination  chemotherapy  with  a  taxane 
has  superior  effects  to  single  agent  carboplatin.  Secondly,  if  combination  treatment  is  the 
first  choice,  which  taxane  is  appropriate  to  use  has  also  been  debated.  The  results  of 
ICON3  concluded  that  single  agent  carboplatin  can  be  regarded  as  reasonable  first-line 
treatment  in  ovarian  cancer  (ICON  Group,  2002),  although  there  was  an  early  trend 
towards  overall  survival  benefit  in  those  treated  with  combination  therapy.  Regarding  the 
choice  of  taxane,  "The  Scottish  Randomised  Trial  in  Ovarian  Cancer"  (SCOTROC) 
compared  docetaxel-carboplatin  with  paclitaxel-carboplatin  in  first-line  treatment. 
Although  there  was  no  overall  survival  benefit  of  the  docetaxel  combination  over 
paclitaxel,  both  were  associated  with  acceptable  toxicities.  Docetaxel-carboplatin  was 
associated  with  significantly  more  myelosuppression  but  significantly  less  neurotoxicity 
and  symptom  scoring  favoured  docetaxel.  Therefore,  the  authors  concluded  that  a 
combination  of  carboplatin  with  docetaxel  may  be  an  appropriate  chemotherapeutic  agent 
in  chemonaive  ovarian  turnours  (Vasey  et  al.,  2004).  In  addition,  there  is  current  debate 
over  whether  current  standard  intravenous  (IV)  carboplatin-paclitaxel  delivery  should  be 
replaced  with  the  intraperitoneal  (IP)  delivery  of  chemotherapy.  IP  delivery  of  drugs, 
specifically  cisplatin,  has  been  examined  in  several  trials  for  optimally  debulked  Stage  III 
ovarian  cancer  (Alberts  et  al.,  1996;  Armstrong  et  al.,  2006;  Markman  et  al.,  2001). 
However,  although  advantages  in  overall  and  progression-free  survival  have  been 
demonstrated,  the  merits  of  using  this  remain  uncertain  due  to  issues  with  efficacy,  quality 
of  life  and  toxicity  of  IP  regimes  versus  standard  IV  carboplatin-paclitaxel. 
Although  a  large  number  of  studies  have  established  carboplatin-paclitaxel  as  standard 
first-line  treatment,  current  chemotherapeutic  regimes  used  in  both  first-  and  second-line 
treatment  will  produce  differing  responses  due  to  the  heterogeneous  nature  of  this  disease. 
Therefore,  stratification  of  current  and  more  novel  therapies  in  patients  are  now  required  to 
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1.2  Potential  mechanisms  of  drug  resistance  in  ovarian 
cancer 
A  first-line  chemotherapy  regimen  of  platinum  and  taxane  will  achieve  response  rates  of 
more  than  80%  in  advanced  ovarian  malignancy,  with  an  overall  complete  response  in  40- 
60%  of  patients  (Greenlee  et  al.,  2001).  Despite  treatment  advances  though,  most  patients 
become  drug  resistant  and  relapse  within  a  median  progression-free  survival  period  of  18 
months  (Greenlee  et  al.,  2001).  Drug  resistance  accounts  for  treatment  failure  and  demise 
in  more  than  90%  of  patients  with  advanced  malignancy,  and  this  is  related  to  numerous 
causative  factors  (Agarwal  and  Kaye,  2003).  Both  intrinsic  and  acquired  drug  resistance  is 
encompassed  in  ovarian  cancer  (Balch  et  al.,  2004),  but  most  clinical  studies  have 
concentrated  on  tumour  characteristics  at  presentation,  rather  than  in  relapsed  disease 
(Teodoridis  et  al.,  2004).  Intrinsic  mechanisms  of  resistance  occur  in  approximately  20% 
of  women,  and  is  clinically  defined  in  those  who  fail  to  respond  to  first  line  chemotherapy 
(platinum-refractory  disease),  have  stable  disease  as  a  best  response  following  first  line 
treatment  or  have  a  short  treatment-free  interval  of  less  than  6  months  (Vasey,  2005).  If  re- 
challenged  with  platinum  agents  or  other  second-line  chemotherapeutics,  these  tumours 
have  a  poor  prognosis  (Agarwal  and  Kaye,  2006). 
Intrinsic  resistance  is  influenced  by  the  gene  expression  of  cancer  cells  prior  to  treatment 
(Balch  et  al.,  2004).  Acquired  drug  resistance,  however,  is  seen  in  patients  who  initially 
respond  to  treatment  but  then  proceed  to  develop  resistance  to  second-line  or  subsequent 
chemotherapeutic  regimes.  It  has  been  suggested  that  acquired  resistance  emerges  either 
from  the  survival  and  expansion  of  drug-resistant  subpopulations  of  cells  under  selective 
pressure  during  turnour  evolution  (Figure  IA),  which  is  induced  by  chemotherapeutic 
measures,  or  that  cancer  stem  cells  can  repopulate  the  tumour  environment  (Figure  113) 
(Agarwal  and  Kaye,  2003).  Stem  cells  may  only  comprise  a  very  small  proportion  of  the 
cells  within  a  tumour,  but  they  are  naturally  chemoresistant  through  their  relative 
quiescence,  i.  e.  due  to  spending  most  of  their  time  in  GO,  and  therefore  avoid  the  toxicity 
of  the  initial  chemotherapy  regime  which  will  target  rapidly  dividing  cells.  In  addition  they 
have  a  capacity  for  DNA  repair  and  have  been  found  to  express  high  levels  of  specific 
ABC  drug  transporters  which  may  contribute  to  chemoresistance  (Dean  et  al.,  2005). 
Subsequent  relapse  due  to  growth  of  these  stem  cells  may  be  chemosensitive  initially,  but 
ultimately  most  patients  develop  resistance  after  an  initial  chemoresponsive  history. 
Therefore,  a  combination  of  these  proposed  models  (Figure  IA  and  IB)  of 
chemoresistance  would  seem  most  likely  (Figure  I  C). Catriona  Hardie,  2007  21 
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Figure  1  Models  of  drug  resistance  in  ovarian  cancer.  (A)  Initial  response  to  chemotherapy 
(CTX)  seen  due  to  drug  sensitive  cells  (green)  followed  by  clonal  expansion  of  a  subpopulation  of 
chemoresistant  cells/regrowth  of  a  chemoresistant  progenitor  cell  population  (red).  (B)  Regrowth  of 
a  persistent  stem  cell  population  (blue)  which  can  be  initially  chemosensitive.  (C)  Most  likely 
scenario  is  a  combination  of  (A)  and  (B)  where  chemoresistance  develops  after  initial 
chemosensitive  relapse.  Illustration  modified  from  Agarwal  and  Kaye,  2003. 
There  are  diverse  possible  mechanisms  which  may  be  responsible  for  drug  resistance  in 
patients.  Firstly,  pharmacokinetic  variability  may  exist  between  patients  and  will  place 
limitations  on  aspects  such  as  the  first  pass  metabolism,  renal  clearance  and  hepatic 
metabolism  of  a  drug.  In  addition,  variation  in  the  tumour  microenvironment  such  as 
hypoxia  and  altered  cell  interactions  exist  and  tumour-cell  specific  mechanisms  can 
contribute  (Agarwal  and  Kaye,  2003).  Each  of  these  three  possible  general  mechanisms 
influence  chemotherapeutic  response  by  principally  affecting  intracellular  active  drug 
concentrations,  drug-target  interaction,  target-mediated  cell  damage,  damage-induced 
apoptotic  signaling  or  the  apoptotic  effector  machinery. 
Various  pathways  within  a  cell  are  probably  altered  in  clinical  drug  resistance  due  to 
polygenic  gene  expression  changes  (Glasspool  et  al.,  2006)  which  will  affect  multiple 
genes  involved  in  key  pathways.  A  number  of  specific  biochemical  pathways  and  gene 
expression  patterns  have  been  identified  as  causes  of  both  intrinsic  and  acquired  resistance Catriona  Hardie,  2007  22 
to  chemotherapy  in  vitro  although  the  clinical  in  vivo  relevance  of  these  remains  unclear 
(Agarwal  and  Kaye,  2003;  Vasey,  2005).  Many  drugs  used  can  be  actively  pumped  from 
cells  by  membrane-based  proteins  and  expression  of  these  proteins  can  lead  to  multidrug 
resistance  (MDR)  towards  numerous  anticancer  agents  (Gottesman  et  al.,  1998).  Such 
proteins,  including  P-Glycoprotein  (MDRI),  can  be  important  in  determining  drug 
resistance  in  vitro  (Borst  et  al.,  2000).  Recent  work  has  also  shown  that  expression  of 
NIRP2,  a  known  ABC  transporter,  is  observed  in  ovarian  cancer  and  confers  resistance  to 
cisplatin  chemotherapy  and  can  predict  clinical  outcome  (Surowiak  et  al.,  2006).  Other 
previous  work  has  investigated  the  role  of  the  p53  protein  in  drug  resistance.  p53  gene 
mutations  can  be  associated  with  poor  response  in  patients  with  ovarian  cancer  who  are 
exposed  to  high-dose  platinum  chemotherapy  regimes  (Righetti  et  al.,  1996).  In  vitro 
studies  have  shown  that  p53  mutations  and  acquired  platinum  resistance  are  associated 
with  increased  sensitivity  to  taxanes  in  ovarian  cancer  cell  lines  (Cassinelli  et  al.,  2001). 
However,  overall  there  remains  no  conclusive  evidence  in  vivo  that,  firstly,  individual 
genetic  modulation  of  genes  such  as  AMR]  and  p53  leads  to  acquisition  of  clinical  drug 
resistance  (Glasspool  et  al.,  2006),  or  that  their  ability  to  predict  clinical  outcome  in 
patients  with  ovarian  cancer  has  advantages  over  currently  used  markers  such  as  the 
tumour  stage  and  grade.  (Agarwal  and  Kaye,  2003;  Hall  et  al.,  2004). 
Increased  knowledge  of  how  platinum  compounds  mediate  cytotoxicity,  i.  e.  through 
formation  of  DNA-platinum  adducts  and  induction  of  apoptosis,  has  increased  our 
understanding  of  potential  drug  resistance  mechanisms  (Kartalou  and  Essigmann,  2001). 
Chemoresistant  tumours  most  likely  evade  apoptosis  due  to  deficient  proapoptotic  and/or 
enhanced  antiapoptotic  signaling  pathways  (Fojo  and  Bates,  2003).  Altered  expression  of 
genes  involved  in  key  DNA  damage  response  pathways  therefore  potentially  contribute  to 
the  drug  resistant  phenotype  (Teodoridis  et  al.,  2004).  The  advent  of  microarray-based 
technologies  has  identified  a  myriad  of  genes  whose  expression  status  are  altered  in 
acquired  drug  resistant  ovarian  turnours  (Jazaeri  et  al.,  2005;  VEsperance  et  al.,  2006). 
There  remains  very  little  evidence  though  that  altered  expression  status  of  genes  by  genetic 
mutations  have  a  key  role  to  play  in  acquired  resistance  mechanisms  in  vivo  (Glasspool  et 
al.,  2006).  Therefore,  if  genetic  alterations  have  little  influence  over  the  control  of  gene 
expression  in  drug  resistant  turnours,  there  must  be  alternative  aberrant  mechanisms 
controlling  the  development  of  this  phenotype. 
Previous  work  in  our  laboratory  has  focused  on  characterising  the  proteins  involved  in  the 
recognition  of  damage  induced  by  platinum  agents.  Mismatch  repair  (MMR)  proteins, 
including  hNILHI  and  hMSH2,  recognise  and  repair  damaged  or  mismatched  nucleotides Catriona  Hardie,  2007  23 
which  can  result  from  DNA  replicative  mechanisms  and  other  repair  processes.  It  has  been 
shown  that  cisplatin  resistance  can  be  associated  with  loss  of  DNA  NMR  activity  in 
ovarian  cancer  cell  lines  (Anthoney  et  al.,  1996;  Brown  et  al.,  1997;  Drummond  et  al., 
1996).  Complete  loss  of  MEHI  protein  expression  in  cisplatin  resistant  cell  lines  was 
observed  with  no  apparent  loss  of  the  hMLHI  gene  (Brown  et  al.,  1997).  Loss  of  hNEHI 
protein  expression  following  chemotherapy  was  shown  in  ovarian  cancer  (Strathdee  et  al., 
1999;  Watanabe  et  al.,  2001),  and  this  was  associated  with  an  epigenetic  alteration  known 
as  CpG  island  (CGI)  methylation  at  the  hMLHI  locus  (Strathdee  et  al.,  1999).  Chapter  I 
will  now  examine  the  contributory  effect  of  CGI  methylation  in  the  pathogenesis  of 
ovarian  cancer  and  its  phenotypic  consequences.  It  is  now  widely  recognised  that  this 
epigenetic  mechanism  can  transcriptionally  repress  genes  involved  in  multiple  biological 
pathways  in  ovarian  cancer.  Furthermore,  co-selection  of  genes  affected  by  these 
epimutations  can  subsequently  affect  its  biological  properties,  including  the  propensity  to 
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1.3  DNA  methylation  and  epigenetic  gene  regulation 
The  term  "epigenetics"  (greek  meaning,  "upon"  genetics)  can  be  defined  as  a  stable, 
heritable  change  in  gene  expression  which  is  retained  during  mitosis  and/or  meiosis.  It 
does  not  involve  a  change  in  the  primary  base  sequence,  but  instead  is  stored  in  the 
distribution  of  the  modified  base  5-methylcytosine,  which  has  previously  been  aptly 
described  as  "the  fifth  base"  (Costello  and  Plass,  2001).  DNA  methylation  is  the  only 
known  epigenetic  modification  of  human  DNA  and  results  in  the  enzymatic  transfer  of  a 
methyl  group  from  the  methyl  donor  S-adenosylmethionine  (SAM)  to  the  carbon-5 
position  of  cytosine  bases  in  DNA  (Bird,  2002).  This  almost  exclusively  occurs  at  the 
sequence  motif  5'-CpG-3'  which  are  known  as  CpG  dinucleotides  (Teodoridis  et  al., 
2004),  although  non-CpG  methylation  in  mammals  has  also  been  reported  (Ramsahoye  et 
al.,  2000).  An  illustration  of  this  chemical  modification  is  shown  in  Figure  2. 
(A) 
NH2 
J,  , 
N 
I 
R 
Substitution 
at  position  5 
NH2 
CH3 
N 
I 
R 
Cytosine  5-methyl-Cytosine 
Figure  2  Chemical  modification  of  cytosine  methylation.  (A)  the  chemical  structure  of  the  base 
cytosine.  (B)  the  chemical  structure  of  5-methylcytosine  following  enzymatic  transfer  of  a  methyl 
(CH3)  group. 
Over  recent  years,  CpG  methylation  and  its  consequences  have  become  more  fully 
understood  (Teodoridis  et  al.,  2004).  The  family  of  enzymes  which  catalyse  the  transfer  of 
a  methyl  group  from  the  donor  molecule,  SAM,  to  a  cytosine  ring  are  known  as  the  DNA 
methyltransferases  (DNMT).  Several  distinct  physiologically  active  members  have  been 
cloned  and  characterised  so  far  in  mammalian  cells  including  DNMTI,  DNMT3a  and 
DNMT3b  (Bird  and  Wolffe,  1999;  Hendrich  and  Bird,  2000).  The  main  role  of  DNMTl  is 
thought  to  be  the  post-replicative  maintenance  of  DNA  methylation  patterns  (Leonhardt  et Catriona  Hardie,  2007  25 
al.,  1992),  which  specifically  involves  the  reinstatement  of  fully  methylated  sites  from 
initially  hemi-methylated  DNA  substrates  in  daughter  cells  (Chuang  et  al.,  1997;  Pradhan 
et  al.,  1999).  DNMTI  has  been  shown  to  bind  to  proliferating  cell  nuclear  antigen  (PCNA), 
an  auxiliary  factor  of  DNA  replication,  during  S  phase  via  a  specific  binding  domain 
(Chuang  et  al.,  1997;  Mortusewicz  et  al.,  2005)  consistent  with  a  function  in  maintaining 
methylation  patterns.  This  enzyme,  though,  is  additionally  able  to  de  novo  methylate  DNA 
substrates  in  cancer  (Jair  et  al.,  2006).  In  contrast  to  this  enzyme,  DNMT3a  and  DNMT3b 
are  involved  in  initiating  methylation  patterns  during  early  embryogenesis,  a  process  which 
is  known  as  de  novo  methylation  (Okano  et  al.,  1999;  Okano  et  al.,  1998).  Both  DNMT3a 
and  DNMT3b  show  a  preference  to  unmethylated  DNA  in  vitro  (Okano  et  al.,  1998), 
however,  there  is  also  data  to  suggest  that  both  DNMT3a  and  DNMT3b  can  maintain 
methylation  patterns  in  the  embryonic  stem  cells  of  mice  (Chen  et  al.,  2003b).  In  addition, 
the  DNMT3-like  protein,  DNMT3L,  has  also  been  identified  which  is  inactive  as  a  DNMT 
per  se,  but  is  essential  for  the  establishment  of  germ  line  DNA  methylation  and  stimulates 
de  novo  methylation  by  DNMT3a  and  DNMT3b  (Chen  et  al.,  2005b).  DNMTs  and  their 
role  in  the  methylation  of  DNA  are  vital  for  mammalian  development.  Homozygous 
knockout  of  DNMTI  or  DNM`F3b  in  mice  has  been  shown  to  be  embryonically  lethal  and 
DNMlr3a  knockout  mice  die  at  four  weeks  old  (Li  et  al.,  1992;  Okano  et  al.,  1999).  Mice 
with  reduced  expression  levels  of  DNMT1  show  genomic  hypomethylation  and  have  an 
increased  likelihood  of  developing  lymphomas  although  they  have  a  lower  incidence  of 
other  tumour  types  (Gaudet  et  al.,  2003;  Laird  et  al.,  1995).  Additionally,  DNNI[TI 
overexpression  or  complete  loss  of  this  results  in  loss  of  genetic  imprinting  and  lethality  of 
the  embryo  (Biniszkiewicz  et  al.,  2002;  Li  et  al.,  1993). 
In  humans,  patterns  of  DNA  methylation  are  first  established  during  gametogenesis. 
However,  after  fertilisation,  dramatic  waves  of  methylation  changes  are  observed.  The 
paternal  genome  has  been  shown  to  be  actively  demethylated  in  mitotically  active  zygotes, 
followed  by  a  passive  and  selective  loss  of  DNA  methylation  continuing  into  the  morula 
stage  (Santos  et  al.,  2002).  After  implantation,  DNA  methylation  patterns  become  re- 
established  and  are  maintained  through  subsequent  cell  divisions  (Gaudet  et  al.,  2004).  The 
primary  role  of  DNA  methylation  in  normal  adult  tissues  is  thought  to  be  the  maintenance 
of  transcriptionally  silent  repetitive  DNA  elements  in  the  genome  (Walsh  et  al.,  1998), 
which  includes  sustaining  satellite  DNA  and  parasitic  elements.  This  allows  the  specific 
targeting  of  transcription  factors  to  important  genomic  sites  (Bird  and  Wolffe,  1999; 
Stratlidee  and  Brown,  2002).  There  is  an  overall  depletion  of  CpG  dinucleotides  spanning 
the  genome  and  this  is  presumably  because  methylated  cytosine  residues  are  mutagenic 
due  to  spontaneous  dearnination  of  5-methylcytosine  to  thymine  (Bird,  1996;  Chan  et  al., Catriona  Hardie,  2007  26 
2001).  In  contrast  to  this,  there  are  small,  unequally  distributed  distinct  stretches  of  DNA 
(500  base  pairs  (bp)  -2  kilobases  (kb)  in  length)  which  are  rich  in  CpG  dinucleotides. 
These  clusters  of  CpGs  are  known  as  CpG  islands  (CGIs),  and  these  frequently  co-localise 
within  and  around  the  promoter  regions  of  mammalian  genes  (Jones,  2002).  It  is  estimated 
that  there  are  around  30,000  CGIs  within  the  human  genome  and  approximately  50-60%  of 
all  genes  contain  a  CGI  (Costello  and  Plass,  2001).  In  contrast  to  the  rest  of  the  genome, 
these  CGIs  remain  largely  unmethylated  in  normal  tissue  (Bird,  1986)  regardless  of  the 
transcriptional  state  of  the  gene.  However,  it  is  now  apparent  that  methylation  of  CGIs  is 
important  in  X  chromosome  inactivation  in  females  (Heard  et  al.,  1997;  Weber  et  al., 
2005),  and  in  genomic  imprinting  where  promoter  methylation  of  either  the  paternally  or 
maternally  inherited  allele  is  associated  with  its  transcriptional  repression  (Bartolomei  and 
Tilghman,  1997).  There  have  also  been  reports  of  some  non-imprinted  autosomal  CGIs 
which  are  methylated  in  normal  cells,  and  that  this  mechanism  may  be  important  in  the 
establishment  and  control  of  cell-type-specific  expression  of  genes.  This  was  initially 
described  for  the  maspin  gene  (Futscher  et  al.,  2002)  but  has  more  recently  been  shown  in 
several  other  genes  including  MCJ  (Strathdee  et  al.,  2004),  14-3-3a  (Oshiro  et  al.,  2005) 
and  HOXA5  (Strathdee  et  al.,  2007).  One  study  has  reported  that  this  epigenetic  mechanism 
is  most  likely  relatively  rarely  involved  in  the  control  of  cell-type-specific  expression  of 
genes  in  normal  tissues  (Yamada  et  al.,  2004),  although  others  dispute  this  (Song  et  al., 
2005). 
The  two  major  mechanisms  which  define  the  epigenome  of  a  cell  are  DNA  methylation 
and  histone  modifications.  Modulation  of  chromatin  structure  is  essential  for  the  regulation 
of  gene  expression,  but  it  remains  unclear  whether  DNA  methylation  is  the  initial  silencing 
event  or  whether  it  is  a  consequence  of  earlier  chromatin-remodelling  events  leading  to 
changes  in  gene  expression.  Several  proposals  have  been  suggested  to  explain  the 
mechanism  by  which  DNA  methylation  may  cause  transcriptional  repression  of  genes. 
Historically,  the  suggestion  was  simply  that  DNA  methylation  could  physically  deter  the 
binding  of  transcription  factors  to  their  binding  sites  in  the  promoters  of  genes  and  inhibit 
gene  transcription  this  way.  This  was  shown  to  affect  the  binding  of  several  important 
transcription  factors  including  AR-2,  E2F  and  NFKB  (Tate  and  Bird,  1993).  Recent  authors 
though  have  described  an  alternative  more  generally  applicable  mechanism  by  which  this 
repression  may  occur,  which  establishes  a  link  between  DNA  methylation  and  higher  order 
chromatin  structure  (Bird  and  Wolffe,  1999;  Tyler  and  Kadonaga,  1999),  as  illustrated 
below  in  Figure  3. Catriona  Hardie,  2007 
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Figure  3  Epigenetic  mechanism  of  transcriptional  repression  and  chromatin  remodeling. 
Active  transcription  is  associated  with  an  open  chromatin  structure,  acetylated  histones  and 
unmethylated  CpGs  (white).  RNA  polymerase  (RNA  Pol  11)  and  transcription  factors  can  access 
and  transcribe  the  gene.  DNMTs  methylate  CpGs  (black)  and  bind  methyl  binding  domain,  MBD, 
proteins  (yellow).  Subsequent  recruitment  of  histone  deacetylases,  HDAC,  (blue)  and  chromatin 
remodeling  proteins,  sin3a/mi-2,  (green)  leads  to  remodeling  of  chromatin  and  deacetylation  of 
histone  tails.  Histone  methyltransferases,  HMTs,  methylate  lysine  residues,  allowing  binding  of 
heterochromatin  protein  1,  HP1,  (red)  to  chromatin. 
Initial  work  in  the  last  decade  brought  together  a  link  between  DNA  methylation  and  gene 
silencing.  In  experimental  systems,  it  was  shown  that  promoter  methylation  does  not  cause 
silenced  transcription  until  chromatin-remodel  ling  proteins  are  recruited  to  the  region 
(Kass  et  al.,  1997),  and  further  work  identified  the  chromatin-remodel  ling  proteins  with 
which  methylcytosine-binding  proteins  associate  (Jones  et  al.,  1998;  Ng  et  al.,  1999;  Wade 
et  al.,  1999).  Methylated  DNA  can  recruit  a  family  of  methyl-binding  domain  (MBD) 
proteins  which  all  share  a  common  MBD  motif.  Several  members  of  this  family  (MeCP2, 
MBD2  and  MBD3)  are  able  to  associate  with  protein  complexes  involving  histone 
deacetylases  (HDAC  I  and  HDAC2)  and  chromatin  remodelling  proteins  (sin3a  and  mi-2). 
Normally,  in  transcriptionally  active  genes,  lysine  residues  on  the  N-terminal  tails  of  the 
core  histones  (H2A,  H213,  H3  and  H4)  are  acetylated  (Marks  et  al.,  2001).  However, Catriona  Hardie,  2007  28 
following  association  with  these  proteins,  deacetylation  of  these  histone  tails  occurs  and 
leads  to  a  tighter  binding  between  positively  charged  lysine  residues  of  histories  and  the 
negatively  charged  phosphodeoxyribose  backbone  of  the  DNA.  This  tighter  binding 
reduces  accessibility  of  DNA  for  transcription  factors.  MBD  proteins  also  engage  histone 
methylases  (HMTs)  which  results  in  the  methylation  of  lysine  9  of  histone  3  (H3-K9)  and 
binding  of  the  heterochromatin  protein  I  (HPI)  which  is  involved  in  maintenance  of  a 
transcriptionally  silenced  state  (Bannister  et  al.,  2001;  Lachner  et  al.,  2001).  Additional 
recent  work  has  revealed  that  NIBD  I  associates  with  a  complex  containing  H3-K9  specific 
methyltransferase  activity  (Sarraf  and  Stancheva,  2004),  providing  another  possible  link 
between  DNA  and  histone  methylation.  An  alternative  mechanism  though  could  be  that 
methylation  of  DNA  occurs  after  the  formation  of  a  closed  chromatin  state.  In  mammals, 
DNA  methyltransferases  interact  with  H3-K9  methylases  (Fuks  et  al.,  2003;  Lehnertz  et 
al.,  2003),  and  loss  of  H3-K9  methylation.  in  knockout  embryonic  stem  cells  decreases 
DNMT3B-dependent  CpG  methylation  at  major  centromeric  satellites  (Lehnertz  et  al., 
2003).  H3-K9  methylation  and  suppression  of  pl6mý"  can  occur  before  CpG  methylation 
which  may  mean  therefore  that  DNA  methylation  is  secondary  to  histone  modification  in 
gene  silencing  (Bachman  et  al.,  2003),  and  that  only  genes  repressed  by  other  mechanisms 
are  then  subject  to  CpG  methylation  (Bird,  2002;  Mutskov  and  Felsenfeld,  2004).  It  has 
also  been  suggested  that  DNA  methylation  could  subsequently  reinforce  the  repressed 
chromatin  structure  (Szyf,  2003).  In  addition,  there  are  also  more  novel  findings  which 
suggest  a  communication  between  DNA  methylation  and  other  histone  modifications, 
including  H3-K27me3  and  H4-K20me3  (Fraga  et  al.,  2005b).  There  is  really  only  a  partial 
understanding  of  the  molecular  interplay  between  these  epigenetic  modifications,  and  the 
mechanisms  which  underlie  this  intimate  link  between  DNA  methylation  and  histone 
modifications  remain  under  intense  scrutiny. 
The  importance  of  DNA  methylation  patterns  in  humans,  and  the  cause  and  possible 
consequences  of  disruption  to  this  epigenetic  mechanism  have  been  studied  intensely  over 
the  last  decade  (Robertson,  2005).  During  development  a  number  of  congenital 
malignancies  are  characterised  by  abnormal  DNA  methylation.  These  include 
immunodeficiency,  centromeric  region  instability,  facial  anomalies  (ICF)  syndrome,  which 
has  been  linked  to  mutations  in  DNMT3B  (Xu  et  al.,  1999),  and  imprinting  disorders  such 
as  Beckwith-Wiedemann  and  Prader-Willi  syndromes  (Robertson,  2005).  DNA 
methylation  aberrations  have  also  been  linked  to  the  phenotypic  disconcordance  that  can  be 
later  identified  in  monozygotic  (MZ)  twins.  Interestingly,  it  is  not  possible  to  distinguish 
epigenetic  differences  between  MZ  twins  at  an  early  age  (Fraga  et  al.,  2005a),  but  older 
MZ  twins  show  striking  differences  in  respect  to  5-methylcytosine  content  and  this  is Catriona  Hardie,  2007  29 
emphasised  in  those  who  are  separated  for  longer  periods  of  time  (Fraga  et  al.,  2005a). 
This  indicates  that  environmental  factors  may  have  influence  over  the  epigenome.  There  is 
also  evidence  to  suggest  that  global  5-methylcytosine  levels  can  be  affected  by  nutritional 
status  including  dietary  deficiencies  in  folate  and  methionine,  and  that  these  may  indeed 
contribute  to  alterations  in  the  DNA  methylation  content  (Pogribny  et  al.,  1995;  Pogribny 
et  al.,  2004).  An  age-dependent  increase  in  methylation  is  observed  in  some  histologically 
normal  tissues  (Ahuja  et  al.,  1998;  Issa  et  al.,  1994),  but  perhaps  the  most  significant  and 
frequently  studied  association  to  date  has  been  that  aberrant  methylation  changes  are 
observed  frequently  in  many  human  cancer  types. Catriona  Hardie,  2007  30 
1.4  DNA  methylation  alterations  in  cancer 
Cancer  is  now  recognised  as  being  both  a  polygenic  and  polyepigenetic  disease.  DNA 
methylation  patterns  are  profoundly  altered  in  human  cancer  (Robertson,  2005),  and  this 
was  first  demonstrated  in  the  genome  of  cancer  cells  which  were  found  to  be 
hypomethylated  in  comparison  to  normal  tissues  (Feinberg  and  Vogelstein,  1983).  In 
cancer,  this  genome-wide  hypornethylation  is  mostly  due  to  loss  of  methylation  from 
repetitive  elements  in  the  genome  (Yoder  et  al.,  1997)  and  results  in  genomic  instability. 
Concomitantly,  de  novo  methylation  of  CGIs  around  the  promoter  region  of  genes  is 
observed  in  cancer  development  correlating  with  transcriptional  repression  of  genes.  This 
is  the  most  well  characterised  epigenetic  alteration  in  neoplastic  cells  (Jones  and  Baylin, 
2002).  An  epigenetic  comparison  of  normal  and  cancer  tissues  is  illustrated  below  in 
Figure  4. 
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Figure  4  DNA  methylation  and  cancer.  A  representation  of  a  region  of  DNA  in  non-cancerous 
(top;  green)  and  cancerous  (bottom;  red)  tissues  showing  the  differences  in  DNA  methylation  in  the 
two  phenotypes.  In  non-cancerous  tissue,  genome  wide  hypermethylation  of  CpGs  (closed  green 
circles)  and  an  actively  transcribed  tumour  suppressor  gene  (TSG)  is  associated  with  a 
hypomethylated  CGI  (green  lines).  In  cancerous  tissue,  the  opposite  is  seen  with  genome  wide 
hypornethylation  (red  lines)  leading  to  genomic  instability,  and  CGI  hypermethylation  (closed  red 
circles)  contributing  to  transcriptional  silencing  of  a  TSG. Catriona  Hardie,  2007  31 
Despite  the  fact  that  we  know  a  great  deal  regarding  the  alteration  of  transcriptionally 
active  euchromatin  into  a  repressive  heterochromatic  state,  the  mechanisms  by  which  CGIs 
remain  protected  against  methylation  in  normal  cells,  but  subsequently  lose  this  protective 
barrier  in  cancer  and  become  hypermethylated  are  yet  to  be  elucidated.  It  has  been 
proposed  that  during  turnourigenesis,  the  segregation  of  the  epigenome  into  unmethylated 
and  methylated  regions  may  be  destroyed  leading  to  a  spread  of  heterochromatin  (Turker 
and  Bestor,  1997).  This  process  has  been  shown  for  the  oestrogen  receptor  gene  in 
association  with  aging  (Issa  et  al.,  2001;  Issa  et  al.,  1994),  and  although  the  exact 
mechanism  is  unclear,  the  protective  barriers  against  CGI  methylation  may  be  more 
vulnerable  in  aging  cells  and  therefore  increase  cancer  "risk7'  in  individuals.  It  has  also 
been  suggested  that  de  novo  methylation  may  be  "seeded"  in  exonic  CGIs  and 
subsequently  spread  into  the  promoter  region  of  genes  in  cancer  (Nguyen  et  al.,  2001). 
Interestingly,  it  has  been  proposed  that  this  exonic  methylation  seen  could  be  an  age- 
related  phenomenon  or  representative  of  a  preneoplastic  lesion.  It  is  also  unclear  what 
dictates  the  specific  CGI-associated  genes  which  will  be  epigenetically  altered  in  different 
cancer  types  and  why  other  CGIs  are  protected  from  methylation  (Frigola  et  al.,  2006). 
Altered  methylation  has  previously  been  considered  to  locally  silence  discrete  genes  in 
cancer  cells  but  recent  work  has  challenged  this  concept  by  showing  that  long-range 
epigenetic  silencing  of  genes  may  exist  in  cancer  (Frigola  et  al.,  2006)  which 
hypermethylates  neighbouring  genes  and  causes  global  gene  silencing  through  chromatin 
remodeling  activities.  Recent  evidence  has  also  argued  that  genes  which  are  methylated  in 
cancers  may  be  vulnerable  to  aberrant  DNA  hypermethylation  and  epigenetic  silencing 
during  turnour  initiation  and  progression  because  of  alterations  in  chromatin  structure  in 
stem  or  progenitor  cells,  including  dimethylated  H3K9  and  trimethylated  H3K9  (Ohm  et 
al.,  2007;  Widschwendter  et  al.,  2007). 
CGI  methylation  and  subsequent  transcriptional  silencing  occurs  at  least  as  often  as  genetic 
alterations  in  turnour  suppressor  genes  (TSGs)  in  cancer  (Herman  and  Baylin,  2003;  Jones 
and  Baylin,  2002).  According  to  Knudson's  "two-hif'  hypothesis,  in  carcinogenesis,  loss 
of  function  of  both  alleles  of  a  gene  is  required  for  malignant  transformation  (Knudson, 
2001).  The  first  hit  is  most  often  mutation  of  a  critical  gene  (e.  g.  TSG),  followed  by  loss  of 
the  wild-type  allele  through  deletion  or  loss  of  heterozygosity  (LOH).  Aberrant  promoter 
methylation  offers  an  alternative  reversible  mechanism  to  inactivate  key  tumour  suppressor 
genes  in  cancer.  For  instance,  it  can  constitute  the  initial  hit  in  many  cancers  with 
subsequent  mutations  or  deletions  eliminating  the  second  allele.  Furthermore, 
hypermethylation  of  both  alleles  has  been  noted  in  tumours  in  the  absence  of  genetic 
aberrations  of  a  given  gene  (Herman  and  Baylin,  2003;  Jones  and  Baylin,  2002). Catriona  Hardie,  2007  32 
On  average,  600  CGIs  are  aberrantly  methylated  in  turnours  although  this  is  dependent  on 
tumour  type  and  particular  histological  subtype  (Costello  et  al.,  2000).  Hundreds  of  genes 
have  the  potential  to  be  regulated  by  CGI  methylation,  affecting  many  properties  of  a 
tumour  during  its  development.  It  has  been  postulated  that  in  order  for  a  cancer  to  develop, 
most  malignancies  need  to  develop  "hallmarks"  such  as  evasion  of  apoptosis,  insensitivity 
to  antigrowth  signals,  limitless  replicative  potential,  self-sufficiency  in  growth  signals, 
sustained  angiogenesis  and  tissue  invasion/metastasis  (Hanahan  and  Weinberg,  2000).  The 
role  of  DNA  methylation  and  its  ability  to  affect  properties  such  as  these  has  been  widely 
reported  in  many  cancers,  including  ovarian  cancer.  Previous  work  has  shown  that  aberrant 
CGI  methylation  can  affect  a  number  of  key  genes  involved  in  multiple  biological 
pathways  in  FIGO  Stage  III  and  IV  ovarian  turnours  (Strathdee  et  al.,  2001).  Epigenetic 
changes  that  confer  these  types  of  traits  could  be  selected  for  during  tumourigenesis 
(Teodoridis  et  al.,  2004).  Examples  of  genes  which  have  been  shown  to  become 
epigenetically  silenced  in  many  cancers  including  ovarian  tumours  and  could  affect  the 
hallmarks  of  cancer  development  are  shown  below  in  Table  1. Catriona  Hardie,  2007  33 
KNOWN  GENE 
REGULATORY  CONSEQUENCE  OF  EXAMPLE  OF 
GENE  REFERENCE 
FUNCTION  EPIGENETIC  SILENCING  SILENCED 
APAF-1  (Furukawa  et  al.,  2005) 
CASP8  (Teitz  et  al.,  2000) 
DAPK  (Balana  et  al.,  2003) 
PERTURBED  DcR1*  (Shivapurkar  et  al.,  2004) 
APOPTOSIS  APOPTOTIC 
Fas 
ARF* 
(Hopkins-Donaldson  et  al.,  2003) 
2001  l 
MECHANISM  p14  ., 
)  (Hashiguchi  et  a 
p73*  (Strathdee  et  al.,  2001) 
RASSFIA*  (Yoon  et  al.,  2001) 
TMSI*  (Terasawa  et  al.,  2004) 
REPLICATION  LIMITLESS  PTEN*  (Yang  et  al.,  2006) 
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CANCER  I  II 
Table  1  Examples  and  biological  consequences  of  genes  which  are  epigenetically  silenced 
In  tumours.  Genes  highlighted  in  bold  print  are  those  reported  to  be  methylated  in  ovarian  tumours 
by  Teodoridis  et  al,  2005.  *indicates  studies  which  have  reported  methylation  of  these  genes 
specifically  in  ovarian  tumours  (and  references  shown).  All  other  genes  mentioned  have  been 
reported  to  be  methylated  in  other  tumour  types,  but  not  specifically  ovarian  cancer.  Other  genes 
which  have  been  reported  to  be  methylated  in  ovarian  cancer  are  shown,  although  their  specific 
function  remains  unknown. 
In  addition  to  the  evidence  that  specific  genes  become  methylated  and  silenced,  there  is 
also  some  evidence  to  support  the  concept  that  clusters  of  CGIs  can  become  co-methylated 
in  cancer,  giving  rise  to  a  "CpG  island  methylator  phenotype"  (CEMP).  This  idea  was 
originally  described  in  colorectal  cancer  (Toyota  et  al.,  1999a)  but  has  now  been  proposed 
in  a  variety  of  tumour  types  including  ovarian  cancer  (Strathdee  et  al.,  2001).  However, 
there  remains  controversy  over  whether  the  OUT  exists  at  all  (Anacleto  et  al.,  2005; 
Yamashita  et  al.,  2003),  and  if  it  does,  whether  it  may  exist  as  gradual  distributions  of 
methylation  (Eads  et  al.,  2001;  Rashid  et  al.,  2001)  rather  than  as  a  categorical  state 
(CIMP+ICM-).  The  most  recent  definition  of  CIMP,  using  an  unbiased  genome-wide 
method  of  analysis,  has  given  the  strongest  evidence  to  support  the  existence  of  a  distinct 
subset  of  tumours  with  a  methylator  phenotype  (Weisenberger  et  al.,  2006).  The  CIMP  was 
originally  thought  to  be  due  to  a  general  defect  in  the  methylation  machinery  but  it  remains Catriona  Hardie,  2007  34 
unclear  whether  there  is  an  underlying  biological  mechanism  for  the  concurrent 
methylation  changes  seen  in  multiple  tumour  suppressor  genes  in  cancer  (Issa,  2003).  One 
such  biological  mechanism  underlying  the  increased  methylation  which  has  been  described 
is  overexpression  of  DNMTs.  This  has  been  shown  recently  in  the  context  of 
overexpression  of  DNMT1  (Nakagawa  et  al.,  2005;  Peng  et  al.,  2006).  Changes  in 
expression  of  DNMTs  due  to  genetic  factors  may  potentially  be  a  cause  for  the  frequent 
methylation  seen  in  those  tumours  defined  as  having  a  CIMP  (De  Marzo  et  al.,  1999).  It 
has  been  shown  that  a  (-149  C>T)  single  nucleotide  polymorphism  (SNP)  can  affect  the 
transcription  of  DNMT3b.  An  association  of  this  SNP  and  methylation  levels  in  turnours 
including  lung  and  ovarian  type  may  exist  (Shen  et  al.,  2002;  Teodoridis  et  al.,  2005).  Most 
recently,  a  genetic  influence  has  also  been  described  in  a  distinct  subset  of  colorectal 
tumours  which  almost  all  had  BRAF  mutations  (Weisenberger  et  al.,  2006).  In  addition, 
factors  that  are  known  to  be  associated  with  methylation  of  CGIs  including  aging  (Ahuja  et 
al.,  1998;  Issa  et  al.,  1994),  chronic  inflammation  (Hsieh  et  al.,  1998;  Issa  et  al.,  2001),  and 
infective  factors  including  viral  infections  e.  g.  Epstein-Barr  Virus  (EBV)-associated  gastric 
carcinoma  (Kang  et  al.,  2002;  Osawa  et  al.,  2002)  and  bacterial  infections  e.  g. 
Helicobacter  pylori  dependent  mucosa  associated  lymphoid  tissue  (MALT)  lymphoma 
(Kaneko  et  al.,  2003)  may  all  potentially  influence  the  methylation  profile  of  tumours  and 
act  in  concert  with  genetic  factors  (Bjornsson  et  al.,  2004)  to  propensiate  a  CIMP. Catriona  Hardie,  2007  35 
1.5  The  impact  of  DNA  methylation  on  drug  resistance 
mechanisms  in  ovarian  cancer 
1.5.1  DNA  methylation  and  intrinsic  drug  resistance 
Drug  resistance  remains  a  major  problem  in  the  successful  treatment  of  patients  with 
ovarian  cancer.  Most  chemotherapeutic  drugs  used  in  patients  with  this  disease  target  stress 
on  rapidly  dividing  cells,  ultimately  leading  to  cell  death  through  apoptotic  mechanisms. 
Specifically,  platinum-based  drugs  form  inter-  and  intra-strand  crosslinks  following  their 
incorporation  into  DNA  (Kartalou  and  Essigmann,  2001).  These  adducts  are  recognised  by 
the  MMR  system  leading  to  apoptosis  and  cell  death  in  turnours  (Agarwal  and  Kaye, 
2003).  Taxanes  stabilise  tubulin,  causing  defective  spindle  formation,  G2/M  arrest  and 
subsequent  apoptosis  (Dumontet  and  Sikic,  1999).  Drug  resistant  turnour  cells  often 
possess  perturbed  proapoptotic  and/or  antiapoptotic  cellular  mechanisms  (Balch  et  al., 
2004).  Consequently,  the  mechanisms  by  which  chemotherapeutic  agents  will  lead  to 
turnour  regression  are  altered  and  therefore  this  leads  to  changes  in  the  response  to 
important  drugs.  Genes  involved  in  key  DNA  damage  response  pathways  including 
control  of  the  cell  cycle,  DNA  repair  and  apoptotic  signalling  can  frequently  become 
methylated  and  silenced  in  cancer  (Teodoridis  et  al.,  2004),  leading  to  such  defective 
mechanisms  in  cancer  cells.  These  epigenetic  changes  may  confer  opposing  effects  on  the 
intrinsic  sensitivity  of  ovarian  turnours  to  drugs  by  modulating  the  apoptotic  response. 
Methylation-mediated  epigenetic  silencing  of  genes  involved  in  DNA  repair  (including 
BRCAI,  MGMT  and  FANCF)  may  increase  chemosensitivity  of  tumours.  In  contrast,  this 
type  of  epigenetic  silencing  in  proapoptotic  genes  (including  OEM  and  APAF-1)  may  aid 
in  chemoresistance  mechanisms  (Esteller  et  al.,  2000a;  Glasspool  et  al.,  2006;  Soengas  et 
al.,  2001;  Taniguchi  et  al.,  2003).  Key  genes  involved  in  the  DNA  damage  response 
pathway  which  have  the  potential  to  be  epigenetically  silenced  in  ovarian  cancer  are 
illustrated  in  Figure  5.  There  have  been  many  reports  of  genes  which  are  downregulated  by 
epigenetic  mechanisms  in  ovarian  cancer  and  examples  of  these  have  been  previously 
shown  in  Table  1.  However,  it  is  important  to  decipher  from  the  myriad  of  epigenetically 
silenced  gene  signatures,  which  of  these  will  be  important  predictive  markers  of  disease 
response  to  treatment. Catriona  Hardie,  2007  36 
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Figure  5  Epigenetic  silencing  of  key  genes  in  ovarian  cancer  drug  resistance.  Methylation  of 
genes  (shown  in  red)  involved  in  key  DNA  damage  response  pathways  in  an  ovarian  cancer  cell. 
Methylation  of  genes  involved  in  the  DNA  repair  pathway  (pale  green),  including  BRCAI,  FANCF, 
MGMT,  or  drug  detoxification  (brown),  including  (GSTP1),  could  enhance  chemosensitivity  by 
blocking  the  ability  of  cell  to  survive.  Methylation  of  genes  involved  in  apoptotic  mechanisms  (dark 
green),  including  MLH1,  APAF-1  and  DAPK  could  enhance  cancer  cell  survival. 
BRCA  I  deficiency  in  mammary  epithelial  cells  and  breast  cancer  cell  lines  has  been  linked 
to  sensitivity  to  cisplatin  and  other  DNA  damaging  agents  in  vitro  (Sgagias  et  al.,  2004; 
Tassone  et  al.,  2003).  However,  although  frequent  methylation  of  BRCAI  has  been 
reported  in  ovarian  cancer  (Esteller  et  al.,  2000b;  Ibanez  de  Caceres  et  al.,  2004),  there 
have  been  no  additional  reports  suggesting  that  this  is  an  important  predictive  marker  of 
chemosensitivity  in  this  disease. 
MGMT  (06  -methylguanine-DNA  methyltransferase)  removes  methyl  groups  as  well  as 
larger  adducts  from  the  06  position  of  guanine.  The  alkylation  of  DNA  by  alkylating  agents 
at  this  position  of  guanine  is  associated  with  the  formation  of  mutations  in  DNA  (Gerson, 
2004).  However,  MGMT  removes  these  groups  and  inhibits  cancer  cell  death  induced  by 
such  agents.  CGI  methylation  of  MGMT  has  been  frequently  reported  in  cancers  including 
ovarian,  glioma  and  colorectal  cancer  (Dhillon  et  al.,  2004b;  Esteller  et  al.,  1999a;  Esteller Catriona  Hardie,  2007  37 
et  al.,  2000d).  This  mechanism  of  epigenetic  silencing  of  MGA1T  has  been  shown  to  be 
associated  with  response  in  other  tumour  types,  including  patients  treated  with 
temozolomide  in  combination  with  radiation  (Hegi  et  al.,  2004).  In  addition, 
hypermethylation  of  the  MGMT  promoter  also  correlated  with  increased  survival  of 
patients  with  diffuse  large  B-cell  lymphoma  after  chemotherapy  (Esteller  et  al.,  2002). 
GSTx  belongs  to  a  group  of  enzymes  which  detoxifies  carcinogens  and  therefore  reduces 
the  ability  of  these  types  of  compounds  to  damage  DNA  (Hayes  and  Strange,  2000). 
GSTPI  is  frequently  methylated  in  many  tumour  types  including  prostate  and  ovarian 
cancer  (Makarla  et  al.,  2005;  Perry  et  al.,  2006).  Epigenetic  silencing  of  GSTPI  may 
improve  chemosensitivity  by  preventing  detoxification  of  chemotherapeutic  agents.  The 
contribution  of  this  enzyme  family  to  chemoresistance  has  been  shown  in  vitro  (Perquin  et 
al.,  200  1). 
Epigenetic  alteration  of  another  gene,  FANCF,  involved  in  the  DNA  repair  complex 
containing  BRCAI  and  BRCA2  has  been  reported  in  ovarian  cancer  (Taniguchi  et  al., 
2003).  In  ovarian  cancer  cell  line  models,  methylation  of  FANCF  was  associated  with 
increased  cisplatin  sensitivity,  however,  FANCF  was  shown  to  become  demethylated  and 
re-expressed  during  the  acquisition  of  drug  resistance  in  ovarian  cancer  (Taniguchi  et  al., 
2003).  The  contribution  of  this  gene  to  acquired  drug  resistant  mechanisms  though  remains 
debatable. 
Methylation  of  pro-apoptotic  genes  may  be  a  causative  factor  in  drug  resistance  in  patients. 
Genes  involved  in  this  type  of  apoptotic  response  have  been  shown  to  be  methylated  in 
ovarian  cancer  (Strathdee  et  al.,  2001).  The  DNA  MMR  protein,  hNIIHI,  is  one  of  the 
most  well  characterised  proteins  involved  in  recognising  platinum-induced  damage 
(Papouli  et  al.,  2004).  Methylation  of  hMLHI  has  been  reported  in  many  tumour  types 
including  ovary  (Geisler  et  al.,  2003;  Strathdee  et  al.,  2001),  colon  (Cunningham  et  al., 
1998)  and  stomach  (Kitajima  et  al.,  2003).  Evidence  has  shown  that  hMLHI  is  required  for 
the  engagement  of  apoptosis  and  that  loss  of  hMI.  HI  protein  expression  could  be  a 
contributing  factor  to  platinum  resistance  (Anthoney  et  al.,  1996;  Brown  et  al.,  1997; 
Drummond  et  al.,  1996).  Coupling  to  cell  death  may  not  occur  when  expression  of  hMLHI 
is  lost  because  of  reduced  attempts  at  processing  06  -methylguanine  or  DNA  lesions  being 
bypassed  during  replication  (Karran  and  Hampson,  1996;  Moreland  et  al.,  1999). 
RASSFIA  is  another  example  of  a  pro-apoptotic  gene  which  is  frequently  methylated  in 
ovarian  turnours  (Yoon  et  al.,  2001).  This  gene  has  been  shown  to  be  methylated  through  a Catriona  Hardie,  2007  38 
"seeding  effect"  where  methylation  spreads  from  the  first  exon  into  the  promoter  region 
(Yan  et  al.,  2003).  In  this  study,  this  spreading  of  methylation  observed  appeared  to  be 
associated  with  tumour  progression  in  breast  cancer.  RASSFIA  binds  to  tubulin  and  leads 
to  the  stabilisation  of  microtubules  (Liu  et  al.,  2003).  This  is  the  target  of  taxane-based 
chemotherapy,  and  therefore,  methylation-induced  silencing  of  RASSFIA  could  abrogate 
this  effect. 
In  mammalian  cells,  nonreceptor-mediated  apoptosis  occurs  predominantly  via  the 
assembly  of  a  cytochrome  c-dependent  apoptosome  complex  containing  caspase-9  and 
apoptotic  protease-activating  factor-1  (APAF-1)  (Adams  and  Cory,  2002).  Dysfunctional 
activity  of  this  apoptotic  mechanism  has  been  implicated  in  ovarian  cancer  and  drug 
resistance  (Liu  et  al.,  2002).  Methylation  of  APAF-I  may  be  associated  with 
chemoresistance  in  other  cancer  types  including  leukaemia  and  melanoma  (Fu  et  al.,  2003; 
Soengas  et  al.,  2001).  Treatment  with  a  DNMT  inhibitor  was  shown  to  reverse  methylation 
and  both  restore  sensitivity  of  leukaemic  cells  to  LJV  light-induced  apoptosis  (Fu  et  al., 
2003),  and  increase  sensitivity  of  melanoma  to  doxorubicin  (Soengas  et  al.,  2001). 
It  is  evident  therefore  that  aberrant  epigenetic  alterations  in  key  genes  may  alter  drug 
response  in  patients  and  enable  the  clinical  prediction  of  outcome  following  chemotherapy. 
Defined  groups  of  genes  can  become  concordantly  methylated  in  ovarian  cancer  (Strathdee 
et  al.,  2001;  Wiley  et  al.,  2006)  which  supports  the  concept  of  the  CIMP,  and  epigenetic 
gene  silencing  in  drug  resistance  has  recently  been  defined  as  polygenic  (Glasspool  et  al., 
2006).  Therefore,  large  scale  genome  wide  analysis  will  enable  the  identification  of 
important  gene  signatures  which  are  predictive  of  disease  response  to  treatment.  A  recent 
study  has  shown  that  patients  with  late-stage  ovarian  tumours  can  be  clustered  into  two 
distinct  groups  based  on  differences  in  CGI  methylation  using  the  high  throughput  global 
technique,  differential  methylation  hybridisation  (DMH)  (Wei  et  al.,  2002).  Tumours  from 
the  group  of  patients  with  shorter  PFS  after  chemotherapy  displayed  higher  concurrent  CGI 
methylation.  This  study  indicates  that  distinct  hypermethylated  CGIs  may  be  important 
prognostic  markers  in  ovarian  cancer.  Other  recent  studies  have  also  shown  that  CIMT+ 
turnours  may  be  associated  with  worse  prognosis/prediction  in  many  cancers  including 
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1.5.2  DNA  methylation  and  acquired  drug  resistance 
The  majority  of  clinical  studies  into  drug  resistance  have  examined  tumour  characteristics 
in  chemonaive  turnours  rather  than  at  the  time  of  relapse  (Teodoridis  et  al.,  2004).  This 
allows  for  the  identification  of  intrinsic  resistance  markers  of  chemoresistance  in  ovarian 
cancer.  However  this  does  not  divulge  the  pathways  or enhance  our  understanding  of  the 
key  genes  which  are  potentially  selected  for  during  acquired  chemoresistance  mechanisms. 
Changes  in  DNA  methylation  may  occur  throughout  cancer  progression,  although  these 
changes  may  not  directly  impact  on  the  phenotype  of  an  ovarian  tumour  until  it  is 
challenged  with  chemotherapy.  Chemonaive  tumours  are  heterogeneous  consisting  of 
subpopulations  of  cells  with  varying  degrees  of  chemosensitivity.  It  has  been  suggested 
that  chemotherapy  may  exert  a  selective  pressure  on  epigenetically  silenced  drug 
sensitivity  genes  present  in  small  subpopulations  of  cells  and/or  may  be  due  to  regrowth  of 
a  cancer  stem  cell  population  in  the  tuniour  cell  environment.  These  can  then  lead  to 
acquired  resistance  alone  or  in  combination  and  a  chemoresistant  tumour  cell  population 
will  regrow  (Agarwal  and  Kaye,  2003).  Therefore,  analysis  of  tumour  at  relapse  will  allow 
for  the  identification  of  these  selected  subpopulations  of  cells. 
Studies  of  in  vitro  models  in  ovarian  cancer  have  shown  that  both  methylation  patterns 
(Wei  et  al.,  2003)  and  methylation  of  genes  individually,  such  as  hMLHI  (Strathdee  et  al., 
1999),  can  be  selected  for  during  chemotherapy.  A  study  in  breast  cancer  showed  that 
reduced  expression  of  the  hMLHI  protein  in  breast  tumour  following  neo-adjuvant 
chemotherapy  in  comparison  to  chemonaive  tumour  samples  was  associated  with  worse 
survival  in  patients  (Mackay  et  al.,  2000).  The  difficulty  in  obtaining  tumour  samples  at 
relapse  from  patients  with  ovarian  cancer  though  has  undoubtedly  impacted  on  the  lack  of 
studies  examining  clinical  acquired  resistance  for  this  disease.  Recently  though,  the  use  of 
plasma  DNA  to  detect  methylation  differences  in  patients  with  ovarian  cancer  has  been 
investigated  successfully  (Gifford  et  al.,  2004).  Methylation  of  the  hMLHI  CGI  was 
examined  in  blood  samples  from  patients  with  EOC  in  both  chemonaive  and  relapse 
samples.  Acquisition  of  hMLHI  methylation  following  chemotherapy  was  predictive  of 
poor  overall  survival  in  patients  with  this  disease  (Gifford  et  al.,  2004).  Therefore,  CGI 
methylation  would  appear  to  be  a  driving  force  behind  the  loss  of  hMLHI  expression  in 
cancer  and  other  genes  may  be  concomitantly  methylated.  Identification  of  these 
polyepigenetic  changes  in  plasma  may  therefore  provide  important  epigenetic  signatures 
during  treatment  and  allow  enrichment  for  patients  who  will  benefit  greatly  from 
epigenetic  treatments  that  lead  to  reversal  of  chemoresistance  (Lyko  and  Brown,  2005). Catriona  Hardie,  2007  40 
There  is  now  an  increasing  wealth  of  evidence  to  suggest  that  epigenetic  alterations  in  stem 
cells  may  be  inherently  linked  to  drug  resistant  properties  in  turnours  (Feinberg  et  al., 
2006).  The  high  incidence  of  relapse  attributable  to  multidrug  resistance  and  the  many 
histological  phenotypes  indicative  of  multipotency  suggests  that  there  may  be  a  stem  cell- 
like  aetiology  to  ovarian  cancer.  Stem  cells  may  only  comprise  a  very  small  proportion  of 
the  cells  within  a  turnour  and  be  relatively  quiescent,  therefore  avoiding  the  toxicity  of  the 
chemotherapy  regime  which  will  target  rapidly  dividing  cells  (Agarwal  and  Kaye,  2003). 
Survival  and  regrowth  of  a  cancer  stem  cell  population  has  been  suggested  to  be  involved 
in  acquired  drug  resistance  (Dean  et  al.,  2005).  Acquisition  of  methylation  post- 
chemotherapy  could  represent  survival,  growth  and  differentiation  of  cancer  stem  cells 
which  were  present  in  the  original  tumour  prior  to  treatment  with  chemotherapy  (Feinberg 
et  al.,  2006).  A  recent  study  has  identified  and  characterised  side  populations  of  cancer 
stem-like  cells  from  mouse  ovarian  cancer  cell  lines  (Szotek  et  al.,  2006).  These  side 
populations  were  found  to  form  measurable  turnours  sooner  than  other  populations,  and 
also  responded  less  well  when  treated  with  doxorubicin  (Szotek  et  al.,  2006).  In  addition, 
the  aggressive  nature  of  EOC  has  also  been  attributed  to  cancer  stem  cell  properties  (Bapat 
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1.6  DNA  methylation  as  an  early  diagnostic  marker  in 
ovarian  cancer 
Despite  advances  in  our  understanding  of  the  molecular  manifestations  of  ovarian  cancer, 
long-term  survival  rates  have  remained  relatively  static  over  the  last  three  decades 
(Bamholtz-Sloan  et  al.,  2003).  Current  modalities  which  are  used  to  detect  ovarian  cancer 
have  limited  success  i.  e.,  physical,  radiological  [Ultrasound  (US)  and  Computed 
Tomography(CT)]  and  biochemical  (CA-125)  assessment  (Bourne  et  al.,  1993;  Sato  et  al., 
2000;  van  Nagell  et  al.,  2000),  and  the  efficacy  of  developing  a  screening  test  for  this 
insidious  and  extremely  aggressive  malignancy  remains  unproven  (Rosenthal  et  al.,  2006). 
Novel  molecular  markers  and  methods  which  allow  the  early  detection  of  ovarian  cancer 
do  have  the  potential  to  impact  on  the  clinical  outcome  of  this  disease  and  improve  the 
current  poor  survival  rates.  The  efficacy  of  a  biomarker  assay  will  be  determined  by  its 
sensitivity  and  specificity.  For  population-based  screening  approaches,  these  are  precisely 
defined.  The  clinical  sensitivity  of  a  biomarker  refers  to  the  proportion  of  sub  ects  with 
confirmed  disease  who  test  positive,  whereas  its  specificity  refers  to  the  proportion  of 
healthy  control  subjects  who  test  negative  for  the  biomarker  being  used  (Pepe  et  al.,  2001). 
Early  detection  of  ovarian  cancer  will  require  a  high  degree  of  sensitivity  (75%)  and  a 
particulary  high  specificity  (99.6%)  to  achieve  an  acceptable  positive  predictive  value 
(Bast,  2003;  Jacobs  and  Menon,  2004).  Hypermethylation  of  CGIs  is  a  potentially 
attractive  marker  for  detecting  this  neoplasm,  and  detection  of  these  changes  have  been 
proposed  previously  as  a  potential  early  diagnostic  tool  in  cancer  (Esteller,  2003). 
In  order  to  use  a  biornarker  in  a  clinical  setting,  it  has  to  be  readily  detected  in  easily 
accessible  surrogate  body  sources  such  as  plasma.  Cancer-specific  methylation  patterns 
can  be  detected  in  free  DNA  released  from  dead  cancer  cells  (Jahr  et  al.,  2001;  Sidransky, 
2002),  and  this  free  DNA  is  thought  to  be  released  from  apoptotic  or  necrotic  tumour  cells 
(Jahr  et  al.,  2001).  It  has  already  been  shown  by  several  groups  that  CGI  methylation  can 
be  detected  in  plasma  with  the  same  characteristic  changes  as  are  found  in  the 
corresponding  tumour  (Esteller  et  al.,  1999b;  Gifford  et  al.,  2004;  Ibanez  de  Caceres  et  al., 
2004;  Weaver  et  al.,  2006),  and  that  this  is  therefore  a  promising  novel  biomarker. 
Additionally,  numerous  genes  have  been  shown  to  be  hypermethylated  in  cells  isolated 
from  other  bodily  fluids  including  urine,  serum,  sputum  and  stool  of  cancer  patients 
(Cairns,  2004;  Dulaimi  et  al.,  2004;  Sidransky,  2002;  Wang  et  al.,  2006b).  In  the  case  of 
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their  potential  use  as  a  diagnostic  tool  (Chang  et  al.,  2002).  In  contrast  to  cancerous  tissues, 
CGIs  in  normal  tissue  are  rarely  methylated  (Bird,  1986;  Hendrich  and  Bird,  2000), 
including  peripheral  blood  mononuclear  cells  (PBMC)  DNA  (Foyota  et  al.,  2001).  The 
development  of  exquisitely  sensitive  PCR-based  techniques,  in  particular  methylation- 
specific  PCR  (MSP)  (Herman  et  al.,  1996)  and  fluorescent-based  equivalents  (Gifford  et 
al.,  2004),  have  enabled  scientists  to  detect  aberrant  methylation  of  specific  genes  in  easily 
obtainable  samples  with  a  small  amount  of  turnour-derived  DNA  present  such  as  plasma 
(Ibanez  de  Caceres  et  al.,  2004).  This  is  feasible  because  these  types  of  PCR-based  assays 
can  detect  I  methylated  allele  in  1,000  unmethylated  alleles  (Herman  et  al.,  1996). 
Epirnutations,  specifically  CGI  methylation,  invariably  occur  in  the  same  region  of  a  gene 
promoter  (Baylin  et  al.,  2000),  which  is  in  contrast  to  genetic  mutations  which  can  often 
occur  in  a  variety  of  genetic  positions.  This  enables  high-throughput  analysis  of  these  types 
of  epigenetic  changes. 
DNA  methylation  has  merits  over  other  assays  which  rely  on  the  detection  of  RNA  or 
protein  markers,  for  several  reasons  (for  review  see  Levenson,  2004).  Firstly,  RNA  and 
protein  analytes  are  less  stable  than  DNA  and  this  instability  leads  to  a  requirement  of 
more  specific  precautions  for  sample  collection,  storage  and  analysis,  which  can  prove 
technically  challenging  in  a  clinical  setting.  DNA  in  clinical  samples  does  not  degrade  as 
easily  and  can  be  isolated  from  frozen  or  paraffin-embedded  tissues  and  then  easily 
amplified  using  PCR  techniques  (Crisan  and  Mattson,  1993;  Lehmann  and  Kreipe,  2001). 
DNA  methylation  itself  can  be  qualitatively  assessed  using  PCR  in  comparison  to  both 
protein  and  RNA  measurements  which  rely  on  quantitative  measures  and  further 
comparison  to  controls.  This  quantification  of  RNA  or  protein  becomes  more  complex  in 
heterogeneous  clinical  tissue  samples.  In  contrast,  DNA  methylation  analysis  will  give  a 
categorical  answer  and  is  a  cancer-specific  biomarker  (Laird,  2003). 
Tumour  heterogeneity  in  ovarian  cancer  means  that  groups  of  potentially  methylated 
markers  may  increase  the  sensitivity  and  specificity  of  such  a  biomarker  in  this  type  of 
cancer  (Levenson,  2004).  There  is  very  little  data  on  the  identification  of  groups  of 
methylated  CGIs  in  the  plasma  or  serum  of  patients  with  early  stage  ovarian  cancer. 
Recently  though,  one  group  have  encouragingly  identified  methylation  of  a  group  of  six 
genes,  including  BRCAI  and  RASSFIA,  in  early  stage  tumours  with  a  high  degree  of 
sensitivity  and  specificity  (Ibanez  de  Caceres  et  al.,  2004),  which  was  not  evident  in 
matched  normal/benign  controls.  BRCAI  or  RASSFIA  was  methylated  in  68%  of  ovarian 
tumour  samples,  but  by  additionally  examining  one  of  four  other  genes  (APC,  p144RF, 
pl6m"A  and  DAPK),  100%  of  tumour  samples  were  methylated.  Encouragingly,  95%  of Catriona  Hardie,  2007  43 
early  stage  tumours  had  detectable  levels  of  methylation  in  at  least  one  of  six  genes, 
confirming  that  hypermethylation  is  a  marker  of  early  stage  disease.  Matched  serum 
showed  identical  patterns  of  methylation  to  the  tumour  in  83%  of  samples.  This  is  an 
important  study  because  it  shows  that  ovarian  cancer  can  be  detected  in  serum  with  a 
specificity  of  100%  and  sensitivity  of  83%.  Further  studies  to  identify  other  useful  markers 
may  improve  the  sensitivity  of  the  test. 
In  addition  to  improving  early  diagnostic  and  chemotherapeutic  strategies,  we  also  need 
better  models  to  investigate  early  stage  disease.  Recent  work  indicates  that  epigenetic 
alterations  may  be  initiating  events  in  the  expansion  of  cells  in  preneoplastic  lesions 
(Baylin  and  Ohm,  2006;  Feinberg  and  Tycko,  2004).  However,  although  epigenetic 
alterations  contribute  to  the  pathogenesis  of  ovarian  cancer,  the  influences  of  these 
alterations  as  initiation  events  in  this  type  of  cancer  have  been  difficult  to  study. 
Methylation  of  specific  genes  alongside  coordinated  genetic  hits  has  been  shown  to 
potentially  drive  the  development  of  a  cancer  (Chen  et  al.,  2004;  Chen  et  al.,  2005a). 
Additionally,  multiple  epigenetic  hits  have  been  shown  to  be  potential  early  events  in  pre- 
cancerous  lesions/cells  prior  to  genetic  alterations  (Derks  et  al.,  2006;  Mei  et  al.,  2006; 
PiJnenborg  et  al.,  2006).  This  epigenetic  silencing  in  early  disease  may  even  addict  cancer 
cells  to  further  mutations  and  increase  the  likelihood  of  tumour  progression  (Baylin  and 
Ohm,  2006).  Further  to  this,  methylation  in  premalignant  breast  and  colorectal  tissue  has 
been  suggested  to  represent  a  field  defect,  perpetuating  further  neoplastic  change  (Shen  et 
al.,  2005;  Yan  et  al.,  2006).  Methylation  has  also  been  previously  shown  to  be  associated 
with  recognised  stress  such  as  inflammation  (Hsieh  et  al.,  1998)  or  chronic  injury  related  to 
infective  causes  (Maekita  et  al.,  2006).  A  complex  series  of  epimutations  may  occur  when 
ovarian  surface  epithelial  cells  are  placed  under  stress.  Recently,  a  group  have  addressed 
the  timing  of  all  of  these  types  of  events  using  a  mouse  model  of  cultured  mouse  ovarian 
surface  epithelium  to  understand  the  chronological  epigenetic  events  which  may  begin  at 
an  early  stage  of  neoplasia,  in  the  ovary  (Roberts  et  al.,  2005). 
There  is  also  recent  opinion  to  suggest  that  epimutations  of  stem  cells  may  be  the  initiating 
progenitor  event  in  turnourigenesis  (Feinberg  et  al.,  2006).  This  has  been  suggested  to 
occur  in  three  steps  involving  epigenetic  interference  of  stem  cells,  an  initiating  mutation 
event  and  thereafter  genetic  and  epigenetic  plasticity  of  cells  (Feinberg  et  al.,  2006).  The 
concept  of  an  initiating  epimutation  in  stem  cells  can  be  supported  by  previous  work. 
Turnour-related  growth  has  been  shown  to  be  stable  but  reversible  in  vitro  (Lotern  and 
Sachs,  2002)  and  DNA  methylation  is  inherited  through  cell  division  (Lorincz  et  al.,  2002). 
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nucleus  can  differentiate  into  multiple  cell  types  and  that  the  phenotypic  properties  of 
cancer  are  reversible,  suggesting  a  largely  epigenetic  code  (Hochedlinger  et  al.,  2004). 
Also,  a  small  subpopulation  of  stem  cells  in  a  brain  tumour  can  propagate  a  cancer 
phenotype  when  consecutively  transmitted  from  mouse  to  mouse  (Singh  et  al.,  2003). Catriona  Hardie,  2007  45 
1.7  Methods  of  detecting  DNA  methylation  and  epigenetic 
alterations  in  cancer 
There  are  a  wide  variety  of  methodologies  which  can  be  applied  to  obtain  DNA 
methylation  data.  The  detection  of  this  epigenetic  alteration  is  based  on  the  ability  to 
differentiate  between  cytosine  and  5-methylcytosine  in  the  DNA  sequence.  There  are  three 
principal  approaches  to  detect  this  difference  in  methylation.  These  involve:  (1)  the  use  of 
the  chemical  modification  of  DNA  with  sodium  bisulphite,  (2)  digestion  of  DNA  with 
either  a  methylation-sensitive  or  -insensitive  restriction  enzyme,  or  (3) 
immunoprecipitation  of  5-methylcytosine  to  distinguish  any  methylated  fractions.  The 
study  of  DNA  methylation  changes  has  been  at  the  forefront  of  epigenetic  research  since 
the  initial  application  of  sodium  bisulphite  conversion  of  genomic  DNA  in  conjunction 
with  PCR  amplification  and  sequencing  (Frommer  et  al.,  1992).  Sodium  bisulphite 
conversion  relies  on  the  differential  deamination  of  cytosine  to  uracil  without  affecting  5- 
methylcytosine  content  as  shown  below  in  Figure  6.  This  conversion  will  produce  a 
difference  in  DNA  sequence,  which  depends  on  the  sequence's  original  methylation  status. 
Methylated 
CACGCCCGCGCCT 
GTGCGGGCGCGGA 
I 
SODIUM  BISULPHITE 
CONVERSION 
UACGUUCGCGUUT 
GTGCGGGCGCGGA 
METHYLATION-BASED  PCR 
I 
TECHNIQUE 
UACGUUCGCGUUT 
ATGCAAGCGCAAA 
METHYLATED. 
SPECIFIC  PRIMERS 
GTGCGGGCGCGGA 
Unmethylated 
CACGCCCGCGCCT 
GTGCGGGCGCGGA 
I 
UAuGUUý-'-UUT 
GTG: 
-  :;  GG  --  ,  GA 
I 
UAu(-,  UUU3uGUUT 
ATACAAACACAAA 
UNMETHYLATED- 
SPECIFIC  PRIMERS 
GTGUGGGUGUGGA 
Figure  6  Principles  of  sodium  bisulphite  conversion  and  subsequent  PCR-based  analysis  of 
DNA.  DNA  is  modified  with  sodium  bisulphite  in  a  methylation-dependent  way  prior  to  PCR 
amplification.  Methylated  cytosines  (red)  remain  unconverted,  whereas  unmethylated  cytosines  are 
converted  to  uracils  (green),  resulting  in  a  difference  in  DNA  sequence.  The  converted  strands  of 
DNA  are  no  longer  complementary,  and  amplification  of  either  strand  (top  strand  shown  above) 
requires  primers  which  are  specific  for  the  methylated  sequence  (blue)  or  the  unmethylated 
sequence  (purple). Catriona  Hardie,  2007  46 
Many  DNA  methylation  assays  will  involve  at  least  one  PCR  step.  The  difference  in 
sequence  which  is  apparent  following  sodium  bisulphite  treatment  can  be  used  to  design 
PCR  primers  which  will  either  amplify  a  region  depending  on  its  methylation  status  or 
alternatively  amplify  a  pool  of  unmethylated  and  methylated  products  as  shown  below  in 
Figure  7. 
(A)  M  ETHYLATION  -SPEC  I  FIC  PRIMING 
M-F  PRIMER  M-R  PRIMER 
BIND  TO  M-CpGs 
U-F  PRIMER  U-R  PRIMER 
BIND  TO  U-CpGs 
(B)  NON-METHYLATION-SPECIFIC  PRIMING 
F  PRIMER  R  PRIMER 
BIND  TO  NON-CpG  SITES 
Figure  7  Design  of  primers  following  sodium  bisulphite  conversion  of  DNA.  (A)  Methylation- 
specific  amplification  using  forward  (F)  and  reverse  (R)  primers  designed  to  anneal  to  a  sequence 
with  either  complementary  methylated  (M)  CpGs  or  unmethylated  (U)  CpGs.  (B)  Alternatively,  non- 
methylation-specific  priming  of  either  M  or  U  sequences  can  be  attained  using  F  and  R  primers 
which  attach  outwith  the  methylation-differential  part  of  the  sequence  and  will  amplify  DNA 
regardless  of  its  methylation  status. 
Established  methods  using  the  initial  bisulphite  conversion  of  DNA  described  above 
include  MSP  (Herman  et  al.,  1996),  bisulphite  sequencing  (Frommer  et  al.,  1992), 
combined  bisulphite  restriction  analysis  (COBRA)  (Xiong  and  Laird,  1997)  and,  more 
recently,  pyrosequencing  (Ronaghi  et  al.,  1996).  MSP  is  a  highly  sensitive,  qualitative 
technique,  which  can  detect  a  small  proportion  of  methylated  alleles  in  a  heterogeneous 
sample,  and  has  been  the  most  widely  accepted  method  of  analysing  CGI  methylation  for 
many  years  (Derks  et  al.,  2004;  Herman  et  al.,  1996).  It  uses  primers  which  are  designed  to Catriona  Hardie,  2007  47 
anneal  either  to  the  methylated  or  unmethylated  sequence  (Figure  7A)  and  has  had  a 
significant  bearing  on  our  understanding  of  epigenetics  events  in  many  types  of  cancer 
including  ovarian  (Shames  et  al.,  2007).  This  is  a  reflection  of  its  accessibility  and  ease  of 
use  in  many  laboratories  (Laird,  2003),  which  is  of  considerable  importance  when 
considering  the  application  of  a  method.  Although  MSP  remains  a  common  assay  used  to 
detect  new  epigenetic  markers  in  cancer,  it  is  acknowledged  that  this  technique  will  only 
produce  a  result  as  categorical  information  (either  methylated  or  unmethylated).  Bisulphite 
sequencing  and  COBRA  provide  more  quantitative  information  using  PCR-primers  which 
do  not  cover  any  potentially  methylated  CpG  sites  (Figure  7B).  Amplification  generates  a 
pool  of  products  with  variable  methylation  states.  COBRA  relies  on  a  methylation- 
sensitive  restriction  enzyme  digest  to  provide  a  quantitative  assessment  of  the  methylation 
status  of  individual  CpG  sites  but  is  not  suited  to  multiplex  reactions.  Bisulphite 
sequencing  has  the  disadvantage  of  being  very  labour  intensive,  and  has  now  been  widely 
replaced  with  a  bisulphite  sequencing  technique  known  as  Pyrosequencing  (Ronaghi  et  al., 
1996;  Ronaghi  et  al.,  1998)  which  can  quantitate  CpG  methylation  at  individual  sites 
following  bisulphite  treatment  (Tost  and  Gut,  2006).  This  sequencing  by  synthesis  based 
technique  involves  the  luminometric  detection  of  pyrophosphate  following  sequential 
single  nucleotide  incorporation.  Pyrosequencing  allows  the  detection  of  up  to  10  CpG  sites 
spanning  an  80-nucleotide  stretch  in  a  single  run  (Tost  and  Gut  2006).  The  main 
advantages  of  this  new  technology  over  traditional  sequencing  methods  are  that  it  is  a  very 
quick  and  efficient  quantitative  method,  it  uses  a  PCR  product  to  directly  obtain 
information,  without  the  requirement  of  cloning  and  multiple  sequencing  reactions,  and  it 
can  be  run  in  multiplex  fashion. 
The  second  approach,  which  detects  methylation  using  enzyme-based  differences, 
historically  involved  Southern  Blot  analysis  (Reed  et  al.,  1996),  but  more  recently  there  has 
been  a  surge  of  interest  in  developing  techniques  which  can  examine  genome-wide 
epigenetic  alterations  in  cancer.  Restriction  landmark  genomic  scanning  (RLGS)  is  one 
such  enzyme-based  technique  which  has  been  used  to  assess  global  CGI  methylation  in 
tumours  (Costello  et  al.,  2002).  The  study  of  global  DNA  methylation  alterations  at  the 
CGI  level  can  also  be  achieved  using  CGI  arrays.  Differential  methylation  hybridisation 
(DME)  was  the  first  technique  of  this  kind  which  was  used  to  assemble  an  array-based 
DNA  methylation  assay  (Huang  et  al.,  1999;  Yan  et  al.,  2001),  and  has  been  successfully 
used  to  detect  such  alterations  in  breast  and  ovarian  cancer. 
The  third  approach  uses  anti-methylcytosine  antibodies  to  enrich  for  methylated  sequences. 
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(MeDIP),  and  has  been  used  in  conjunction  with  a  comparative  genomic  hybridisation 
(CGH)  microarray  (Weber  et  al.,  2005).  This  allows  simultaneous  assessment  of 
methylation  status  and  copy  number. 
Analysis  of  methylation  on  a  global  scale  using  robust  high  throughput  platforms  still 
represents  a  significant  challenge.  Most  recently,  methylation  profiling  has  involved  the 
use  of  novel  technologies  such  as  universal  bead  arrays  (Bibikova  et  al.,  2006),  promoter- 
associated  methylated  DNA  amplification  DNA  chip  (PMAD)  (Fukasawa  et  al.,  2006),  and 
quantitative  assays  such  as  bio-COBRA  (COBRA  coupled  with  the  Agilent  2100 
Bioanalyser  platform)  (Brena  et  al.,  2006)  and  COMPARE-MS  (combination  of 
methylated-DNA  precipitation  and  methylation-sensitive  restriction  enzymes) 
(Yegnasubramanian  et  al.,  2006). 
There  are  limitations  in  any  of  the  methodologies  described  which  means  that  no  single 
method  is  unanimously  better  than  another  to  examine  methylation  changes.  Methods  vary 
in  how  sensitive  they  are  to  detect  methylation  differences,  their  ability  to  quantitate 
methylation  and  their  potential  application  in  different  tissues  and  preparations  (e.  g. 
paraffin-embedded  versus  snap  frozen  tissue)  (Laird,  2003).  Additionally,  the  potential  to 
make  comparisons  and  interpret  different  datasets  originating  from  a  variety  of 
methodologies  is  difficult.  For  instance,  many  studies  will  use  variable  conditions  for  the 
same  methodologies,  such  as  altered  PCR  cycling  numbers,  which  can  change  the 
threshold  of  a  positive  result  e.  g.  investigation  of  CGI  methylation  of  FANCF  (Taniguchi 
et  al.,  2003;  Teodoridis  et  al.,  2005).  Studies  may  also  amplify  different  promoter  regions 
of  a  gene  which  could  lead  to  discrepancies  in  results  obtained  depending  on  methylation 
status.  Techniques  which  rely  on  restriction  enzyme  digests  (e.  g.  COBRA,  RLGS  and 
DMH)  are  limited  by  the  sites  available  for  methylation-sensitive  enzymes  and  the  digest 
efficiency,  as  incomplete  digestion  could  lead  to  false  positive  results.  Additionally,  care 
must  be  taken  in  the  interpretation  of  data  from  CGI  libraries  used  in  microarray-based 
experiments  as  more  than  80%  of  all  CGIs  are  not  related  to  genes  and  are  not  likely  to  be 
involved  in  the  regulation  of  gene  expression  (Takai  and  Jones,  2002). 
Ultimately,  the  scientist's  method  of  choice  will  depend  on  how  the  technology  is  to  be 
applied  (Laird,  2003),  but  carefully  validated  data  using  an  independent  method  will  be  of 
utmost  importance.  The  application  of  these  novel  tools  in  clinical  research  for  genome- 
wide  analysis  of  methylation  will  be  critical  in  ovarian  cancer.  It  will  not  only  allow  the 
identification  of  novel  methylation  targets,  but  will  also  enable  assessment  of  the 
effectiveness  and  safety  of  regimes  which  can  reverse  methylation  and  identify  patients  for Catriona  Hardie,  2007  49 
whom  it  may  be  advantageous  to  treat  with  novel  epigenetic  therapies  (Lyko  and  Brown, 
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1.8  The  therapeutic  implications  of  DNA  methylation 
Aberrant  CGI  hypermethylation  requires  an  active  mechanism  for  its  maintenance  during 
cell  proliferation  in  cancer.  Therefore,  this  type  of  epimutation  is  pharmacologically 
reversible  by  small  molecule  inhibitors,  which  makes  it  an  attractive  focus  for  the 
development  of  novel  epigenetic  therapies  in  cancer  (Egger  et  al.,  2004;  Yoo  and  Jones, 
2006).  In  vitro  work  has  shown  that  double  inactivation  of  DNMTI  and  DNMT3b  in  a 
colon  cancer  cell  line  reduces  cell  growth  and  reverses  global  methylation  of  previously 
dormant  turnour  suppressor  genes  (Paz  et  al.,  2003;  Rhee  et  al.,  2002).  Inhibition  of  this 
family  of  enzymes  in  cancer  could  lead  to  suppression  of  the  growth  of  a  tumour  or 
increase  the  ability  of  turnour  cells  to  undergo  apoptosis  induced  by  chemotherapeutic 
agents  and  hence  overcome  drug  resistance  (Teodoridis  et  al.,  2004).  The  DNMT  family  of 
enzymes  are  recognised  as  potential  targets  for  the  development  of  epigenetic  therapies. 
Inhibitors  of  these  enzymes  represent  the  most  widely  studied  demethylating  agents  in 
phase  I-III  clinical  trails  (Lyko  and  Brown,  2005).  Several  small  molecule  drugs  which  are 
nucleoside  analogues  of  2'-deoxycytidine  have  been  studied.  These  potent  inhibitors  of 
DNA  methylation  include  the  prototype  5-azacytidine  (5-azaC)  and  the  deoxyribose 
analogue  of  5-azaC,  known  as  5-aza-2'-deoxycytidine  (DAC,  Decitabine).  These  are 
incorporated  into  the  DNA  and  trap  DNMTs  during  movement  of  the  replication  fork 
(Lyko  and  Brown,  2005).  This  leads  to  passive  demethylation  of  nascent  DNA  and  re- 
activation  of  epigenetically  silenced  tumour  suppressor  genes.  5-aza-C  and  DAC  have  been 
used  to  inhibit  DNMTs  and  reverse  methylation  in  tissue  culture  work  for  many  years 
(Brown  and  Plumb,  2004).  In  the  clinical  setting,  DNMT  inhibitors  have  been  studied  most 
intensely  with  regard  to  treatment  of  haernatological  malignancies  (Issa  et  al.,  2004; 
Lubbert,  2000).  The  originally  described  DNMT  inhibitor  5-azaC  (Vidaza(&)  was  first 
approved  by  the  Food  and  Drug  Administration  (FDA)  for  use  in  myelodysplastic 
syndrome  (Kaminskas  et  al.,  2005),  and  more  recently,  5-aza-2'-deoxycytidine 
(Decitabine,  DacogenS)  has  also  gained  FDA  approval  for  use. 
The  use  of  these  types  of  nucleoside  analogues  in  clinical  trials  have  been  hindered  by  their 
innate  cytotoxic  side  effects  including  thrombocytopenia  and  neutropenia.  These  side 
effects  are  most  likely  due  to  cytotoxicity  associated  with  drug  incorporation  into  DNA 
independent  of  their  DNA-hypomethylating  value  (Esteller,  2005).  Indeed,  the  in  vitro 
effect  of  decitabine  at  higher  concentrations  has  been  shown  to  produce  less  differentiation 
and  more  cytotoxicity  (Taylor  and  Jones,  1979).  Higher  doses  of  these  DNA- 
demethylating  drugs  have  cytotoxic  actions  which  are  independent  of  their  ability  to  cause Catriona  Hardie,  2007  51 
hypomethylation,  but  if  the  dose  is lowered,  they  are  more  dependent  on  their  role  to  re- 
express  epigenetically  silenced  genes.  Therefore,  it  may  be  more  appropriate  to  use  lower 
dose  scheduling  as  shown  for  haernatological  malignancies  (Issa  et  al.,  2004)  which  will 
reduce  myelosuppressive  side-effects.  However,  although  these  drugs  have  shown  promise 
as  single  demethylating  agents  in  haernatological  malignancies,  their  use  in  the  treatment 
of  patients  with  solid  tumours  remains  disappointing  (Glasspool  et  al.,  2006).  The  disparity 
seen  between  these  different  types  of  malignancy  may  be  due  to  differing  pharmacokinetic 
and  pharmacodynamic  mechanisms  in  solid  and  haernatological  malignancies.  Therefore, 
to  improve  use  in  solid  malignancies,  combination  with  currently  used  cytotoxics  or  more 
novel  epigenetic  therapies  may  be  best. 
The  re-expression  of  genes  following  the  use  of  a  demethylating  agent  is  not  finite,  and 
following  a  period  of  time,  genes  will  become  silenced  again  by  methylation  (Bender  et  al., 
1999).  The  reactivation  of  multiple  tumour  suppressor  genes  could  enhance  the  action  of 
other  chemotherapeutic  agents  used  within  a  certain  time  frame,  thereby  increasing 
apoptosis  in  cells  induced  by  DNA  damaging  agents  and  overcoming  drug  resistance 
(Teodoridis  et  al.,  2004).  Decitabine  has  been  shown  to  cause  demethylation  and  re- 
expression  of  the  hMLHI  gene  (maximal  effect  at  day  9)  which  sensitises  drug  resistant 
tumour  xenografts  grown  in  nude  mice  to  a  range  of  cytotoxic  chemotherapeutic  drugs, 
including  carboplatin  (Plumb  et  al.,  2000).  This  re-sensitisation  shown  to  conventional 
cytotoxic  drugs  may  be  particularly  useful  in  tackling  the  management  of  patients  with 
drug  resistant  ovarian  cancer.  Crucial  histone  modifications  in  the  promoter  regions  of 
genes  silenced  through  methylation  have  also  been  shown  (Fahmer  et  al.,  2002;  Kondo  et 
al.,  2003).  The  combination  of  an  HDAC  inhibitor  and  a  demethylating  agent  have  been 
shown  to  enhance  re-expression  of  epigenetically  silenced  genes  compared  to  the  use  of 
either  drug  alone  (Cameron  et  al.,  1999;  Gore  et  al.,  2006).  Together,  these  drugs  can  also 
lead  to  enhanced  sensitivity  to  chernotherapeutics  in  cell  lines  and  increase  the  antiturnour 
effect  seen  (Boivin  et  al.,  2002). 
If  novel  epigenetic  agents  are  to  be  used  in  a  clinical  setting,  stratification  of  patient 
populations  will  be  required.  Methylation  of  particular  genes,  such  as  the  DNA  repair 
genes,  may  bestow  enhanced  chemosensitivity  in  some  patients,  and  therefore  it  may  be 
inappropriate  to  treat  these  patients  with  agents  which  will  reverse  the  methylation  status 
and  reduce  their  sensitivity.  Concurrently,  some  patients  may  be  chemosensitised  with 
epigenetic  therapies  (Teodoridis  et  al.,  2004).  Additionally,  it  has  also  been  shown  that 
genes  with  metastasis-related  functions  such  as  synuclein-y  (Gupta  et  al.,  2003)  can 
become  epigenetically  upregulated  through  hypornethylation  and  subsequently Catriona  Hardie,  2007  52 
overexpressed  in  aggressive  turnour  types.  Therefore,  in  order  to  identify  appropriate 
patients,  robust  technology  and  better  pharmacodynamic  endpoints  will  be  required  (Lyko 
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1.9  Specific  aims  and  approaches  of  this  research 
project 
The  specific  airns  of  this  research  project: 
To  investigate  if  methylation  patterns  in  primary  EOC  can  predict  response  to 
chemotherapy. 
To  identify  DNA  methylation  markers  for  acquired  cisplatin  chemoresistance  in  an 
ovarian  cancer  model  system. 
To  investigate  if  aberrant  DNA  methylation  is  an  early  event  in  ovarian 
tumourigenesis  and  if  it  has  potential  use  as  an  early  detection  marker  in  plasma. 
The  approaches  used  to  reach  these  aims: 
24  CGIs  were  analysed  in  a  group  of  late  stage  EOCs  (FIGO  Stage  III/IV). 
Association  of  methylation  with  response  was  analysed  by  grouping  of  genes 
according  to  their  biological  function. 
DMH  was  performed  on  a  panel  of  16  ovarian  cancer  cell  lines  (6  cisplatin- 
sensitive  and  10  cisplatin-resistant).  2  CGIs  close  to  known  genes  were  analysed  in 
EOC  specimens. 
15  CGIs  were  analysed  in  a  group  of  early  stage  EOCs  (FIGO  Stage  I/Il)  and  the 
most  frequently  methylated  CGIs  were  analysed  in  plasma. Catriona  Hardie,  2007 
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2  Materials  and  Methods 
2.1  General  equipment 
Casy-I  haernocytorneter  Scharfie  System 
CR422  centrifuge  Jouan 
Gilson  Pipettes  Anachem 
Heating  block  Dri-Block  DB  2A  Techne 
Incubator  (37'C)  Genlab 
Innova  4000  incubator  shaker  New  Brunswick  Scientific 
Microcentaur  microcentrifuge,  MSE  and  EBA12  Rettich  Zentrifugen 
Microwave  Sanyo 
Nanodrop  ND-1000  spectrophotometer  LabTech 
PCR  workstation  Labcalre 
Rocking  Table  Luckham 
Set  of  scales  PM  300  Mettler 
Tetrad  DNA  Engine  PTC  225  MJResearch 
Vortex  Whirlmixer  Fisons 
Water  bath  SUB36  Grant 
2.2  General  chemicals 
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All  chemicals  were  of  the  highest  quality  available  and  were  supplied  by  Sigma  unless 
otherwise  stated. 
2.3  General  glass  and  plasticware 
Bijous  (5ml) 
Eppendorf  tubes  (1.5ml) 
Falcon  tubes  (I  5ml  and  50ml) 
Glass  pipettes  (5,10,25ml) 
Pasteur  pipettes 
Bibby-Sterilin  Limited 
EppendorfAG 
Becton  Dickinson  Labware Catriona  Hardie,  2007 
Sterile  Pipette  filter  tips  (10,20,200,1  000pl) 
Universals  (20ml) 
Universal  containers  (30ml  and  100ml) 
Greiner  bio-one 
Bibby-Steriline  Limited 
Sterilin 
2.4  Patient  samples  and  characteristics 
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Tumour  samples  were  collected  from  chemonaive  patients  undergoing  cytoreductive 
surgery  for  suspected  ovarian  cancer.  Matched  blood  samples  were  collected  from  a 
number  of  patients  in  the  prospective  "DNA  Methylation  Study"  at  the  time  of  admission 
to  hospital  for  surgery.  Only  those  patients  with  pathologically  confirmed  EOC  were 
included  in  the  analysis.  Ethical  approval  for  all  samples  collected  was  obtained  from 
relevant  authorities  and  samples  were  collected  according  to  Medical  Research  Council 
operational  and  ethical  guidelines  on  "Human  tissue  and  biological  samples  for  use  in 
research".  All  tumour  and  separated  blood  samples  were  stored  at  -70'C  until  required  for 
analysis.  Pathology  reports,  including  histological  subtype  and  grade,  were  obtained  where 
possible. 
Reasonably  complete  clinical  data  sets  were  available  for  the  following  clinical  factors: 
FIGO  stage  at  diagnosis,  age,  performance  status  (PS)  and  size  of  residual  disease  at 
primary  surgical  procedure.  These  data  were  collected  prospectively  through  the  Clinical 
Trials  Unit.  Stage  was  categorised  using  FIGO  criteria  into  early  (Stage  I/II)  versus  late 
(Stage  III/IV),  age  was  categorised  on  the  median  value,  PS  was  classified  as  0,1  or  2/3 
and  residual  disease  as:  52cm  or  >2cm. 
PFS  was  defined  as  the  time  from  first  chemotherapy  or  date  of  entry  onto  trial  (within  6 
weeks  of  surgery)  until  date  of  second  line  chemotherapy  or  progression  or  cancer  related 
death.  Progression  was  defined  as  either  a  ý:  25%  increase  in  size  of  at  least  one 
measureable  lesion,  worsening  previously  evaluable  disease,  recurrence  of  a  previously 
successfully  treated  lesion  or  appearance  of  a  new  lesion  as  measured  on  CT  scan.  Overall 
survival  (OS)  was  calculated  from  the  date  of  first  chemotherapy  or  date  of  entry  onto  trial 
until  the  date  of  cancer  related  death.  Response  to  chemotherapy  was  measured  in  all 
patients  that  had  evaluable  disease  Le  had  measurable  disease  following  cytoreductive 
surgery  prior  to  chemotherapy.  This  was  done  anonymously,  blinded  to  the  methylation 
status  of  each  patient  and  response  was  defined  by  modified  Southwest  Oncology  Group 
(SWOG)  criteria  (Vasey  et  al.,  2004).  Patients  who  were  evaluable  for  response  to Catriona  Hardie,  2007  57 
chemotherapy  were  classified  into  two  groups:  responders  were  those  with  complete 
response  (CR)  or  partial  response  (PR)  and  non-responders  were  those  with  stable  disease 
(SD)  or  progressive  disease  (PD). 
2.5  DNA  extraction  from  ovarian  tissue  samples 
2.5.1  Materials 
100%  ethanol 
Microdismembrator  II 
Mortar  and  pestle 
Phenol  and  chloroform:  isoamyl  alcohol  (24:  1) 
3M  sodium  acetate 
B.  Braun 
2.5.2  Recipe 
Lysis  Buffer 
0.3M  sodium  acetate  (pH  8.0) 
0.5%  SDS 
5mM  EDTA 
50pg/ml  proteinase  K 
2.5.3  Method 
Genomic  DNA  was  isolated  from  ovarian  tissue  samples  by  crushing  frozen  samples  with 
a  mortar  and  pestle.  Samples  were  then  powdered  with  a  microdismembrator  11,  lysed  in 
10ml  of  lysis  buffer  and  shaken  overnight  at  37T.  Proteins  were  extracted  with  phenol  and 
chloroform:  isoamyl  alcohol  (24:  1)  and  DNA  was  then  precipitated  in  1:  10  volume  of  3M 
sodium  acetate  and  2  volumes  of  100%  ethanol. Catriona  Hardie,  2007 
2.6  Separation  of  plasma  and  PBMCs  from  whole  blood 
2.6.1  Materials 
EDTA  vacutainers 
Histopaque-1077 
Greiner  Bio-one 
Sigma-Aldrich 
2.6.2  Method 
58 
Two  EDTA  vacutainers  per  patient  containing  10ml  whole  blood  were  received  and 
processed  within  2  hours  and  accurately  logged  with  time/date  of  sample  collection. 
Plasma  was  separated  by  centrifuging  an  EDTA  vacutainer  at  1500xg  at  20'C  for  10 
minutes,  aspirating  the  supernatant  into  a  15ml  Falcon  tube  and  then  repeating  the 
centrifugation  step  under  the  same  conditions.  The  plasma  was  then  aliquoted  into  2 
labelled  1.5ml  centrifugation  tubes  and  frozen  at  -70*C.  To  separate  PBMCs,  3ml  of  whole 
blood  was  layered  onto  3ml  of  Histopaque-1077  in  a  15ml  Falcon  tube  and  centrifuged  at 
400xg  for  30  minutes  at  room  temperature  with  the  centrifuge  brake  off.  The  upper  phase 
was  discarded  and  the  opaque  interface  containing  the  PBMCs  was  transferred  to  a  fresh 
15ml  Falcon  tube  and  suspended  in  10ml  of  PBS  (see  Chapter  ZI72  for  PBS  recipe).  This 
was  then  centrifuged  at  250xg  for  10  minutes  at  room  temperature  with  the  centrifuge 
brake  low  (-2)  and  the  cell  pellet  was  resuspended  in  5ml  of  PBS  and  centrifuged  again  at 
250xg.  The  cell  pellet  was  then  resuspended  in  0.5ml  of  PBS  and  stored  as  above  for 
plasma. 
.1 
2.7  Extraction  of  DNA  from  plasma  and  PBMCs 
2.7.1  Materials 
Ethanol 
QlAamp  DNA  Blood  Mini  Kit  (Kit  size  50)  Qiagen 
RNase  A  (100mg/ml)  Qiagen Catriona  Hardie,  2007  59 
2.7.2  Method 
DNA  was  extracted  and  purified  using  the  QIAwnp  DNA  Blood  Mini  Kit  according  to 
manufacturer's  instructions.  Buffer  AWI,  AW2  and  Q[Agen  protease  were  prepared 
according  to  the  manufacturers  instructions  and  all  centrifugation  steps  were  performed  at 
6000xg  at  room  temperature  unless  otherwise  stated  below.  Iml  plasma/0.5ml  PBMCs 
were  thawed  and  PBMCs  were  spun  down  and  resuspended  in  200AI  PBS.  Samples  were 
lysed  and  ethanol  precipitated  by  adding  20pl/4gl  of  RNase  A  and  125pl/25[tl  of  QIAgen 
Protease  to  the  plasma  and  PBMCs  respectively.  Iml/200PI  of  Buffer  AL  was  added  and 
samples  were  incubated  at  56T  in  a  water  bath  for  10  minutes  and  briefly  centrifuged. 
1050gl/210pt  of  100%  ethanol  was  added,  pulse  vortexed  and  briefly  centrifuged  to 
complete  the  precipitation  step.  The  precipitated  material  was  bound  to  a  QIAamp  spin 
column  and  centrifuged  for  I  minute  at  high  speed  in  a  benchtop-centrifuge  (filtrate 
discarded).  Samples  were  washed  in  500gI  of  Buffer  AW1  and  centrifuged  for  I  minute 
(filtrate  discarded).  500gl  of  Buffer  AW2  was  added  and  centrifuged  for  3  minutes  at  full 
speed  (filtrate  discarded)  and  then  centrifuged  at  full  speed  for  a  further  I  minute.  DNA 
was  eluted  by  adding  200pl  of  Buffer  AE,  incubating  at  room  temperature  for  5  minutes 
and  then  centrifuging  at  6000xg  for  I  minute.  The  eluted  sample  was  pipetted  into  the 
same  spin  column  and  incubated  for  5  minutes  and  centrifuged  for  I  minute  as  before.  To 
complete  the  elution,  this  was  repeated  five  times  for  plasma  and  twice  for  PBMCs. 
Following  extraction  of  DNA  from  ovarian  tissue  samples  and  blood  products,  the 
concentration  of  each  specimen  was  determined  using  the  Nanodrop(V  ND-1000 
spectrophotometer.  The  "Nucleic  Acid"  application  module  was  selected  from  the  software 
package.  IgI  of  DNA  was  pipetted  onto  the  sample  pedestal  to  ensure  that  the  liquid 
sample  column  was  formed  and  the  light  path  was  completely  covered  by  the  sample.  This 
accurately  and  reproducibly  measures  DNA  concentrations  by  utilising  the  0.2mm. 
pathlength  to  calculate  the  absorbance  and  then  converts  this  into  a  specific  concentration. 
2.8  Sodium  bisulphite  modification  of  extracted  DNA 
2.8.1  Materials 
P-Mercaptoethanol  Sigma 
CpGenorneTm  DNA  Modification  Kit  Chemicon  Intemational Catriona  Hardie,  2007 
dH20 
EDTA  Fishers 
Ethanol  Hayman 
NaOH  pellets  Fishers 
Sterile  H20  for  injection  B  Braun 
Tris  Base  Metford 
2.8.2  Recipes 
. 
8-MercaptoethanotIH20 
P-Mercaptoethanol  IPI 
dH20  20ml 
3M  NaOH 
NaOH  pellets  Ig 
dH20  8.3ml 
20mM  NaOH  /  90%  Ethanol  (freshly  prepared  for  each  experiment) 
100%  Ethanol  900[11 
dH20  93.4[tl 
3M  NaOH  6.6gl 
TE 
I  OmM  Tris 
0.  ImM  EDTA 
pH  7.5 
Per  modification:  Reagent  1,  supplied  with  kit  (make  up  fresh  each  time) 
Reagent  I  227mg 
dH20  571  gl  (vortex) 
3M  NaOH  20gl  (vortex) 
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Per  modification:  Reagent  11,  supplied  with  kit  (can  be  stored  In  dark  for  6 
weeks.  )  Do  not  use  if  reagent  H  has  turned  yellow. 
Reagent  II  1.35g 
P-mereaptoethanol/H20  750ý1 Catriona  Hardie,  2007  61 
2.8.3  Method 
Sodium  bisulphite  modification  is  based  on  the  selective  dearnination  of  unmethylated 
cytosines  to  uracils  whereas  methylated  cytosines  remain  unchanged.  This  chemical 
reaction  converts  a  difference  in  methylation  into  a  difference  in  sequence. 
I  gg  of  genomic  DNA  was  modified  with  sodium  bisulphite  using  the  CpGenome  DNA 
Modification  Kit  according  to  the  manufacturer's  instructions  in  a  Category  I  environment. 
I  gg  of  DNA  was  denatured  at  an  alkaline  pH  by  mixing  with  2ýd  of  Reagent  IV  and  7ýd  of 
3M  NaOH  in  a  1.5ml  centrifugation  tube  and  bringing  the  total  volume  to  100PI  with 
sterile  H20.  Samples  were  incubated  at  500C  for  10  minutes  and  following  this,  550ýd  of 
freshly  prepared  Reagent  I  was  added  to  each  sample  and  incubated  at  50'C  for  16-20 
hours.  This  reagent  contains  HS03'  which  causes  sulphonation  and  hydrolytic  dearnination 
of  unmethylated  cytosines.  5pI  of  Reagent  III  (a  micro-particulate  carrier)  and  750gl  of 
Reagent  II  were  added  to  the  reaction  and  incubated  at  room  temperature  for  10  minutes, 
which  allowed  the  beads  to  bind  to  the  DNA  (in  the  presence  of  Reagent  II).  Samples  were 
then  centrifuged  at  5000xg  for  10  seconds  leading  to  formation  of  bound  DNA  in  pellet 
form  and  the  supernatant  was  discarded.  The  bound  DNA  was  then  desalted  by  washing  in 
Iml  of  70%  ethanol  three  times.  After  the  supernatant  from  the  third  wash  was  removed, 
the  samples  were  centrifuged  at  top  speed  for  2-3  minutes  and  the  remaining  supernatant 
was  removed.  The  conversion  to  uracil  was  completed  by  alkaline  desulphonation  which 
involved  incubating  samples  in  50gl  of  20mM  NaOH  at  room  temperature  for  5  minutes 
and  further  desalting  by  washing  twice  in  90%  ethanol.  The  remaining  supernatant  was 
removed  and  the  cell  pellets  were  air-dried  for  20  minutes  at  room  temperature.  DNA  was 
eluted  from  the  carrier  by  incubating  in  40pl  of  TE  at  55*C  for  15  minutes.  The  samples 
were  then  centrifuged  at  high  speed  for  2-3  minutes  and  the  supernatant  was  pipetted  to 
freshly-labelled  eppendorf  tubes.  This  modified  DNA  was  stored  at  -20'C  until  required 
for  MSP  or  other  methylation-related  experiment. 
2.9  Verification  of  successful  bisulphite  modification 
using  PCR 
Incomplete  bisulphite  modification  can  lead  to  false  positive  results  using  MSP  (Rand  et 
al.,  2002).  Therefore  it  is  important  to  avoid  using  incompletely  modified  DNA  samples  as Catriona  Hardie,  2007  62 
these  could  result  in  an  overestimation  of  methylated  cytosines.  In  order  to  address  this 
problem,  successful  bisulphite  modification  of  the  DNA  was  verified  before  proceeding  to 
MSP  by  amplifying  a  DNA  sequence  that  contains  cytosines  with  COBRA  primers  (for 
details,  see  Table  3).  These  primers  do  not  contain  CpG  sites  and  will  only  give  an 
amplified  product  if  the  cytosines  in  the  original  sequence  have  been  successfully 
converted  to  uracils,  irrelevant  of  its  methylation  status.  For  this  purpose,  a  promoter 
region  of  the  CALPONEV  gene  (sequence  as  shown  in  Table  3)  was  amplified  with  every 
modified  DNA  sample.  Samples  that  did  not  give  a  band  of  similar  intensity  were 
considered  unmodified  or  incompletely  modified  and  the  modification  reaction  was 
repeated  for  those  samples.  The  materials  and  methods  used  for  this  are  described  in 
Chapter  2.10.1  and  2.10.2. 
2.10  Methylation  Specific  PCR  (MSP) 
2.10.1  Materials 
dH20 
dNTPs  0.2mM  Applied  Biosystems 
70%  Ethanol  (to  wash  down  workstation) 
Fast  Start  Taq  DNA  Polymerase  Kit  Roche 
Human  Genomic  Male  DNA  Promega 
In  Vitro  Methylated  DNA  (IVM)  Chemicon 
Mineral  Oil  Sigma 
Oligonucleotides  (detailed  below  in  Table  2)  TA  GN 
Semi-skirted  96  well  PCR  plate  (0.2ml)  Abgene 
Sterile  H20  for  injection  B  Braun 
Microseal  A  Film  MJResearch 
Z10.2  Method 
MSP  is  a  qualitative  PCR-based  technique  which  is  highly  sensitive  and  has  the  potential 
to  detect  small  subpopulations  of  methylated  sequences  (Herman  et  al.,  1996).  It  is  used  to 
detect  a  sequence  corresponding  to  a  particular  methylation  state  (either  methylated  or 
unmethylated)  in  extracted  bisulphite  modified  genomic  DNA.  Primers  were  specifically Catriona  Hardie,  2007  63 
designed  to  utilise  the  sequence  differences  between  methylated  and  unmethylated  DNA 
resulting  from  sodium  bisulphite  treatment. 
To  avoid  contamination  of  the  amplification  reaction  (Kwok  and  Higuchi,  1989),  all  MSP 
related  equipment  and  consumables  were  stored  in  a  pre-PCR  environment  in  the  Category 
I  room.  The  MSP  reactions  were  set  up  in  a  vertical  laminar  airflow  in  a  pre-PCR 
Category  I  environment  (PCR  workstation).  All  MSP  reactions  were  carried  out  on  an  MJ 
Research,  Tetrad  DNA  Engine  PTC  225. 
For  all  MSP  assays,  a  series  of  positive  and  negative  controls  plus  H20  blank  were  run 
simultaneously  with  each  reaction.  Undiluted  IVM  DNA  and  serial  dilutions  (1:  5,1:  10, 
1:  20)  of  this  in  male  whole  blood  genomic  DNA  were  used  as  positive  controls  and  a 
negative  control  of  male  whole  blood  genomic  DNA  was  used. 
Reaction  mixes  were  prepared  in  a  PCR  workstation  which  was  washed  down  with  70% 
ethanol  spray  prior  to  use.  All  tubes  and  tips  were  exposed  to  UV  light  prior  to 
commencing  the  experiment.  A  master  mix  with  the  appropriate  primer  sets  was  then 
prepared  before  addition  of  DNA.  MSP  master  mixes  were  made  using  reagents  from  the 
Fast  Start  Taq  DNA  Polymerase  kit  which  were  thawed  and  vortexed  prior  to  use  except 
Taq  polymerase  was  kept  at  -20'C  until  required.  MSP  reactions  were  performed  in  96 
well  PCR  plates  using  I  pl  of  modified  DNA,  150ng  of  each  forward  and  reverse  primer, 
0.2mM  dNTPs  and  IU  Faststart  Taq  in  a  total  volume  of  25pl.  The  H20  blank  control 
consisted  of  24gl  master  mix  and  lul  of  sterile  H20  in  place  of  DNA.  Specific  reaction 
mixes,  primers  and  cycling  conditions  are  described  below. 
A  master  mix  for  one  reaction  contained: 
Fast  Start  I  Ox  Buffer 
dNTPs 
Forward  sequence  primer 
Reverse  sequence  primer 
MgC12  25mM 
Fast  Start  Taq  DNA  Polymerase 
Sterile  H20 
2.5ýtl 
0.5pl 
0.5pt 
0.5gl 
14ýfl,  depending  on  primer  conditions 
0.2ýtl  (add  immediately  prior  to  use) 
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Wells  were  sealed  with  microseal  film  and  reactions  were  run  on  a  Tetrad  DNA  Engine 
PTC  225.  Each  MSP  reaction  underwent  an  initial  denaturation  and  enzyme  activation  step 
at  95'C  for  5  minutes,  followed  by  35  amplification  cycles  of  95'C  for  30  seconds  (unless 
otherwise  indicated),  appropriate  annealing  temperature  for  30  seconds  and  elongation  at 
72*C  for  30  seconds.  This  was  followed  by  a  final  extension  step  at  72'C  for  5  minutes.  as 
below. 
MSP  conditions  were  as  follows: 
Initial  Denaturation  Step  of  5mins  at  95'C  then  35  cycles  of: 
Denaturation  30s  95'C 
Anneal  30s  Temp.  dependent  on  primer 
Elongation  30s  72'C 
Following  these  35  cycles,  final  elongation  step  of  5  mins  at  72'C 
2.10.3  MSP  oligonucleotides  and  cycling  conditions 
Primer  sequences  and  conditions  for  MSP  are  shown  below  in  Table  2. 
Gene  Primer  Sequence  Product  Annealing 
*  Imirl 
Z 
Forward  (1)  /  Reverse  (R)  5'--*3'  Size  (bp)  Temp  (  Q 
APAR  F:  TTTCGGGTAAAAGGGATAGAATTAGA  140  63  2 
R:  TATAACGCCCTTCCCCCGACGACG 
BLU  F:  TTCGTGGGTrATAG  GAGAAAGCG  157  61  2 
R:  AACGAATTAACCGCGCCTACGC 
BRCAI  F:  GAGTTTCGAGAGACGTTTGG  176  63  3 
R:  AATCTCAACGAACTCACGCC 
CASP8  F:  TAGGGGATTCGGAGATTGCGA  321  53  2 
R:  CGTATATCTACATTCGAAACGA 
DAPK  F:  GGATAGTCGGATCGAGTTAACGTC  98  60  2 
R:  CCCTCCCAAACGCCGA 
DcRI  F:  TTACGCGTACGAATTTAGTTAAC  127  55  2 
R:  CATCAAACGACCGAAACG 
FancF  F:  T=GCGTTTGTTGGAGAATCGGGTTTTC  153  65  2 
R:  ATACACCTCAAACCGCCGACGAACAAAACG 
Fas  F:  GAAAGGGTAGGAGGTCGG=CGAG  269  65  2 
R:  CACTCTTACGCGAAATCAAAAACGAACTCA 
GSTpi  F:  AGTTGCGCGGCGAMC  140  61  2 
R:  GCCCCAATACTAAATCACGACG 
HIM  F:  TCGGTMCGCGT-MGTrCGT  95  60  2 
R:  AACCGAAAACTATCAACCCTCG 
MINT25  F:  GCGAAAGCGAAAGTCGTTCG  213  58  2 
IR:  CCCAACGCACATAACGAACC 
MGMT  F:  TTTCGACGTTCGTAGG=CGC  81  58  2 
R:  GCACTCTTCCGAAAACGAAACG 
MLHI  F:  ACGTAGACGTMATTAGGGTCGC  115  64  2 
R:  CCTCATCGTAACTACCCGCG 
OPCML  F:  GCGCGGTGCGGGTITA=C  135  61  2 
R:  TCCCGATACCGCCTCGAAACGAACG Catriona  Hardie,  2007  65 
P14  F:  GTGITAAAGGGCGGCGTAGC  122  62  2 
R:  AAAACCCTCACTCGCGACGA 
P16  F:  ITATTAGAGGGTGGGGCGGATCGC  150  65  2 
R:  GACCCCGAACCGCGACCGTAA 
P21  F:  TAGTACGCGAGGTTTCG  ATC  197  58  2 
I  R:  AACTAACG,  CAACTCAACGCGAC 
P73  F:  GTTCGCGGTG=ITTCGCG  315  62 
R:  AATACCTACCCAACGCTACG 
PTEN  F:  ITAGGGTTGGGAACGTCGGAG  227  61  2 
R:  CAACAACCAAAAACCTAACAACGACGACAA 
RASSFIA  F:  CGAGAGCGCGTTTAGMCGIT  192  52  2 
I  R:  GATTAAACCCGTACTTCGCTAA 
SFRP-1  F:  CGTA=AGI'MGTAGTMCGG  163  64  2 
R:  CCCCCGACCAATAACG 
SOCS-3  F:  =GTGGA=ACGGTCGT  134  57  2 
R:  GAAAAACTAATCCCGAATCGAA 
Survivin  F:  TCGGTATATITCGCGTCGTITC  280  61  2 
I  R:  AAACCGAACAATCTCACCCGCT 
TMSI  F:  ITGTAGCGGGGTGAGCGGC  191  65  2 
R:  AACGTCCATAAACAACAACGCG 
5D4(m)  F:  ATATAGAGTAAAAAGCGACGTTCGT  112  57  2 
R:  ACTTITAAACTTACCCAACCTCGA 
5D4"7ý  F:  GATATAGAGTAAAAAGTGATGMGT  113  52  2 
R:  AC=AAACTTACCCAACCTCAAA 
119A6(')  F:  TCGTAGCGATAGGTATAAAGTTACG  100  55  2 
R:  AAAAAAACGACCAAATCCGA 
119A6(")  F:  TGTAGTGATAGGTATAAAGTTATGG  100  55  2 
R:  AAAAAAAACAACCAAATCCAAA 
41D9  F:  CGTATTAGVITAMATTATTATCGG  102  60  2 
R:  TACCTAACTAAATTTCTACTACGCT 
41D9(`  F:  TTTGTTGGTAGATGGA=AGAGTG  99  52  2 
R:  AATAAATAAACTAATACAAAATCACC 
66G6(m)  F:  GTTCGGGAGAGT=GATAGTC  115  58  2 
R:  AAACAAATTACCTAATAAAAACGAA 
66G677-  F:  TTGGGAGAGT=GATAGTTGT  114  57  2 
1  R:  AAAACAAATTACCTAATAAAAACAAA 
Table  2  IVISP  oligonucleotides  and  cycling  conditions  Primers  amplify  methylated  ýmý  DNA 
sequences  unless  otherwise  stated.  Primers  which  are  specific  for  the  unmethylated  sequence  are 
indicated  (uý.  Primers  were  all  designed  using  MethPrimer  (Li  and  Dahiya,  2002) 
(hfti3*/hvww.  urociene.  or-q/methprimer  . 
2.11  Fluorescent  MSP  and  CEQ  fragment  analysis 
2.11.1  Materials 
Beckman  CEQ  8000  Genetic  Analysis  System 
CEQ  Sample  Loading  Solution  (SLS),  6ml 
GenomeLab  DNA  Separation  Capillary  Array 
GenomeLab  Separation  Gel  LPA-  1,1  Oml 
GenomeLab  Sequencing  Separation  Buffer 
Mineral  oil  (supplied  with  size  standard) 
Beckman  Coulter 
Beckman  Coulter 
Beckman  Coulter 
Beckman  Coulter 
Beckman  Coulter 
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Oligonucleotides  (WellRed  fluorescent  tag)  Sigma 
Sample  Microtiter  96  well  PCR  plates  Beckman  Coulter 
Size  standard  400  Beckman  Coulter 
96-well  plates  non-sterile  Beckman  Coulter 
2.11.2  Method 
Fluorescent  MSP  was  performed  on  bisulphite  modified  DNA  extracted  from  plasma  and 
PBMCs  as  described  above  in  Chapter  2.10.  Primers  used  (OPCML,  RASSF  I  A,  HIC  I  and 
5D4(m)  and  cycling  conditions  were  as  shown  in  Table  2,  labelling  each  forward  primer 
with  a  WellRed  Fluorescent  tag. 
Fragment  analysis  of  fluorescently  tagged  PCR  was  performed  with  the  Beckman  CEQ 
8000  Genetic  Analysis  System.  This  automatically  filled  the  capillary  array  with  a  patented 
linear  polyacrylamide  (LPA)  gel,  denatured  and  loaded  the  samples,  applied  a  voltage 
program  and  analyzed  the  data.  A  dye  signal  level  of  ?:  5000  was  taken  as  a  positive  value. 
Any  level  less  than  this  was  interpreted  as  a  signal  consistent  with  background  noise. 
2.12  Combined  bisulphite  restriction  analysis  (COBRA) 
2.12.1  Materials 
BSA  New  England  Biblabs 
I  Ox  NEBuffer  2  or  4  (detailed  below  in  Table  4)  New  England  Biblabs 
Oligonucleotides  (detailed  below  in  Table  3)  TAGN 
QIAquick  PCR  purification  kit  Qiagen 
Restriction  enzymes  (detailed  below  in  Tables  3  and  4)  New  England  Biolabs 
2.12.2  Method 
COBRA  was  performed  to  confirm  selective  data  obtained  by  MSP  (Xiong  and  Laird, 
1997).  COBRA  is  a  quantitative  PCR-based  technique  which  measures  the  methylation 
state  of  individual  cytosines  in  bisulphite  modified  genomic  DNA  using  primers  which 
amplify  DNA  irrespective  of  its  methylation  state  (ie  do  not  contain  CpG  sites)  followed 
by  restriction  digest  of  the  product.  PCR  was  carried  out  as  per  Chapter  2.10.2  but  included Catriona  Hardie,  2007  67 
45  cycles  of  amplification  to  obtain  a  stronger  product  which  could  be  detected  following 
the  restriction  enzyme  digestion  step. 
After  amplification,  PCR  products  were  purified  using  the  QlAquick  PCR  purification  kit 
according  to  the  manufacturer's  instructions.  All  centrifugation  steps  were  carried  out  at 
15700xg.  DNA  was  bound  to  the  QlAquick  column  supplied  with  the  kit,  washed  and 
eluted  in  30gl  of  elution  buffer. 
The  eluted  product  was  digested  with  a  restriction  enzyme  which  cut  specific  sites  whose 
sequence  depended  on  the  methylation  state  of  the  unmodified  DNA.  lOx  NEBuffer  was 
required  for  each  restriction  endonuclease  and  supplemented  with  lOOPg/mI  BSA  when 
required  as  detailed  below  in  Table  4.  A  master  mix  for  one  reaction  contained: 
Eluted  product  14gl 
1  Ox  buffer  2VI 
Restriction  enzyme  I  til 
100x  BSA  0.2gl 
Sterile  H20  To  20gl 
Digestion  was  performed  on  a  heating  block  at  37'C  for  2  hours.  Following  digestion, 
products  were  separated  on  a  2%  agarose  gel  as  described  below  in  Chapter  2.13. Catriona  Hardie,  2007 
2.12.3  COBRA  oligonucleotides 
conditions 
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and  restriction  digestion 
Gene  Primer  Sequence  Product  Annealing  jMg,  *j  Restriction 
Forward  (F)  /Reverse  (A)  S-3'  Size  Temp  Min  enqme 
(*0 
BRCAI  F:  TTI'r=GTTII-=ATT=GATT  193  59  4  Fnu4HI  ýu) 
R:  TATCTAAAAAACCCCACAACCTATC 
Calponin  F:  GGAAGGTAGTTGAGGTTGTG  333  63  3  Not  used 
, 
R:  CCCAAACTCAA,  AACTCTAACCTAAC 
MCI  F:  TAGTTGGAAAA=IT=AAGMG  443  53  2  H  y118111  W 
R:  AATTACCCCAATTAAAAAAAATAATAC 
MLHI  F:  GTGAAGGAGGTTAYGGGTAAG  354  55  2  BSTYI17M 
R:  ATACTTAACACTTCTCAAACTCCTCC  Fnu4HI 
OPCML  F:  GTI-1-r=GTAGGGGAAGT  243  59  2  Fnu4HI 
R:  CAACAACTCCATCCCTAACC 
RASSFIA  F:  GTGGGTAGGTrAAGTGTGTTGT  438  58  1  BsiEI 
R:  CAACTCAATAAACTCAAACTCCC 
SFRPI  F:  YGTATTTTAGTTTTGTAGTTTTYGG  163  53  2  BsiEI  (m) 
R:  CCCCCRCCAATAACR 
TMSI  F:  GTTTGGGGT=AATTTAGAGGTTr  288  57  2  BsiEI  (M) 
R:  TCAACTTAAACTTCTTAAACTCCTC  /  Fnu4HI 
(MY 
Hpyl  18111 
1  I(M) 
Table  3  COBRA  oligonucleotides  and  cycling  conditions.  (M)  and  (U)  indicate  that  the 
restriction  enzyme  cleaves  a  sequence  resulting  from  modified  methylated  and  unmethylated  DNA 
respectively.  The  nomenclature  of  IUPAC  is  used.  Restriction  enzymes  were  mapped  using 
NEBcutter2  (http:  //tools.  neb.  com/NEBcufter2)  and  primers  were  designed,  as  before,  using 
Methprimer  (Li  and  Dahiya,  2002). 
Enzyme  NEBuffer  BSA  Restriction  enzyme  cut  site 
Fnu4HI  4  No  5'....  GC/NGC  ....  3' 
3'....  CGN/CG....  5' 
Hpyll8111  4  Yes  5'....  TC/NNGA....  3' 
3  .....  AGNN/CT  ....  5' 
BsaHI  4  Yes  5'....  GR/CGYC  ....  3' 
3'....  CYGC/RG....  5' 
BsiEl  2  Yes  5  .....  CGRY/CG 
....  3' 
1 
3  .....  GCIYRGC 
.... 
5' 
Table  4  Restriction  enzyme  conditions  and  cutting  site.  Details  of  enzyme,  NEBuffer,  whether 
supplemented  with  BSA  and  restriction  site  cut.  The  IUPAC  nomenclature  is  used  in  the  sequence. Catriona  Hardie,  2007 
2.13  Agarose  gel  electrophoresis 
2.13.1  Materials 
Agarose 
Amresco  Ethidiurn  Bromide  solution 
Boric  acid 
dH20 
100bp  DNA  Ladder 
EDTA 
Electrophoresis  unit  and  power  pack 
GeneGenius  Bioimaging  System 
Glycerol 
Orange  G 
Tris  Base 
Melford 
NBS  Biologicals 
Fisher 
Invitrogen 
Fisher 
Pharmacia 
Syngene 
Fisher 
Sigma 
Melford 
2.13.2  Recipes 
TBE  (5x) 
69 
Tris  base  108g 
Boric  acid  55g 
0.5M  EDTA  40ml 
Make  up  to  2L  with  dH20  and  then  dilute  to  0.5x  with  dH20  for  use  in  agarose,  gel 
electrophoresis. 
2%  Agarose  Get 
0.5x  TBE  Buffer  100ml 
Agarose  2g 
Heat  in  microwave  for  2mins  until  agarose  is  completely  dissolved.  Allow  to  coot  to  "hand 
warm"  before  adding  2  droplets  of  ethidiurn  bromide  solution. 
Loading  Buffer 
Glycerol  loml 
dH20  30ml 
Orange  G  0.25g Catriona  Hardie,  2007 
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After  the  PCR  step,  the  products  were  separated  through  size  by  agarose  gel 
electrophoresis.  5gl  of  loading  buffer  was  added  to  each  PCR  product  and  20gl  of  this 
mixture  was  pipetted  into  wells  of  a  2%  agarose  gel  immersed  in  600ml  0.5x  TBE  Buffer. 
A  DNA  ladder  was  run  at  the  same  time  to  confirm  that  products  were  of  the  expected  size. 
Gels  were  run  for  3545  minutes  at  150  volts. 
DNA  was  visualised  with  UV  light  using  a  Syngene  GeneGenius  Bioirnaging  System  with 
GeneSnap  version  6.03  software.  For  each  primer  sequence,  samples  which  were  positive 
displayed  visible  bands  in  their  corresponding  lanes.  The  MSP  assay  including  samples  of 
unknown  methylation  status  was  only  regarded  as  being  successful  if  there  was  a  visible 
band  in  the  positive  control  lanes  and  no  visible  bands  in  both  the  negative  control  and 
H20  blank  lane. 
2.14  Differential  methylation  hybridisation  (DMH) 
In  a  collaborative  study  described  in  Chapter  4.1,  DMH  was  performed  similarly  as 
previously  described  (Paz  et  al.,  2003),  with  some  modifications.  Figure  8  illustrates  the 
method  of  sample  preparation  for  DMH.  Genomic  DNA  was  digested  with  Msel  (TTAA) 
which  has  only  a  few  restriction  sites  within  CpG  islands.  The  DNA  fragments  were  then 
ligated  to  endlinker  oligonucleotides  and  divided  into  two  equal  aliquots.  One  aliquot  was 
mock-treated,  the  other  aliquot  was  digested  with  the  methylation-sensitive  restriction 
enzyme  McrBC  which  cuts  methylated  DNA  at  the  degenerate  recognition  site 
(G/A)'CN4o-3ooo(G/A)'C  (Stewart  and  Raleigh,  1998).  PCR  amplification  was  performed 
with  primers  binding  to  the  endlinkers.  Unmethylated  fragments  are  amplified  in  both  the 
McrBC  digest  and  the  mock-treated  aliquot.  In  contrast,  methylated  fragments  are  digested 
with  McrBC  but  remain  intact  in  the  mock-treated  aliquot.  The  amplicons  were  then 
labelled  with  Cy3  or  Cy5  and  hybridised  to  the  Human  CpG  12K  Array  (Heisler  et  al., 
2005)  (University  Health  Network,  Toronto,  Canada)  overnight.  This  array  is  based  on  a 
CpG  island  library  containing  approximately  12,000  CpG-rich  sequences  (Cross  et  al., 
1994).  Arrays  were  washed  with  IxSSC,  0.1%  SDS  and  0.2xSSC,  rinsed  with  H20  and 
scanned  with  an  Axon  GenePix  4000A  scanner.  GenePix  Pro  6.0  was  used  for  image Catriona  Hardie,  2007  71 
analysis.  Dye  swap  experiments  were  performed  for  all  cell  lines  to  ensure  quality  control 
and  reproducibility.  An  example  of  such  a  dye  swap  experiment  is  shown  in  Figure  16. 
Genomic  DNA 
ýAm6116ý 
I  Msel  digest 
WOOOOý 
-ý666ý 
McrBC  Mock 
PCR  with  primers  binding  to  linkers  I 
Label  with  Cy3  or  Cý 
Hybridisation  to  Microarray 
Yellow  unmethylated 
Red  methylated 
Figure  8  DMH  sample  preparation.  Genomic  DNA  digested  with  Msel,  ligated  to  endlinkers  and 
divided  into  equal  aliquots.  One  mock-treated,  the  other  digested  with  McrBC,  which  is  a 
methylation-sensitive  restriction  enzyme.  PCR  performed  with  primers  binding  to  endlinkers. 
Unmethylated  fragments  are  labelled  in  both  aliquots.  Methylated  fragments  remain  intact  only  in 
the  mock  treated  aliquot.  Amplicons  are  labelled  with  Cy3  or  Cy5  and  hybridised  to  microarray. 
2.15  Sodium  bisulphite  sequencing 
2.15.1  Materials 
Ampicillin  I  00mg/ml  stock  solution 
Dual  Promoter  TA  Cloning  Kit 
imMedia  Amp  Blue  sachets 
LB  medium 
QlAquick  Gel  Extraction  Kit 
Oligonucleotides  (detailed  below  in  Table  5) 
Petri  dishes  (90mm) 
Sigma 
Invitrogen 
Invitrogen 
Beatson  Institute  stores 
QL4GEN 
TAGN 
Sterilin Catriona  Hardie,  2007  72 
SOC  Medium  Invitrogen 
Sterile  inoculating  loops  Nunc 
2.15.2  Method 
Sodium  bisulphite  sequencing  is  a  genomic  sequencing  technique  (Frommer  et  al.,  1992) 
allowing  generation  of  methylation  maps  with  single  nucleotide  resolution  based  on 
bisulphite  modification  of  DNA  and  sequencing  of  PCR  products.  The  method  involves  the 
subcloning  of  a  PCR  product  into  an  appropriate  vector  and  sequencing  of  the  inserts  of 
several  individual  clones.  The  resulting  final  sequence  pattern  shows  that  all  original 
cytosines  appear  as  thymines  whereas  methylated  cytosine  bases  are  displayed  as 
cytosines,  resulting  in  quantification  of  CGI  methylation  at  every  CpG  position. 
Bisulphite  modified  cell  line  DNA  (from  A2780,  A2780p6,  MCPI,  MCP6  and  MCP9) 
were  PCR  amplified  in  25ýd  reactions.  Primer  sequences  and  conditions  are  shown  below 
in  Table  5.  PCR  reagents  and  primer  concentrations  used  were  as  for  MSP.  The  PCR 
product  was  extracted  and  purified  from  a  2%  agarose  gel  using  a  QlAquick  Gel  Extraction 
Kit  as  per  manufacturer's  instructions. 
This  product  was  then  ligated  into  a  pCeIl  vector  (supplied  with  TA  Cloninge  Kit). 
This  vector  is  linearized  with  3'-T  overhangs.  The  use  of  Taq  polymerase  in  the  initial 
PCR  reaction  adds  a  single  A  to  the  3'  ends  of  the  PCR  product  and  allows  efficient 
ligation  of  the  PCR  insert  with  the  vector  due  to  compatible  end.  The  ligation  mixture  was 
incubated  overnight  at  14*C  in  10ýtl  reactions  containing  6gl  PCR  product,  IgI  lOx 
ligation  buffer,  2gl  pCeIl  and  1ý1  T4  DNA  ligase.  A  negative  control  of  H20  was 
included  in  each  sequencing  experiment  which  comprised  6ýd  H20  in  place  of  PCR 
product. 
The  ligation  reaction  mixture  was  then  transformed  into  competent  DH5a  E.  coU  (kindly 
provided  by  the  Beatson  Institute  Stores).  This  utilises  the  ability  of  the  plasmid  to  be 
replicated  within  the  dividing  bacteria  and  therefore  provide  sufficient  quantities  of 
plasmid  DNA.  40gl  of  DI-15a  cells  were  thawed  on  ice  and  added  to  2VI  of  ligation 
reaction  mixture  which  was  then  incubated  on  ice  for  30  minutes.  This  was  followed  by  a 
heat  shock  at  42'C  for  30  seconds  to  allow  plasmid  entry  into  the  bacterium.  The  mixtures 
were  then  placed  on  ice  and  250gl  of  SOC  Medium  was  added.  The  resulting  mixtures 
were  shaken  for  1  hour  at  37'C  to  allow  expression  of  the  ampicillin-resistance  gene  before 
plating  out. Catriona  Hardie,  2007  73 
The  features  of  the  pC02.1  vector  are  illustrated  below  in  Figure  9.  These  include  an 
ampicillin  resistance  gene  which  allows  growth  of  Rcoli  in  ampicillin  containing  medium 
and  the  lac  promoter  which  allows  bacterial  expression  of  the  lacZa  fragment.  This 
fragment  encodes  for  P-galactosidase  which  is  used  for  blue-white  colony  screening  as 
described  below. 
+1 
pCR!  2ml 
3.9  kb 
Figure  9  Features  of  pCIRO  2.1  vector.  Features  include  an  ampicillin  resistance  gene,  and  the 
lac  promoter  which  permits  bacterial  expression  of  the  lacZa  fragment.  This  encodes  for 
galactosidase  which  is  used  for  blue-white  colony  screening. 
Agar  plates  were  made  up  by  dissolving  an  imMedia  Amp  Blue  sachet  in  200ml  of  dH20 
and  pipetting  out  approximately  18ml  per  90mm  Petri  dish  once  mixture  cooled  slightly.  In 
addition  to  ampicillin,  nutrients  and  agar,  this  media  contained  both  IPTG  which  induces 
the  lac  promoter  and  X-Gal  which  is  cleaved  by  0-galactosidase  yielding  a  blue  product. 
75pl  of  shaken  mixture  was  plated  out  evenly  on  plates  using  a  sterilised  cell  spreader  and 
incubated  overnight  at  37*C.  If  transformation  was  successful,  plates  yielded  both  blue  and 
white  colonies.  Transformants  were  identified  by  genetic  selection:  blue  colonies  result 
from  cleavage  of  X-Gal  due  to  LacZa  expression  but  if  the  PCR  product  had  successfully 
inserted  into  the  vector,  the  LacZa  gene  was  disrupted  and  X-Gal  was  not  cleaved  leading 
to  formation  of  white  colonies.  White  colonies  were  cultured  overnight  in  the  37*C  shaker 
in  1  ml  LB  media  containing  I  jil  of  I  00mg/ml  ampicillin  stock  solution.  Overnight  cultures 
were  then  submitted  to  the  Beatson  Institute  Molecular  Services  for  mini-prep  and 
sequencing.  Primers  used  for  sequencing  encompassed  the  T7  promoter  within  the  vector. 
Methylation  density  was  calculated  from  at  least  10  complete  sequences,  and  the Catriona  Hardie,  2007  74 
methylation  percentage  for  each  individual  CpG  was  rounded  to  the  nearest  increment  of 
10%. 
2.15.3  Bisulphite  sequencing  oligonucleotides  and  cycling 
conditions 
Primer  Primer  Sequence  Product  Size  Annealing  Imel  Name  Forward  (F)  /  Reverse  (R)  5'-3'  (bp)  T-p  (C)  mm 
LMXIA  F:  TGTTATTGTAAGTTTATTATTTGGGGG  200  61  2 
Seq  I  R:  CAATAAATATAAACCCAACAACTCCTAAC 
LMXIA  F:  GAAGTTGGAAATTGGTATGAG=  379  61  2 
Seq  2  R:  ATACTCCCTTTCCCAACCTAACTAC 
LMXIA  F:  AGTTAGGTTGGGAAAGGGAGTATTA  206  55  2 
Seq  3  R:  ATTACTTCTCCAAAACTAAAAAAAA 
LMXIA  F:  ATTTAGGA=GGGT=G=  334  57  2 
Seq  4  R:  AACAACCTrAMACCTAATAAAC 
5D4  F:  TTr=ATTrATTTTGT"=GGAGTTT  208  58  2 
Seq  II  R:  AAAATrCCTCACTAAATTTAATTTCTCC 
5D4  F:  TTGTTGGAGAAATTAAATrTAGTGAG  333  50  2 
Seq  2  R:  AATAAAAAAAATTAAAAAAAACAAC 
5D4  F:  GTTGTI-11=AATTrr=ATT  277  55  2 
Seq  3  R:  AAACTITATA=ATTCCTTTAATTTATA 
NR2EI  F:  GTAGGGGATGAGGGTITT=  455  58  2 
Seq  I  I  R:  CCTCTCTCCAAAATACCAAATAAATr 
NR2EI  F:  AMAMGGTATTTrGGAGAGAGG  233  58  2 
Seq  2  R:  ACTAATAATATTAATAAACCTCCAAAC 
NR2EI  F:  GAGTrATAT=ATAT"ITATATT=AA  250  54  2 
Seq  3  R:  AATCCCCTATAATATCTCCAAAAAC 
NR2EI  F:  GGAGATATTATAGGGGATTTAGTT  271  58  2 
Seq  4  R:  CATACAAAATATAAACAATCTCTACC 
NR2EI  F:  TTrGTATGTTTATGTAGAGGGAGAGAT  347  57  2 
Seq  5  R:  TCCAACCTACAAAACTCCTAAAC 
NR2EI  F:  AT=GTT=AATATTI-I-=  361  53  2 
Seq  6  R:  CTAACTTACTCATACTAACTATCCC 
NR2EI  F:  GAGTTTTGTAGGTTGGAGGGTAGT  355  58  2 
1  Seq  7  JR:  AAAAATCAAACAATCCAAAAACAAC  I 
Table  5  Bisulphite  sequencing  oligonucleotides  and  conditions.  All  primers  were  designed  as 
before  using  MethPrimer.  I  pi  of  DNA  and  45  cycles  of  PCR  were  used  in  each  reaction. 
2.16  Pyrosequencing 
2.16.1  Materials 
Ix  Annealing  Buffer 
Binding  Buffer 
Denaturation  solution  (0.2M  NaOH) 
70%  ethanol 
Oligonucleotides  @  10ýM  (detailed  below  in  Table  6) 
Biotage 
Biotage 
Biotage 
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PSQ  96  Plate  Low 
PSQ  96MA  Pyrosequencer 
PSQ  96  Reagent  Cartridge 
PSQ  96  SNP  Reagent  Kit 
Pyrosequencing  Thermoplate 
Pyrosequencing  Vacuum  Prep  Workstation 
Streptavidin  sepharose  BP 
Thermofast  96  well  semi-skirted  PCR  plates 
I  Ox  Washing  Buffer 
2.16.2  Method 
Biotage 
Biotage 
Blotage 
Biotage 
Biotage 
Biotage 
Amersham  Biosciences 
Abgene 
Biotage 
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Pyrosequencing  was  used  to  sequence  short  regions  within  specific  CGIs  and  provided 
quantitative  information  on  levels  of  methylation  at  individual  CpG  sites  which  had 
previously  been  assessed  in  a  qualitative  manner  using  MSP.  This  high  throughput 
technique  involves  sequencing  by  synthesis  and  detection  of  hydrolysis  of  pyrophosphate 
(PPi)  by  pyrophosphatase.  Pyrosequencing  uses  sodium  bisulphite  modified  DNA; 
methylation  sites  are  treated  as  "C/T  SNPs"  (methyISNP)  with  an  allele  frequency 
spectrum  spanning  the  entire  range  (0-  100%). 
DNA  was  bisulphite  modified  and  PCR  performed,  as  described  previously  in  Chapter  2.8 
and  2.10,  in  a  total  volume  of  50pl  including  2pl  of  modified  DNA  template  using  35 
cycles  of  PCR.  Either  the  forward  or  reverse  PCR  primer  was  biotinylated  to  allow 
immobilisation  to  streptavidin  coated  sepharose  beads.  40pl  of  PCR  product  was 
immobilised  to  sepharose  beads  and  single  stranded  templates  prepared  using  the  Vacuum 
Prep  Workstation  in  a  series  of  wash  steps  with  70%  ethanol,  0.2M  denaturation  solution, 
wash  buffer  and  dH20.  lOpM  sequencing  primer  was  annealed  to  the  template  (80'C  for  3 
minutes)  before  analysis  in  the  PSQ  96MA  Pyrosequencer. 
Analysis  using  the  pyrosequencer  involves  the  DNA  template  and  primer  complex  being 
incubated  with  the  enzymes  DNA  polymerase,  ATP  sulfurylase,  luciferase,  apyrase  and  the 
substrates,  adenosine  5'  phosphosulphate  (APS)  and  luciferin  per  sample.  dNTPs  are  added 
to  the  reaction  and  incorporated  into  the  sequencing  strand  if  complementary  to  the 
template  strand.  This  is  accompanied  by  release  of  PPi  which  is  then  hydrolysed  into  ATP 
in  the  presence  of  APS.  AT?  drives  the  conversion  of  luciferin  to  oxyluciferin  which 
generates  visible  light  which  can  be  detected  and  translated  into  a  peak  by  the 
pyrosequencing  software.  As  the  process  continues,  the  complementary  DNA  strand  is Catriona  Hardie,  2007  76 
built  up  and  the  nucleotide  sequence  determined  from  the  signal  peaks  within  the 
pyrosequencing  programme.  Incorporation  of  aT  at  a  CpG  site  indicates  unmethylated 
DNA  and  incorporation  of  aC  indicates  methlyation  of  that  given  site.  The  degree  of 
methylation  at  individual  CpG  sites  is  then  analysed  using  the  AQ  software. 
Z  16.3  Pyrosequencing  oligonucleotides,  cycling  conditions  and 
sequence  analysed 
Sequence 
name  used 
Primer  Sequence 
Forward  (F)  /  Reverse  (R)  /  Sequencing  (S)  51-  31 
Product 
Size  (bp) 
Annealing 
Temp  (*Q 
Imel 
MM 
5D4  F:  ATGAATGTGGAGGATGAGATAGTT  (Fbiotinylated)  323  53  2 
R:  CCCAA=ACAATTCTA=CT 
S:  CAA=ACAATTCTATTTT 
119A6  F:  TTTGGAGATATTATAGGGGATTTA  288  50  2 
R:  TCCCTCTACATAAACATACAAAA(5'biotinylated) 
IS:  GGGGTAATGAATTT 
Table  6  Pyrosequencing  oligonucleotides  and  conditions.  Primers  were  designed  using  the 
Biotage  PSQ  Pyrosequencing  software  package. 
Sequence 
name  used 
Sequence  analysed  Number  of  CpG  sites  examined 
5D4  CTTTYGATAAAATCTYGAYGTCCTAAACCAYGTT  6 
- 
AAAAAYGAAYGTA 
MUE1  YGGGGAT=YGTYGTTGYGTGYGYGGTTT=  7 
IYGGAAATT  II 
Table  7  Sequences  and  number  of  CpG  sites  analysed  using  pyrosequencing.  YG  is  a 
potential  site  of  methylation  otherwise  known  as  OC/T  SNP". 
2.17  Cell  culture 
All  tissue  culture  media  was  stored  at  4'C. 
2.17.1  Materials 
Cryotubes 
DMSO 
Fetal  Bovine  Serum  (FBS) 
L-Glutamine  200mM 
Petri  dishes  (5cm  and  10cm) 
Penicillin-Streptomycin 
Pipet-aid  pipettor 
Nunc 
Fisher 
Autogen  Bioclear 
Gibco 
Sterilin 
Gibco 
Drummond  Scientific Catriona  Hardie,  2007 
RPMI  growth  medium  Gibco 
25,75  and  175cm2  sterile  tissue  culture  flasks  Iwaki 
Stericup  vacuum-driven  filtration  System  Millipore 
NaOH  Fisher 
6,24  and  96  well  tissue  culture  plates  Iwaki 
Trypsin  2.5%  Gibco 
2.17.2  Recipes 
PBS  (Phosphate  Buffered  Saline) 
NaCl  137mM 
Na2HP04  8.5mM 
KCI  44mM 
KH2P04  1.4mM 
RPMI 
RPMI  1640  500ml 
L-Glutarnine  (2mM,  final)  5mI 
Penicillin/Streptomycin  (100mg/ml  -  optional)  2.5ml 
IM  NaOH  0.5ml 
FBS  (10%,  final)  50ml 
Trypsin 
2.5%  Trypsin  (stock)  20ml 
PBS/EDTA*  180ml 
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,2  *P/E  is  used  because  cellular  adhesion  is  in  part  dependent  on  the  presence  of  Mg  +  which 
is  complexed  and  effectively  removed  by  EDTA. 
2.17.3  Method 
Aseptic  manipulations  were  performed  using  sterile  glassware  and  plasticware  in  a  class  II 
microbiological  safety  cabinet  with  vertical  airflow.  All  cell  lines  were  regularly  analysed 
for  mycoplasma  infection. 
Ovarian  epithelial  cancer  cells  lines  were  grown  and  maintained  at  370C  in  RPMI  1640 
medium  supplemented  with  10%  FBS  and  2mM  L-Glutamine  as  monolayers  in  25,75  or 
175cm2  flasks  in  the  presence  of  5%  C02.  The  cisplatin-sensitive  cell  lines  used  in  these Catriona  Hardie,  2007  78 
experiments  were  the  parental  cell  line  A2780  and  5  clonal  derivatives  (A2780p3, 
A2780p5,  A2780p6,  A2780p13  and  A2780pl4).  The  10  cisplatin-resistant  cell  lines  used 
were  A2780cp7O  (Behrens  et  al.,  1987)  and  MCPI-9  (Brown  et  al.,  1997).  In  addition,  6 
additional  cisplatin-resistant  cell  lines  derived  from  exposing  A2780  cells  to  a  single  dose 
of  cisplatin  (McLaughlin  et  al.,  1991)  were  used  which  included  Clcis6,  C2cis6,  C2E3, 
C3Cis6,  C5E4  and  C5E4(15). 
For  the  re-expression  studies  described  in  Chapter  4.5,  cells  were  treated  with  the  DNMT 
inhibitor  5-aza-2'-deoxcytidine  (DAC)  (Jones  and  Taylor,  1980)  (0.5gM)  for  4  days  with 
daily  change  of  medium. 
Cell  stocks  were  formed  by  freezing  10  6  cells  in  Iml  growth  medium  with  10%  DMSO  at 
-70*C  in  cryotubes.  After  24h,  samples  were  transferred  to  liquid  nitrogen.  Cell  lines  were 
replaced  regularly  from  frozen  stocks  to  reduce  the  chances  of  genetic  drift. 
2.18  RNA  extraction  from  cell  lines 
2.18.1  Materials 
P-Mercaptoethanol  Sigma 
DEPC  treated  H20  Invitrogen 
Ethanol  Hayman 
QIAshredder  spin  columns  Qiagen 
RNeasy  Mini  Kit  Qiagen 
RNase-Free  DNase  Set  Qiagen 
2.18.2  Method 
Total  RNA  was  extracted  using  the  RNeasy  Mini  Kit  spin  protocol  according  to  the 
manufacturer's  instructions,  with  the  homogenisation  step  being  carried  out  using 
QIAshredder  spin  columns.  All  centrifugation  steps  were  carried  out  at  room  temperature 
and  at  ?:  8000xg.  DEPC  treated  H20  was  used  in  all  steps  to  reduce  the  probability  of 
RNase  contamination.  This  kit  combines  the  guanidine-isothiocyanate  lysis  with  silica-gel- 
membrane  purification.  Samples  were  lysed  by  adding  600PI  of  Buffer  RLT  to  100pl  of 
cells.  Samples  were  then  homogenised  using  the  QlAshredder.  I  volume  of  70%  ethanol Catriona  Hardie,  2007  79 
was  added  to  the  lysate  to  provide  ideal  binding  conditions  and  mixed  by  pipetting.  The 
lysate,  was  then  loaded  onto  the  RNeasy  silica-gel  membrane  column  and  centrifuged  for 
15  seconds.  350[d  of  Buffer  RWI  was  added  to  the  column  and  centrifuged  for  15  seconds. 
RNase-Free  DNase  Set  was  used  to  provide  efficient  digestion  of  DNA.  The  DNase  was 
removed  in  subsequent  wash  steps.  The  Iyophilised  DNasel  was  dissolved  in  550gl  of 
RNase-free  H20  and  gently  inverted  to  mix.  lOgI  of  this  DNasel  stock  solution  was  added 
to  70[tl  of  Buffer  RDD  and  mixed  by  gentle  inversion.  The  DNasel  incubation  mix  was 
then  pipetted  directly  onto  the  RNeasy  silica-gel  membrane  and  incubated  at  room 
temperature  for  15  minutes.  350gl  of  Buffer  RWI  was  then  added  to  the  column  and 
centrifuged  for  15  seconds.  The  column  was  then  placed  in  a  new  2ml  collecting  tube  and 
5OOgI  of  RPE  was  added  and  centrifuged  for  15  seconds.  A  further  500[11  of  RPE  was 
added  to  the  column  and  centrifuged  for  2  minutes.  This  centrifugation  step  was  then 
repeated  again  in  a  clean  2ml  collecting  tube.  These  steps  allow  RNA  to  bind  to  the 
column  and  contaminants  are  washed  away.  RNA  was  eluted  twice  in  40gl  of  RNase-free 
H20.  RNA  was  then  stored  at  -70'C  until  required. 
2.19  cDNA  synthesis  (Reverse  Transcription,  RT) 
2.19.1  Materials 
SuperScript  First-Strand  Synthesis  Kit  Invitrogen 
2.19.2  Method 
cDNA  was  prepared  according  to  the  manufacturer's  instructions  by  reverse  transcribing 
5gg  of  RNA  using  the  Superscript  11  first  strand  synthesis  system.  This  kit  contains  dNTP 
mix,  oligo  dT,  DEPC  treated  H20,  RT  buffer,  MgC12  solution,  DTr,  RNase  OUT,  RNase 
inhibitor  and  superscript  Il  reverse  transcriptase  (RTase).  A  no  RTase  control  was  included 
for  each  sample.  Each  reaction  contained  the  following: 
Ingredients  +RTase  No  RTase 
RNA  16pl  8ýtl 
I  OmM  dNT?  2pl  1ý1 
oligodT  2pl  1  ýd Catriona  Hardie,  2007  80 
This  was  incubated  at  65*C  for  5  minutes  and  then  put  on  ice  for  at  least  I  minute. 
A  master  mix  as  follows  was  made  up  for  each  no  RTase  reactions  and  volumes  were 
doubled  for  the  +  RTase  reactions: 
I  OX  RT  Buffer  2pl 
25mM  M9CI2  4gl 
DTT  2gl 
RNase  OUT  IPI 
This  reaction  mix  was  incubated  at  42'C  for  2  minutes  and  then  2pl  of  superscript  RTase 
was  added  to  each  +RTase  reaction  at  420C.  This  was  then  incubated  at  420C  for  50 
minutes,  70'C  for  15  minutes  and  put  on  ice.  RNase  was  added  to  each  tube  (2PI  per 
+RTase;  I  [d  per  no  RTase  reaction)  and  incubated  at  37C  for  20  minutes.  cDNA  was  then 
stored  at  -20'C  until  required  for  qRT-PCR. 
2.20  Quantitative  RT-PCR  (qRT-PCR) 
2.20.1  Materials 
DyNAmo  HS  SYBR  green  qRT-PCR  kit  Finnzymes 
Flat  cap  strips  Biorad 
Low  96-well  white  multiplate  PCR  plate  Blorad 
Opticon  2  DNA  Engine  (conditions  as  for  Table  9)  MJResearch 
RT-PCR  oligonucleotides  (detailed  below  in  Table  8)  TAGN 
All  other  reagents  used  as  described  in  Chapter  2.10 
2.20.2  Method 
qRT-PCR  was  used  to  quantitatively  evaluate  the  change  in  RNA  expression  levels  of 
NR2EI  and  LAMIA  in  cell  lines  before  and  after  treatment  with  Decitabine  as  described  in 
Chapter  4.5.  qRT-PCR  master  mixes  were  made  up  using  the  DyNAmo  HS  SYBR  green 
qRT-PCR  kit.  The  2x  master  mix  provided  contained  a  hot  start  version  of  modified 
Thermus  brockianus  DNA  polymerase,  SYBR  Green  I  binding  dye,  optimized  PCR  buffer, Catriona  Hardie,  2007  81 
M902  and  dNTPs  in  a  pre-mixed  form.  Reactions  included  Ix  SYBR  green  master  mix, 
150ng  of  each  forward  and  reverse  primer  and  2gl  cDNA  made  up  to  25pl  with  dH20- 
Reaction  mixes  and  plates  were  prepared  in  a  PCR  workstation.  A  negative  control 
containing  H20  instead  of  template  cDNA  was  included  and  a  standard  curve  derived  from 
a  range  of  known  concentrations  of  cDNA  was  set  up  in  triplate  for  each  sample.  The 
constitutively  expressed  gene  GAPDH  was  used  as  an  internal  control  to  normalise,  the  data 
and  the  average  value  of  3  independent  RT-PCR  reactions  once  standardised  to  GAPDH 
was  taken  as  the  concentration  of  PCR  product.  Reactions  were  run  on  an  Opticon  2  DNA 
Engine  according  to  cycling  conditions  below  in  Table  9. 
2.20.3  RT-PCR  oligonucleotides  and  cycling  conditions 
Gene  Primer  Sequence  Genontic  Product  Annealing  IM91*1  _M/ 
ForwardlReverse  5'ý3'  Position  Size  (bp)  Temp  (T) 
GAPDH  F:  GTCAAGCTCAMCCTGGTATG  Exon  214  61  2 
R:  GTCTACATGGCAACTGTGAG  8-9 
LMXIA  F:  TCATGAACCCCTACACGG  Exon  143  61  2 
:  GGGCTCGGCACCATAA  9-10  ,  I  I 
NR2EI 
I 
:  ATCAACAAGCCGCATTTTAG  Exon  160  65  2 
R:  GCCTCCCTGGTTTCCAG  1-3 
1 
Table  8  RT-PCR  oligonucleotides  and  conditions. 
Gene  Cycling  conditions 
GAPDH  1.94T  15  mins;  2.94T  30  secs;  3.63T  30  secs;  4.720C  30  secs; 
5.820C  10  secs;  6.  plate  read;  7.  Go  to  Step  2x  39  times; 
8.  Melting  curve  70-930C 
LMXIA  1.940C  15  mins;  2.94T  30  secs;  3.61T  30  secs;  4.72T  30  secs; 
5.80T  10  secs;  6.  plate  read;  7.  Go  to  Step  2x  42  times; 
8.  Melting  curve  70-930C 
NR2EI  1.940C  15  mins;  2.94T  30  secs;  3.620C  30  secs;  4.720C  30  secs; 
5.800C  10  secs;  6.  plate  read;  7.  Go  to  Step  2x  42  times; 
8.  Melting  curve  70-93*C 
Table  9  Cycling  conditions  for  qRT-PCR. Catriona  Hardie,  2007  82 
2.21  Statistical  methods  of  analysis 
2.21.1  Chi-squared  (X2)  test 
The  Chi-squared  test  is  a  non-parametric  test  of  statistical  significance  which  is  used  to  test 
associations  between  categorical  variables.  The  chi-squared  statistic  is  computed  from  a 
cross  tabulation  of  the  two  variables.  This  goodness-of-fit  test  compares  the  observed  and 
expected  frequencies  in  each  category  (Armitage,  1994).  Fisher's  Exact  Test  was  used  if 
the  smallest  expected  value  was  less  than  5. 
2.21.2  Mann  Whitney  U  Test 
This  is  a  non-parametric  test  to  investigate  whether  two  independent  samples  come  from 
the  same  population.  Mann-Whitney  U  tests  whether  two  samples  populations  are 
equivalent  in  location.  The  observations  from  both  groups  are  combined  and  ranked,  with 
the  average  rank  assigned  in  the  case  of  ties  (Armitage,  1994). 
2.21.3  Unsupervised  gene  shaving 
Gene  shaving  is  based  on  a  dimension  reduction  method,  Principal  Components  Analysis 
(PCA),  to  identify  subsets  of  genes  that  vary  concordantly  across  samples.  This  was  used 
in  this  thesis  to  identify  consistently  methylated  groups  of  genes  associated  with  clinical 
outcome  (CIMP).  PCA  extracts  the  most  important  features  of  the  data  and  re-maps  the 
data  into  a  reduced  dimensional  space.  Weights  are  allocated  to  objects  depending  on  their 
contribution  to  the  projection  with  the  larger  the  absolute  value  of  the  weight,  the  larger  the 
contribution  from  that  item.  Gene  shaving  uses  the  dimension  reducing  capacity  of  PCA  to 
identify  subsets  of  features  with  high  weights  that  maximally  separate  the  samples. 
2.21.4  The  cluster  quality  R2statistic 
The  W  statistic  (W  ý  IOOVB/VT)  is  used  to  estimate  the  quality  of  an  identified  pattern. 
The  larger  the  W  statistic,  the  better  the  separation  of  the  patient  population  and/or  the 
higher  the  coherence  between  selected  features.  VB  is  a  measure  of  variance  between 
samples  and  VT  measures  the  total  variance  of  a  cluster. Catriona  Hardie,  2007 
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3  Methylation  analysis  of  candidate  genes  during 
epithelial  ovarian  cancer  development 
3.1  CGI  methylation  in  late  stage  ovarian  tumourigenesis 
The  aim  of  this  chapter  was  to  identify  markers  which  are  methylated  in  late  stage  EOC. 
These  could  potentially  be  translated  into  clinically  useful  predictive  DNA  methylation 
biomarkers  of  response  to  chemotherapy.  The  methylation  status  of  24  candidate  CGIs 
(APAF-1,  BLU,  BRCA1,  CASP8,  DAPK,  DCRI,  FANCF,  FAS,  GSTPI,  HICI,  MGAIT, 
AHNT25,  MLHI,  OPCML,  P14,  P16,  P21,  P73,  PTEN,  RASSFIA,  SFRPI,  SOCS-3, 
SURVIUV  and  TMSI)  which  had  previously  been  reported  to  be  methylated  were 
examined  in  a  group  of  106  late  stage  epithelial  ovarian  tumours.  The  samples  obtained 
were  from  chemonaive  tumours  taken  at  the  time  of  initial  cytoreductive  surgery.  The 
CGIs  overlapped  the  promoter/1'  exon  of  genes  and  included  genes  specifically  involved 
in  DNA  repair  and  drug  detoxification  (BRCAI,  FANCF,  GSTPI  and  MGM7),  regulators 
of  proliferation  (PTEN,  SFRPI  and  SOCS-3),  regulators  of  apoptosis  (APAF-1,  DCRI, 
FAS,  MLHI,  P14,  P73,  RASSFIA,  SURVIV17V  and  TMSI)  and  genes  that  had  previously 
been  reported  to  be  methylated  in  ovarian  cancer  (HICI,  MIN725  and  OPCML). 
Methylation-specific  PCR  (MSP)  was  used  to  assess  CGI  methylation  (see  chapter  2.10). 
Primers  for  MSP  were  designed  to  amplify  methylated  sequences  whose  methylation  status 
had  previously  been  correlated  with  transcriptional  silencing  of  the  corresponding  gene  in 
other  studies.  MSP  is  a  highly  sensitive  assay  (Herman  et  al.,  1996)  and  has  been  widely 
used  to  analyse  CGI  methylation  patterns  in  various  turnour  types.  Incomplete  bisulphite 
modification  of  DNA  can  lead  to  false  positive  results  (Rand  et  al.,  2002)  therefore 
stringent  controls  and  scoring  criteria  were  applied  in  this  study.  Successful  bisulphite 
modification  of  the  DNA  sample  was  verified  using  a  region  of  the  CALPONIN  promoter 
as  described  in  chapter  2.9.  This  sequence  will  only  be  amplified  if  the  cytosines  in  the 
template  sequence  are  converted  to  uracils  (Teodoridis  et  al.,  2005).  Samples  which  did  not 
give  a  band  of  similar  intensity  were  considered  unmodified  or  incompletely  modified  and 
the  modification  experiment  was  repeated  for  these,  as  illustrated  in  Figure  10. Catriona  Hardie,  2007  85 
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Figure  10  Examples  of  successful  sodium  bisulphite  modifications.  H20,  reaction  without 
template  DNA;  unmodified  (red)  and  successfully  modified  (black)  IVM,  in  vitro  methylated  DNA 
and  PMN,  DNA  from  whole  male  blood;  4  modified  tumour  samples. 
MSP  is  not  a  quantitative  assay  but  by  using  a  stringent  modification  control  as  well  as 
including  a  standard  curve  of  IVM  DNA  in  male  genomic  DNA  dilutions,  the  results 
obtained  here  were  semi-quantitative.  No  PCR  product  using  methylation-specific  primers, 
and  hence  no  evidence  of  methylation  of  these  CGIs,  was  observed  for  normal  or 
immortalised  ovarian  surface  epithelium  or  DNA  extracted  from  PBMCs.  In  each 
experiment,  MSP  gave  a  product  using  IVM  DNA  and  low  level  methylation  signals 
comparable  to  <1:  10  dilution  of  IVM  DNA  into  normal  unmethylated  DNA  which  were 
not  reproducible  were  disregarded.  A  maximum  number  of  35  cycles  of  PCR  was  used  in 
each  reaction  to  avoid  amplification  of  very  low  intensity  signals  or  low  levels  of 
unmodified  DNA  which  could  lead  to  false  positive  results.  All  MSP  data  obtained was 
repeated  on  at  least  two  independent  reactions  and  those  results  which  did  not  correlate 
were  repeated  again.  Finally,  frequently  positive  MSP  results  were  confirmed  using 
COBRA  (Xiong  and  Laird,  1997),  (see  chapter  2.12).  This  is  a  quantitative  assay 
measuring  methylation  at  individual  CpG  residues  and  allowed  verification  of  MSP  scores 
obtained. 
Overall,  methylation  of  at  least  one  gene  was  observed  in  60%  of  late  stage  turnours. 
Frequent  methylation  was  observed  for  OPCML,  DCRI,  RASSFIA,  HICI,  BRCAI  and 
MINT25  (33%,  31%,  26%,  17%,  12%  and  12%,  respectively),  whereas  no  methylation  was 
observed  for  APAF-I,  DAPK,  FANCF,  FAS,  P14,  P21,  P73,  SOCS-3  and  SURVIVIN.  The 
remaining  genes  showed  only  a  low  frequency  of  methylation,  <10%.  The  methylation 
frequencies  of  the  group  of  epithelial  ovarian  turnours  examined  here  are  shown  below  in 
Table  10  and  examples  of  MSP  results  are  shown  in  Figure  11. 
MSP  results  were  confirmed  using  COBRA  which  is  an  independent  quantitative  method 
of  assessing  methylation  at  individual  CpG  residues.  54  MSP  results  were  quantified  using 
COBRA  and  this  covered  7  selected  CGIs  (BRCAI,  HICI,  MLHI,  OPCML,  RASSFIA, Catriona  Hardie,  2007  86 
SFRPI  and  TMSI).  There  was  87%  (47/54  samples)  concordance  between  the  MSP  and 
COBR-A  results  and  examples  of  this  are  shown  below  in  Figure  12. 
Chapter  5.2  and  5.3  will  discuss  the  analysis  and  validation  of  these  results  as  clinically 
useftil  predictive  biornarkers  in  ovarian  cancer. 
H20  IVM  1:  5  1:  10  1:  20  PMN  01  02  03  04  05  06  07  08  09 
OPCML  (1 
H20  IVM  1:  5  1:  10  1:  20  PMN  01  02  03  04  05  06  07  08  09 
RASSFI  A  (1  92bp) 
H20  IVM  1:  5  1:  10  1:  20  PMN  01  02  03  04  05  06  07  08  09 
HIC1  (95bp) 
Figure  11  Examples  of  MSP  results.  CGI  methylation  of  tumour  samples  (numbered  01-09) 
determined  at  loci  indicated  (product  size).  H20,  reaction  without  template  DNA;  IVM,  in  vitro 
methylated  DNA;  1:  5,1:  10  and  1:  20  serial  dilutions  of  IVM  in  PMN;  PMN,  DNA  from  whole  male 
blood. Catriona  Hardie,  2007 
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Figure  12  Examples  of  COBRA  results.  Quantitative  methylation  assay  using  restriction  digest 
confirming  MSP  results  for  OPCML,  RASSF1A  and  HIC1.  Each  MSP  score  is  shown  below  each 
COBRA  gel  image.  MSP  scores  which  did  not  correlate  with  COBRA  are  indicated  in  red.  Controls 
included  IVM,  in  vitro  methylated  DNA;  75%  IVM,  50%  IVM  and  25%  lVM  dilutions  of  IVM  in  PMN; 
PMN,  DNA  from  whole  male  blood.  Tumour  sample  numbers  indicated  above  each  image. 
As  discussed  in  the  introduction,  it  has  been  shown  that  clusters  of  CGIs  can  become  co- 
methylated  in  cancers,  including  late  stage  ovarian  cancer  (Strathdee  et  al.,  2001).  Groups 
of  genes  may  exist  which  can  define  particular  CpG  island  methylator  phenotypes  (CIMP) 
of  cancers  including  colorectal  cancer  that  are  independent  of  histological  type  (Toyota  et 
al.,  1999a).  This  concept  of  a  CIMP  existing  in  a  subset  of  ovarian  turnours  was 
investigated  using  a  bioinformatics  approach  called  unsupervised  gene  shaving  (Chapter 
2.21.3)  to  identify  concordant  patterns  of  methylation  that  separate  the  samples  into 
subgroups,  in  collaboration  with  Dr.  Jacqueline  Hall.  This  was  applied  to  all  of  the  106 
stage  IIIAV  samples  and  23  genes.  SOCS-3  was  not  included,  because  the  CGI  associated 
with  this  gene  was  examined  following  the  statistical  analysis.  The  primary  aim  of  this 
approach  was  to  investigate  the  coherence  of  gene  methylation  and  identify  patterns  of 
methylation  that  are  non-random  in  this  group  of  late  stage  ovarian  turnours. 
Pattern  I  (Figure  13A)  was  identified  which  has  a  cluster  score  (R  2)  of  0.34  (Chapter 
221.4)  and  accounts  for  87.1  %  of  the  PCA  (Principal  Components  Analysis)  solution.  The 
derivation  of  Pattern  I  is  unlikely  to  have  occurred  by  chance  as  shown  by  the  distribution Catriona  Hardie,  2007  88 
of  the  cluster  quality  Rý  statistic  for  200  permutations  (Figure  13B).  Pattern  identification 
ceased  here  as  the  next  pattern  only  accounted  for  a  small  proportion  of  the  full  PCA 
solution  (<3%).  Pattern  1  shows  concordant  positive  methylation  between  genes  and  is 
mostly  comprised  of  frequently  methylated  genes  OPCML,  DCRI,  RASSFIA,  MINT25  and 
HICI,  but  also  SFRPI  which  shows  less  methylation.  This  group  of  loci  was  identified  as 
having  a  degree  of  concordance  which  was  unlikely  to  have  occurred  by  chance  (p=0.002) 
but  the  cluster  quality  score  (le)  suggested  only  a  weak  degree  of  concordance  between 
these  genes.  No  CGIs  were  identified  in  the  pattern  to  have  negative  concordance,  which 
the  gene  shaving  approach  would  have  identified  if  present.  One  frequently  methylated 
gene  which  is  not  present  here  in  the  non-random  patterns  is  BRCAI  suggesting 
methylation.  of  this  gene  may  occur  via  a  different  underlying  process  or  biological 
selection.  This  is  consistent  with  a  previous  observation  using  different  analysis  on  a 
different  group  of  Stage  III/IV  ovarian  turnours  within  our  group  (Strathdee  et  al.,  2001) 
which  suggested  that  BRCA1  had  negative  concordance  with  the  methylator  phenotype 
defined.  The  methylation  pattern  from  unsupervised  gene  shaving  was  independent  of  age 
(p=0.239,  N=100)  and  histological  subtype  (p=0.247,  N=80). 
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MINT25 
HICI 
SFRPI 
RASSFiA-  I  IN  01  111  Till 
TMSi 
PTEN  0.30- 
BLU 
APAM  - 
P21  - 
Ple  .  P14ARF  - 
MGMT  -  0.25- 
GSTP  - 
S  i  -  urviv  n 
CASPe  CY 
BRCAI  S.  I 
FancF  41 
V,  0.20-  F"  1  3 
DAPK 
P73 
MLHI  . 
....  . 
Samples 
Figure  13  Gene  shaving  analysis  to  Identify  co-methylated  CGIs.  (A)  The  pattern  of  gene 
methylation  (black)  identified  by  unsupervised  gene  shaving  separates  patients  using  a  co- 
methylated  sub  sample  of  all  methylation  events  (shading).  Samples  are  ordered  from  right  to  left 
according  to  the  frequency  (no.  of  methylation  events  per  sample)  of  methylation  in  the  pattern. 
This  cluster  explains  87.1  %  of  the  equivalent  principal  components  analysis  solution  (n=1  06).  (B) 
The  boxplot  shows  the  distribution  of  the  cluster  quality  R2  statistic  for  200  permutations.  The 
square  signifies  the  upper  confidence  interval  of  this  distribution;  the  triangle  shows  the  R2  value  of 
pattern  1.  A  larger  R2  suggests  a  tighter  cluster  of  coherent  genes. Catriona  Hardie,  2007  89 
Chromsome 
Gene 
alignment  I 
MSP  product  Function 
MSP  primer 
Reference 
Methylation  Frequency 
distance 
from  TS*  (bp) 
Stage  III  Stage  IV 
APAF-1 
12q23.1 
+34  to  +173 
Apoptosis  (Fu  et  al.,  2003)  0  0 
BLU 
3p2l.  3  / 
Unknown  (Agathanggelou  et  al.,  1.2(1/80)  0 
+972  to  +1128  2003) 
BRCA1 
17q2l/  DNA  repair  (Strathdee  et  al.  , 
2001)  8.8(7/80)  23.1  (6/26) 
-80  to  +96 
CASP8 
2q33/ 
+536  to  +856 
Apoptosis  (Teitz  et  al.,  2000)  1.2(1/80)  0 
DAPK 
9q34.1  / 
+4  to  +101 
Apoptosis  (Balana  et  al.,  2003)  0  0 
DCR1 
8p2l 
* 
3/ 
+27  to  +153 
Apoptosis  (van  Noesel  at  al.,  2002)  28.1  (16/57)  38.9(7/18) 
FANCF 
I  1p14.3  / 
+280  to  +432 
DNA  repair  (Taniguchi  et  al.,  2003)  0  0 
FAS 
10q23 
' 
3/  Apoptosis  (Hopkins-Donaldson  et  al.,  0  0 
-260  to  +9  2003) 
GSTP1 
I  1q1  3.2  / 
+29  to  +168 
Drug 
detoxification  (Jeronimo  et  al.,  2001)  1.2(1/80)  0 
HICI 
17p  13.3  / 
-230  to  -135 
Unknown  (Dong  et  al.,  2001)  10.5(6/57)  38.9(7/18) 
MGMT 
I  Oq26.3  / 
+26  to  +106 
DNA  repair  (Balana  et  al.,  2003)  0  3.8(1/26) 
MINT25 
22q11/ 
+38  to  +250 
Unknown  (Strathdee  et  al.,  2001)  12.3(7/57)  11.1(2/18) 
MLHI 
3p2l.  3  / 
-476  to  -361 
DNA  repair/ 
Apoptosis  (Strathdee  et  al.,  1999)  5(4/80)  7.7(2/26) 
OPCML 
11q25/  Ovarian  tumour 
(Sellar  et  al.,  2003)  36.8  (21/57)  22.2(4/18) 
from  -500**  suppressor 
P14 
9p21  / 
+201  to  +322 
Apoptosis  (Esteller  et  al.,  2000c)  0  0 
P16 
9p2l  / 
+  192  to  +341 
Cell  cycle  (Herman  et  al.,  1996)  0  3.8(1/26) 
P21 
6p2l.  3  / 
-142  to  +55 
Cell  cycle  This  thesis  0  0 
P73 
1  p36.3  / 
-166  to  +149 
Apoptosis  (Strathdee  et  al.,  2001)  0  0 
PTEN 
I  Oq23.3  / 
+925  to  +1151 
Proliferation  This  thesis  8.6(5/58)  0 
RASSFIA 
3p2l.  3  / 
-65to+127 
Apoptosis  (Honorio  et  al.,  2003)  26.2  (21/80)  26.9(7/26) 
SFRP-11 
8pl  1.2  / 
+2  to  +164 
Proliferation  This  thesis  5.2(3/58)  5.6(1/18) 
SOCS-3 
17q25.3  / 
+205  to  +338 
Proliferation  This  thesis  0  0 
Survivin 
17q25.3  / 
-31  to  +249 
Apoptosis  This  thesis  0  0 
1 
TMS1 
16PI  1.2  / 
-44  to  +147 
I 
Apoptosis  (Conway  et  al.,  2000)  5.1(3/59)  5.6(1/18) 
1 
Table  10  Methylation  frequencies  In  late  stage  epithelial  ovarian  turnours.  Methylation 
frequency  %  (number  methylated  /  total  number  of  samples)  of  each  candidate  gene  examined  in 
FIGO  Stage  IIIAV  epithelial  ovarian  tumours.  Chromosome  alignment,  *amplified  MSP  product 
distance  up(-)/down(+)  stream  from  predicted  transcriptional  start  site  (TS)  shown  in  bp,  gene 
function  and  MSP  primer  reference  given.  "according  to  Sellar  et  a/  (2003). Catriona  Hardie,  2007  90 
3.2  CGI  methylation  in  early  stage  tumours 
The  aim  of  this  chapter  was  to  identify  candidate  CGIs  which  are  methylated  in  early  stage 
EOC  and  uncover  CGI  methylation  changes  which  occur  during  disease  progression. 
Previous  reports  have  suggested  that  epigenetic  aberrations  including  methylation  events 
occur  more  frequently  as  a  cancer  develops  (Guo  et  al.,  2006;  Jones  and  Baylin,  2002; 
Mehrotra  et  al.,  2004). 
The  methylation  status  of  14  of  the  candidate  CGIs  examined  in  chapter  3.1  (APAF-1, 
BLU,  BRCAI,  DCRI,  HICI,  MGMT,  ADNT25,  MLHI,  OPCML,  P16,  P21,  RASSFIA, 
SFRPI  and  TMSI)  were  examined  in  a  group  of  36  early  stage  epithelial  ovarian  tumours 
as  shown  below  in  Table  11.  The  turnours  comprised  12  borderline,  18  stage  I  and  6  stage 
II  epithelial  ovarian  tumours  and  the  same  acceptance  criteria  for  MSP  as  detailed  in 
Chapter  3.1  were  used  again. 
Overall,  methylation  of  at  least  one  gene  was  observed  in  78%  of  early  stage  tumours. 
Specifically,  75%  of  borderline  turnours,  83%  of  stage  I  turnours  and  67%  of  stage  II 
turnours  showed  methylation  of  at  least  one  gene.  Frequent  methylation  of  OPCML, 
RASSFIA,  HICI  and  A=5  (53%,  31%,  22%  and  14%  respectively)  was  observed  in 
this  group  of  early  stage  turnours.  Taken  together,  64%  of  tumours  were  methylated  in  at 
least  one  of  3  genes  (OPCA9,  RASSFIA  and  HIC1).  The  remaining  genes  showed  either  a 
low  frequency  of  methylation,  <10%  (DCRI,  P21,  SFRPI,  TMSI),  or  no  methylation 
(APAF-1,  BLU,  BRCAI,  MGMT,  MLHI  and  P16). 
As  expected,  methylation  frequency  of  some  genes  increased  with  advancing  stage  of  early 
disease  (RASSFIA  and  TMS1).  Early  stage  disease  included  borderline,  stage  I  and  stage  Il 
turnours.  Unexpectedly,  however,  this  pattern  was  reversed  in  other  genes  where 
methylation  frequency  decreased  as  early  stage  disease  progressed  (DcR1,  MINT25, 
OPCML  and  SFRPI).  For  the  remaining  genes,  no  general  trend  (HICI  and  P21)  or  no 
change  in  methylation  (APAF-1,  BLU,  BRCAI,  MGAIT,  MLHI  and  P16)  was  observed. 
These  trends  are  illustrated  in  a  panel  of  three  graphs  shown  below  in  Figure  14  and  Table 
11. Catriona  Hardie,  2007 
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Figure  14  Methylation  trends  of  genes  observed  in  early  stage  ovarian  turnours.  As  early 
stage  ovarian  tumours;  became  more  advanced,  a  trend  of  increasing  frequency  of  methylation  was 
observed  for  RASSFIA  and  TMSI.  Decreasing  frequency  of  methylation  was  observed  for  DcR1, 
MINT25,  OPCML  and  SFRP.  No  methylation  trend  was  observed  for  HIC1  and  p2l.  For  absolute 
numbers  of  methylated  genes,  see  Table  11. Catriona  Hardie,  2007  92 
A  reduction  in  methylation  frequencies  with  advancing  tumour  stage  (early  vs.  late  stage 
disease)  was  observed  for  some  genes  (OPCML,  53%  vs.  33%  and  RASSFIA,  31%  vs. 
26%)  whereas  for  other  genes,  we  observed  increased  methylation  frequencies  for  late 
stage  disease  (BRCA  1,0%  vs.  12%,  DCRI  6%  vs.  31%  and  MLH1,0%  vs.  6%).  Fisher's 
Exact  Test  was  used  to  determine  if  these  differences  observed  for  each  CGI  with 
advancing  stage  of  turnour  were  statistically  significant.  Methylation  of  BRCAI  (p=0.039) 
and  DCRI  (p=0.003)  both  significantly  increased  with  stage  when  comparing  late  stage 
with  early  stage  disease.  MSP  bands  were  of  variable  intensity  for  some  CGIs  examined  in 
both  early  and  late  stage  disease  which  may  indicate  tumour  heterogeneity  within  a  sample 
(e.  g.  HICI).  In  contrast,  some  CGIs  showed  bands  of  similar  intensity  in  all  tumour 
specimens  examined,  as  shown  above  in  Figure  11. 
Gene  Methylation  Frequency 
Borderline  Stage  I  Stage  11  Stage  III/IV 
APAF-1  0  0  0  0 
BLU  0  0  0  0.9(1/106) 
BRCA1  0  0  0  12.3  (13/106) 
DCRI  16.7(2/12)  0  0  30.7  (23/75) 
HIM  16.7(2/12)  27.8(5/18)  16.7(1/6)  17.3  (13/75) 
MGMT  0  0  0  0.9(1/106) 
MINT25  16.7(2/12)  16.7(3/18)  0  12(9/75) 
MLH1  0  0  0  5.7(6/106) 
OPCML  58.3(7/12)  55.6  (10/18)  33.3(2/6)  33.3  (25/75) 
P16  0  0  0  0.9(1/106) 
P21  8.3(1/12)  0  16.7(1/6)  0 
RASSNA  25(3/12)  27.8(5/18)  50(3/6)  26.4  (28/106) 
SFRP-1  8.3(1/12)  5.6(1/18)  0  5.3(4/76) 
TMS1  0  11.1(2/18)  16.7(1/6)  5.2(4/77) 
Table  11  Methylation  frequencies  In  early  stage  versus  late  stage  epithelial  ovarian  turnours. 
Methylation  frequency  %  (number  methylated  /  total  number  of  tumours)  of  each  candidate  gene 
examined  in  borderline,  and  FIGO  Stage  HV  epithelia[  ovarian  turnours. Catriona  Hardie,  2007  93 
3.3  CGI  methylation  in  non-turnour  tissue 
The  methylation  status  of  the  24  CGIs  previously  examined  in  the  tumour  samples  in 
Chapter  3.1  and  3.2  were  analysed  in  4  normal  ovarian  surface  epithelium  (nOSE)  and  3 
immortalised  ovarian  surface  epithelium  (iOSE)  samples.  No  methylation  signal  was 
detected  in  any  of  these  samples. 
16  specimens  were  obtained  from  biopsies  of  normal  tissue  immediately  adjacent  to  the 
ovarian  turnour  and  included  tissue  next  to  3  borderline  turnours,  8  stage  I  turnours  and  5 
stage  11  turnours.  Overall,  63%  of  these  normal  samples  showed  methylation  of  at  least  one 
of  the  14  CGIs  analysed  in  early  stage  turnours.  Specifically,  methylation  of  HICI,  DCRI, 
APAFI,  OPCML  and  RASSFIA  (50%,  3  8%,  6%,  6%  and  6%  respectively)  was  observed  in 
these  adjacent  normal  epithelial  tissues.  However,  methylation  within  the  corresponding 
tumour  was  not  always  observed  as  illustrated  in  Figure  15.  In  addition,  methylation  of 
BLU,  BRCAI,  MGMT,  MINT25,  MLHI,  P16,  P21,  SFRP-1  and  TMS1  was  not  observed  in 
adjacent  nortnal  tissue,  although  methylation  of  MINT25  and  TMS1  was  noted  in  13%  and 
19%  of  the  corresponding  turnour  samples  respectively. 
Methylation  of  CGIs  in  adjacent  normal  tissue 
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Figure  15  Methylation  of  CGIs  in  adjacent  normal  tissue.  Percentages  of  methylation  observed 
in  normal  tissue  adjacent  to  tumours.  Grey  bar:  methylation  only  detected  in  normal  adjacent  tissue 
but  not  in  corresponding  tumour  sample;  Blue  bar:  methylation  only  detected  in  tumour  samples, 
White  bar:  methylation  in  both  normal  adjacent  tissue  and  matched  tumour. 
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The  acquisition  of  aberrant  CGI  methylation  is  a  now  a  widely  accepted  hallmark  of  cancer 
and  it  has  been  previously  shown  that  multiple  CGIs  can  become  methylated  in  late  stage 
epithelial  ovarian  tumours  compared  to  normal  ovarian  surface  epithelium  (Strathdee  et  at., 
2001;  Wei  et  al.,  2002).  In  this  Chapter,  MSP  and  COBRA  methods  were  firstly  used  to 
analyse  methylation  of  24  candidate  CGIs  (APAF-1,  BLU,  MCA],  CASP8,  DAPK,  DCRI, 
FANCF,  FAS,  GSTP1,  HICI,  MGMT,  A=5,  MLH1,  OPCML,  P14,  P16,  P21,  P73, 
PTEN,  RASSFIA,  SFRPI,  SOCS-3,  SURVIVIN  and  TMSI)  in  106  late  stage  I1I/IV 
epithelial  ovarian  turnours  (Teodoridis  et  al.,  2005)  and  4  normal  ovarian  surface 
epithelium  samples.  Further  to  this,  the  methylation  status  of  14  of  these  candidate  loci 
(APAF-1,  BLU,  BRCAI,  DCRI,  HICI,  MGAff,  AHNT25,  MLHI,  OPCML,  P16,  P21, 
RASSPA,  SFRPI,  TMS1)  were  examined  in  early  stage  disease  (12  borderline,  18  stage  I 
and  6  stage  II)  and  matched  non-tumour  tissue  samples.  The  CGIs  examined  were  linked  to 
genes  biologically  involved  in  the  cellular  responses  to  DNA  damage.  This  included  genes 
involved  in  DNA  repair/drug  detoxification,  control  of  cell  cycle,  apoptosis,  proliferation, 
and  those  which  have  been  previously  shown  to  be  frequently  methylated  in  ovarian 
cancer. 
Aberrant  DNA  methylation  in  ovarian  carcinogenesis 
A  comparison  between  the  methylation  percentages  reported  in  this  study  for  the  late  stage 
turnours  and  previous  publications  show  similar  CGI  methylation  frequencies  in  ovarian 
turnours  for  BRCAI  (Baldwin  et  al.,  2000;  Esteller  et  al.,  2000b;  Strathdee  et  al.,  2001), 
CASP8  (Strathdee  et  al.,  2001),  DAPK  (Terasawa  et  al.,  2004),  DCRI  (Shivapurkar  et  al., 
2004),  HICI  (Strathdee  et  al.,  2001),  ADN725  (Strathdee  et  al.,  2001),  MLHI  (Strathdee  et 
al.,  2001),  P16  (Brown  et  al.,  2001;  Marchini  et  al.,  1997;  Strathdee  et  al.,  2001;  Wong  et 
al.,  1999),  P73  (Chen  et  al.,  2000),  SFRPI  (Takada  et  al.,  2004)  and  SOCS-3  (Sutherland  et 
al.,  2004). 
The  methylation  frequencies  observed  for  FANCF,  OPCML  and  TMSI  in  the  late  stage 
turnours  (0%,  33.3%  and  5.2%  respectively)  were  not  in  agreement  with  previous  reports 
in  ovarian  cancer.  FANCF  had  originally  been  reported  to  be  methylated  in  21%  of  ovarian 
tumours  (Taniguchi  et  al.,  2003).  The  MSP  cycling  number  used  in  the  aforementioned 
study  was  45  cycles  compared  to  this  study  which  used  35  cycles  for  the  results  obtained 
above  and  this  may  have  accounted  for  the  observed  differences  in  methylation 
frequencies.  A  frequency  of  FANCF  methylation  (24%),  similar  to  that  of  Taniguchi  et  al, Catriona  Hardie,  2007  95 
was  reported  in  a  more  recent  study  (Dhillon  et  al.,  2004a).  However,  the  tumours 
examined  were  of  the  gramilosa  sub-type  and  this  difference  in  histological  type  may 
contribute  to  the  percentage  differences  seen  here.  OPCML  methylation  frequency  had 
previously  been  reported  in  83%  of  ovarian  turnours  (Sellar  et  al.,  2003)  which  is  the 
highest  reported  frequency  of  aberrant  CGI  methylation  in  ovarian  malignancy  to  date. 
However,  the  stage  of  tumour  examined  was  not  shown  in  this  previous  study.  The  results 
of  this  thesis  show  that  methylation.  in  the  group  of  borderline  and  early  stage  turnours  was 
higher  than  that  seen  in  late  stage  disease  (58.3%  and  50%  versus  33.3%  respectively).  It 
may  be  that  different  stage  proportions  were  examined  in  the  study  by  Sellar  et  aL  leading 
to  higher  frequencies  (ie  more  early  stage  tumours)  reported.  An  alternative  reason  for 
differences  seen  may  be  that  OPCML  methylation  varies  with  histology.  Histological  data 
available  for  the  late  stage  group  of  tumours  in  the  work  here  showed  variability  in 
methylation  frequencies.  Specifically,  0%  and  33%  in  clear  cell  and  mucinous  tumours, 
respectively.  The  decrease  in  methylation  frequency  seen  with  turnour  progression  may  be 
due  to  loss  of  the  methylated  OPCML-allele,  but  this  is  unlikely  here  because  in  the 
previous  study  lower  frequencies  of  methylation  for  those  turnours  without  LOH  was 
observed,  indicating  preferential  loss  of  the  unmethylated  allele  (Sellar  et  al.,  2003). 
Methylation  of  TMSI  was  reported  previously  in  19%  (Terasawa  et  al.,  2004)  and  40% 
(Akahira  et  al.,  2004)  of  ovarian  cancers  but  frequency  was  variable  between  histological 
types  which  may  account  for  the  differences  seen  in  this  current  study. 
Overall,  CGI  methylation  was  a  frequent  event  in  early  stage  disease  (780/o),  and 
specifically,  methylation  of  OPCML,  RASSF1A  and  HICI  were  frequently  observed  in 
borderline  and  early  stage  ovarian  turnours  (53%,  31%  and  22%  respectively).  One 
previous  study  reported  that  RASSFIA  was  frequently  methylated  in  11/17  Stage  I  ovarian 
tumours  (Ibanez  de  Caceres  et  al.,  2004),  but  there  have  been  no  other  studies  examining 
CGI  methylation  of  these  specific  genes  in  early  stage  ovarian  cancer.  Similar  methylation 
frequencies  of  these  CGIs  were  reported  in  the  group  of  late  stage  tumours  examined 
(Teodoridis  et  al.,  2005)  and  this  compares  favourably  with  previous  reports  examining 
methylation  of  HICI  (Strathdee  et  al.,  200  1)  and  RASSFIA  (Yoon  et  al.,  200  1).  However, 
it  is  important  to  note  that  these  reports  have  examined  late  stage  disease  and  are  therefore 
not  directly  comparable  with  the  results  for  the  early  stage  group  of  tumours. 
Different  methylation  events  may  be  important  when  considering  the  initiation, 
progression  and  phenotype  of  ovarian  tumours.  The  identification  of  frequent  methylation 
events  occurring  at  an  early  stage  of  carcinogenesis  supports  the  concept  that  HICI, 
RASSFIA  and  OPCML  may  constitute  tumour  suppressor  genes  whose  inactivation  may Catriona  Hardie,  2007  96 
favour  tumour  development  (Dammann  et  al.,  2000;  Hoff  et  al.,  2000;  Sellar  et  al.,  2003) 
and  provide  a  driving  force  in  the  formation  of  a  tumour  at  an  early  stage.  Perhaps  early 
epigenetic  changes  in  cells  could  lead  to  a  tendency  to  genetic  and  epigenetic  alterations 
that  further  advance  the  neoplastic  process  and  "addicf'  cells  to  various  oncogenic 
pathways  (Baylin  and  Ohm,  2006).  It  is  interesting  to  consider  that  there  may  be  tumour- 
specific  methylation  events  leading  to  the  initiation  and  development  of  turnours  and  what 
those  may  be.  In  keeping  with  the  concept  of  methylation  of  HIC],  OPCML  and  R,  4SSFIA 
being  initiating  epigenetic  events,  methylation  of  HICI  has  been  shown  to  cooperate  with 
the  genetic  disruption  of  p53  in  mouse  knockout  models  and  drive  the  development  and 
progression  of  cancer  (Chen  et  al.,  2004).  More  recent  work  has  demonstrated  the 
functional  cooperation  between  HICI  and  p53  and  how  these  are  homeostatically  regulated 
in  a  feedback  loop  through  the  histone  deacetylase,  SIRTI  (Chen  et  al.,  2005a).  Actively 
transcribed  HICI  forms  a  repressive  complex  with  SIRTI,  which  leads  to  acetylation  of 
p53,  allowing  p53  to  trans-activate  HICL  However,  if  HICI  is  epigenetically  silenced, 
SIRTJ  is  upregulated  which  causes  deacetylation  and  inactivation  of  p53.  This  initial 
epigenetic  silencing  of  the  HICI  gene  may  ultimately  allow  cells  to  survive  DNA  damage 
and  promote  the  development  of  turnours  (Chen  et  al.,  2005a). 
A  recent  report  examining  methylation  of  RASSFIA  in  childhood  gliomas  reported 
frequent  methylation  in  tumours  and  widespread  CGI  methylation  across  the  entire  CGI 
which  indicates  that  this  epigenetic  alteration  may  be  an  early  event  rather  than  a  late 
clonal  event  (Hamilton  et  al.,  2005).  RASSFIA  is  thought  to  be  responsible  for  Ras- 
dependent  growth  inhibition  due  to  its  proapoptotic  function  (Vos  et  al.,  2000),  since 
elimination  of  Ras  inhibits  apoptosis  induced  by  transient  transfection  of  RASSFIA  into 
293-T  cells.  RASSFIA  has  also  been  shown  to  induce  cell  cycle  arrest  by  inhibition  of 
cyclin  DI  accumulation,  thereby  preventing  GI/S-phase  cell  cycle  progression 
(Shivakumar  et  al.,  2002).  A  recent  study  has  shown  a  high  prevalence  of  RASSFIA 
promoter  methylation  in  both  endometrial  turnours  and  pre-cancerous  hyperplastic  tissues 
(Pijnenborg  et  al.,  2006)  whereas  mutation  of  K-RAS  and  B-RAF  were  infrequent.  A  further 
study  in  colorectal  cancer  has  examined  the  timing  of  methylation  of  a  group  of  genes, 
including  RASSFIA,  and  has  shown  that  promoter  methylation  of  these  genes  was  present 
in  early  adenomas  without  mutations  or  chromosomal  alterations  (Derks  et  al.,  2006), 
suggesting  that  this  may  be  an  early  event  in  cancer  development.  Therefore,  inhibition  of 
expression  of  RASSFIA  through  methylation  may  be  an  early  initiating  event  in  the 
carcinogenic  process  which  is  independent  of  genetic  mutations.  This  epigenetic  silencing 
would  lead  to  a  loss  of  the  proapoptotic  and  cell  cycle-suppressive  functions  of  RASSFIA 
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Opioid  binding  protein/cell  adhesion  molecule-like  gene,  OPCML,  is  a  member  of  the 
IgLON  family  (LSAMP,  OPCML/OBCAM)  and  is  likely  to  play  a  role  in  cell  adhesion 
and  cell-cell  recognition  (Schofield  et  al.,  1989).  OPCML  has  the  functional  characteristics 
of  a  tumour  suppressor  gene  in  an  ovarian  cancer  cell  line  in  vitro  and  in  vivo  when 
xenografted  into  nude  mice  and  is  frequently  inactivated  by  allele  loss  and  CGI  promoter 
methylation  in  sporadic  ovarian  cancer  (Sellar  et  al.,  2003).  Reduced  expression  of  other 
members  of  the  IgLON  family  (LSAMP  and  NEGRI)  have  also  recently  been  shown  in 
sporadic  EOC  (Ntougkos  et  al.,  2005),  and  epigenetic  silencing  has  been  shown  to  be 
accountable  for  this  reduced  expression  in  LSAMP  (Chen  et  al.,  2003a).  However,  there  is 
still  a  necessity  to  understand  the  function  of  OPCML  and  other  members  of  the  IgLON 
family  in  the  normal  ovary,  and  how  methylation  of  this  family  of  genes  may  be  related  to 
the  malignant  phenotype.  The  molecular  mechanism  leading  to  the  epigenetic  inactivation 
of  OPCML  in  EOC  remains  largely  unknown  but  it  has  been  shown  that  activation  of  the 
oncogene  RAS  may  play  an  important  role  in  epigenetic  inacitivation  of  OPCML  in  EOC 
(Mei  et  al.,  2006).  This  RAS-mediated  epigenetic  silencing  of  OPCML  was  shown  in 
immortalized  human  ovarian  surface  epithelial  cells  and  may  therefore  represent  an  early 
event  in  ovarian  carcinogenesis,  which  would  be  in  keeping  with  the  results  described  in 
this  thesis.  RAS-induced  hypermethylation  of  genes  involved  in  key  apoptotic  pathways, 
cell  cycle,  DNA  repair  and  differentiation  has  been  reported  previously  (Alcock  et  al., 
2002;  Contente  et  al.,  1999;  Guan  et  al.,  1999;  Peli  et  al.,  1999).  These  may  be  early  events 
which  are  important  in  the  development  and  progression  of  a  turnour.  OPCML  contributes 
to  cell  adhesion  properties  and  the  epigenetic  loss  of  this  gene  may  have  important 
biological  consequences.  Adhesion  molecules  can  trigger  intracellular  signaling  which  may 
then  alter  proliferative  changes.  In  addition,  silencing  of  OPCML  could  play  an  important 
role  at  a  later  stage  of  ovarian  carcinogenesis  when  propensity  for  metastatic  peritoneal 
spread  becomes  important.  In  this  case,  the  methylation  events  that  a  tumour  cell 
accumulates  during  its  history  may  not  always  contribute  to  the  turnour  phenotype  until  a 
later  stage  of  development. 
Methylation  of  BRCAI  was  not  observed  in  early  stage  tumours  which  is  similar  to  a 
previous  report  (Wang  et  al.,  2004)  where  BRCAI  hypermethylation  was  not  detected  in 
benign  or  borderline  ovarian  tumours.  Some  studies  have  reported  methylation  of  BRCAI 
in  ovarian  tumours  but  either  did  not  mention  tumour  stage  or  analysed  late  stage  disease 
(Geisler  et  al.,  2002;  Hilton  et  al.,  2002;  Strathdee  et  al.,  2001).  One  group  have  speculated 
that  BRCAI  methylation  may  be  an  early  event  in  ovarian  tumourigenesis  (Baldwin  et  al., 
2000)  which  is  in  contrast  to  the  results  here.  No  methylation  of  APAF-I,  BLU,  MGMT, 
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comparable  to  previous  findings  in  ovarian  turnours  (Strathdee  et  al.,  2001)  and  the  results 
above  for  late  stage  disease  (Teodoridis  et  al.,  2005).  The  results  in  this  thesis  would 
suggest  that  methylation  of  these  six  loci  are  not  early  events  during  the  development  and 
progression  of  ovarian  carcinogenesis.  Three  of  these  genes  (BRCA1,  MGMT  and  MLHI) 
are  involved  in  DNA  repair  and  were  methylated  in  late  stage  tumours,  suggesting  that 
epigenetic  changes  in  these  DNA  repair  genes  do  not  significantly  contribute  to  the  early 
stages  of  sporadic  ovarian  tumourigenesis.  Impaired  DNA  repair  and  genomic  instability 
may  be  considered  to  be  "hallmarks  of  cancer"  (Hanahan  and  Weinberg,  2000).  The 
findings  here  suggest  that  epigenetic  silencing  of  BRCAI,  MGMT  and  MM  are  late 
events  in  ovarian  cancer.  There  may  be  alternative  mechanisms  and  genes  affected,  which 
have  not  been  investigated  within  the  scope  of  this  work,  but  which  may  contribute  to 
genetic  instability.  Alternatively,  this  instability  may  not  be  a  frequent  event  during 
initiation  and  early  development  of  a  tumour. 
An  alternative  explanation  for  the  methylation  differences  seen  between  early  stage  and 
late  stage  epithelial  ovarian  tumours  may  be  that  these  are  independent,  separate  disease 
entities.  There  remains  continued  controversy  over  whether  benign,  borderline  and 
malignant  ovarian  tumours  are  part  of  a  continuous  spectrum  of  disease  or  if  they  arise  de 
novo  (Cvetkovic,  2003).  Perhaps  this  is  not  always  a  disease  which  progresses  stepwise 
from  a  very  early  lesion  to  late  stage  metastatic  cancer.  The  methylation  differences  such 
as  those  seen  above  could  influence  the  phenotypic  behaviour  of  the  turnour  itself  and 
determine  its  metastatic  potential. 
Methylation  events  in  non-tumour  adjacent  tissue 
Methylation  of  HICI,  DCRI,  APAF-1,  OPCML  and  RASSFIA  (50%,  3  8%,  6%,  6%  and 
6%  respectively)  was  observed  in  normal  adjacent  non-tumour  tissue.  In  the  case  of 
RASSFIA,  methylation  in  the  non-tumour  tissue  could  be  due  to  tumour  cell  infiltration 
since  the  matched  tumour  also  showed  RASSFIA  methylation  and  MSP  can  detect  as  little 
as  0.1%  methylated  sequence  (Herman  et  al.,  1996).  However,  it  is  unlikely  that  this  alone 
can  explain  the  observed  methylation  frequency  of  HIC1,  DCRI,  APAF-1  and  OPCML  in 
non-turnour  tissue.  Firstly,  if  methylation  in  adjacent  normal  tissue  is due  to  tumour  cell 
infiltration,  methylation  should  also  occur  in  the  matched  tumour  which  was  not  observed 
in  the  majority  of  cases.  Secondly,  if  this  is  the  case,  the  ranks  of  methylation  frequencies 
should  be  similar  in  turnour  and  non-tumour  matched  tissues,  with  OPCML  and  RASSFIA 
methylation  being  more  frequent  in  non-turnour  tissue  than  HICI  or  DCR1  which  is  not  the 
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ovarian  cancer.  It  is  possible  that  multiple  biopsies  of  the  ovarian  tumour  samples  would 
yield  more  information  on  methylation  status  than  one  individual  biopsy  and  corroborate 
the  findings  in  non-tumour  tissue,  but  again  this  would  seem  unlikely  to  be  the  main  issue 
here. 
An  alternative  explanation  is  that  methylation  of  these  genes  in  normal  tissues  could 
represent  a  premalignant  epigenetic  lesion  which  is  a  mediator  of  a  "field  defect"  in  these 
tissues,  although  the  origin  of  this  field  defect  remains  unknown  (Yan  et  al.,  2006). 
Although  perhaps  not  transforming  on  their  own,  epigenetic  inactivation  of  specific  genes 
due  to  methylation  may  then  be  permissive  for  acquisition  of  additional  genetic  and 
epigenetic  changes  which  ultimately  lead  to  cancer  growth.  This  concept  has  been  shown 
in  sporadic  colorectal  cancer  (Shen  et  al.,  2005)  and  it  has  been  suggested  that  detection  of 
this  epigenetic  lesion  may  be  useful  in  the  risk assessment  for  colorectal  cancer  although 
the  idea  of  a  field  defect  in  patients  with  colorectal  adenomas  has  been  disputed  by  others 
(Rashid  et  al.,  2001).  However,  a  more  recent  study  examining  normal  adjacent  breast 
tissue  suggested  that  there  is  indeed  a  localised  field  of  R,  4SSFIA  hypermethylation  in  both 
tumours  and  associated  normal  tissues,  and  that  premalignant  epigenetic  changes  spreading 
out  from  the  epicentre  of  the  turriour  may  be  more  widespread  than  currently  thought  (Yan 
et  al.,  2006).  Aberrant  CGI  methylation  has  previously  been  observed  in  normal  tissue 
samples  adjacent  to  several  cancers  (Eads  et  al.,  2001;  Florl  et  al.,  2004;  Kanaya  et  al., 
2003;  Leung  et  al.,  2001;  Yu  et  al.,  2002).  In  addition,  a  recent  study  showed  defined 
epigenetic  changes  in  the  stromal  cells  surrounding  breast  cancers  and  suggested  that  these 
may  play  a  role  in  maintaining  the  cellular  microenvironment  during  breast  cancer 
development  (Hu  et  al.,  2005).  Previous  studies  have  reported  absence  of  methylation  in 
non-malignant  tissues  adjacent  to  ovarian  cancer  or  normal  ovarian  tissues  for  DCRI  and 
R,  4SSFIA  (Shivapurkar  et  al.,  2004;  Yoon  et  al.,  200  1).  However,  methylation  of  HICI  has 
been  detected  in  normal  breast  ductal  tissue,  normal  bone  marrow  samples  and  normal 
cerebellum  (FuJii  et  al.,  1998;  Lindsey  et  al.,  2004;  Melki  et  al.,  1999).  Methylation  of 
HICI  has  also  been  reported  in  19%  of  non-malignant  ovarian  tissues  from  patients 
undergoing  surgery  for  benign  gynaecological  disease  (Rathi  et  al.,  2002).  Therefore, 
although  we  did  not  observe  methylation  in  nOSE  or  iOSE,  the  possibility  of  HICI 
methylation  in  nOSE  cannot  be  excluded  here. 
Another  possible  explanation  of  the  findings  in  non-tumour  adjacent  tissue  may  also 
involve  the  idea  of  a  cancer  stem  cell  population.  There  is  an  increasing  body  of  evidence 
that  suggests  the  cellular  and  molecular  events  surrounding  the  initiation  of  tumour 
development  are  fuelled  by  mutation  of  cancer  stem  cell-like  cells  (Marx,  2003;  Singh  et Catriona  Hardie,  2007  100 
al.,  2003)  and  that  this  small  subpopulation  of  stem  cells  can  maintain  the  cancer 
phenotype  (Singh  et  al.,  2004)  in  solid  turnours.  This  view  has  now  been  extended  to 
encompass  the  idea  that  early  epigenetic  alterations  of  stem  cells  may  substitute  for  genetic 
mutation  and  be  the  initiating  factor  in  the  carcinogenic  process  and  evolve  in  normal 
tissue  before  the  recognised  turnour  arises  (Feinberg  et  al.,  2006).  The  methylation  of  non- 
tumour  adjacent  tissue  in  this  study  which  occurs  even  in  the  absence  of  epigenetic  change 
in  the  corresponding  tumour  may  represent  an  epigenetic  disruption  of  progenitor  cells 
which  leads  to  cancer  through  a  stepwise  process,  setting  the  scene  for  further  epigenetic 
alterations  later.  These  initial  epigenetic  events  may  lead  to  a  polyclonal  population  of  cells 
which  have  potential  for  neoplastic  change.  If  this  is  the  case,  then  the  goal  will  be 
detection  of  these  pre-neoplastic  epigenetic  lesions  (further  discussed  in  Chapter  5), 
defining  risk  and  ultimately  treating  patients  with  epigenetic  therapies  before  the  tumour 
mass  develops.  The  caveat  is  the  current  technical  difficulty  in  isolating  and  identifying 
these  cancer  stem  cells  from  solid  turnours  (Hill,  2006). 
Potential  epigenetic  changes  within  normal  ovarian  surface  epithelium 
Although  no  methylation  of  the  24  candidate  CGIs  was  detected  in  4  nOSE,  it  would  be 
intriguing  to  examine  a  greater  number  of  nOSE  samples  from  female  patients  with 
differing  clinical  histories  and  pathological  diagnoses.  There  may  be  many  factors  which 
lead  to  methylation  in  ovarian  surface  epithelium.  However,  the  difficulty  is  obtaining  OSE 
cells  and  maintaining  them  in  culture,  because  they  are  very  fragile  and  easily  disrupted  at 
the  time  of  surgical  removal  while  handling  the  ovary.  It  has  previously  been  proposed  that 
ovulatory  rupture  and  repair  predispose  the  OSE  to  mutations  (Fathalla,  1971).  Tberefore, 
decreasing  the  number  of  ovulatory  cycles  in  a  female's  reproductive  lifetime  using  the 
oral  contraceptive  pill  (OCP)  may  potentially  reduce  the  lifetime  risk  of  developing 
ovarian  cancer.  It  would  be  interesting  to  examine  the  OSE  from  patients  with  an  OCP 
history  versus  those  without,  allowing  us  to  investigate  differences  in  the  methylation 
status  of  these  tissues. 
The  effect  of  aging  can  potentially  alter  the  epigenetic  environment  within  nOSE.  It  was 
firstly  reported  that  a  NotI  restriction  site  within  exon  I  of  the  oestrogen  receptor  was 
methylated  in  normal  colonic  mucosa  in  association  with  aging  (Issa  et  al.,  1994). 
Findings  such  as  this  led  to  the  established  idea  that  some  CGIs  are  methylated  in 
association  with  aging  in  normal  tissues  (Waki  et  al.,  2003).  These  changes  in  the 
epigenetic  environment  of  nOSE  associated  with  the  aging  process  may  then  increase  the 
risk  of  malignancy  and  this  has  previously  been  proposed  (Chen  et  al.,  2005a). Catriona  Hardie,  2007  101 
When  examining  nOSE  from  patients,  it  is  also  potentially  important  to  consider 
inflammatory  conditions  which  may  alter  the  epigenetic  status  of  tissues.  Chronic 
inflammation  has  been  shown  to  be  associated  with  increased  methylation.  For  instance, 
normal-appearing  colonic  mucosa  of  patients  diagnosed  with  ulcerative  colitis  is  associated 
with  increased  methylation  of  the  p16  INK4a  promoter  (Hsieh  et  al.,  1998).  It  has  recently 
been  proposed  that  NFO  may  be  a  key  modulator  in  the  link  between  chronic 
inflammation  and  cancer  (Dobrovolskaia  and  Kozlov,  2005;  Zaenker,  2006).  Further  to 
this,  the  integration  of  NFrB  cell  signaling  by  proinflarnmatory  cytokines  and  chemokines 
with  epigenetics  has  recently  been  proposed  (Vanden  Berghe  et  al.,  2006),  linking  the 
spectrum  of  inflammatory  changes  with  epigenetics  and  cancer  risk.  The  ovary  can  be 
subject  to  a  variety  of  inflammatory  insults  during  its  reproductive  lifetime  including 
polycystic  ovarian  syndrome  (PCOS),  oophoritis  secondary  to  acute  or  chronic  pelvic 
inflammatory  disease  (PID)  and  endometriosis. 
Any  of  these  conditions  could  potentially  increase  methylation  in  the  nOSE.  Further  nOSE 
analyses  are  essential  to  avoid  using,  for  example,  age-dependently  methylated  sequences 
as  a  turnour  marker. 
The  potential  existence  of  CIMP 
It  has  been  shown  that  concordant  promoter  hypermethylation  of  multiple  genes,  which  is 
known  as  the  "CpG  island  methylator  phenotype"  (CIW),  may  exist  in  gastric  and 
colorectal  carcinomas  (An  et  al.,  2005;  Toyota  et  al.,  1999a;  Toyota  et  al.,  1999b;  Toyota 
et  al.,  2000)  although  there  has  been  some  debate  regarding  the  validity  of  CIMP  (Anacleto 
et  al.,  2005).  However,  a  recent  study  using  an  unbiased  genome-wide  method  of  analysis 
has  given  the  strongest  support  of  its  existence  to  date  (Weisenberger  et  al.,  2006).  One 
previous  study  has  examined  the  concept  of  CIMP  in  EOC  and  suggested  that  potentially 
two  groups  of  CIMP-positive  tumours  may  exist  (Strathdee  et  al.,  2001).  In  this  previous 
work,  one  group  exhibited  methylation  of  HIC],  MINY25,  AffNT31  and  P73,  and  the 
second  group  showed  susceptibility  to  BRCAI  methylation.  The  concept  of  concordant 
methylation  in  EOC  was  addressed  in  this  study  using  a  bioinformatics  approach  called 
gene  shaving  (Hastie  et  al.,  2000)  which  objectively  identifies  coherent  methylation 
patterns.  A  non-random  pattern  of  methylation  was  observed  for  CGIs  including  OPCML, 
DCR1,  RASSFIA,  A=5,  HICI  and  SFRPI  (Teodoridis  et  al.,  2005)  which  supports  the 
existence  of  MIR  This  non-random  pattern  observed  could  potentially  be  due  to  either  a 
specific  defect  driving  active  co-methylation  of  certain  genes  or  through  a  more  passive 
mechanism.  A  possible  explanation  may  be  that  aberrations  in  the  DNMT  enzyme Catriona  Hardie,  2007  102 
machinery  may  result  in  co-methylation  of  certain  genes  (De  Marzo  et  al.,  1999).  There  is 
also  modest  evidence  to  suggest  that  DNMT  overexpression  or  functional  polymorphisms 
are  related  to  CGI  methylation  in  cancer  (Teodoridis  et  al.,  2005).  The  analysis  presented 
shows  that  a  single  group  of  genes  were  identified  to  be  concordantly  methylated.  Of  the 
identified  loci  in  this  study,  only  M17VT25  has  previously  been  found  to  be  associated  with 
the  CMT  by  other  authors  (An  et  al.,  2005;  Kusano  et  al.,  2006;  Toyota  et  al.,  1999a), 
although  not  in  ovarian  cancer.  This  statistical  method  may  represent  a  new  way  of 
identifying  genes  which  are  concordantly  methylated.  Methylation  of  MINT25  may  be 
common  to  the  CIMP  and  allow  identification  of  further  genes  which  are  concordantly 
methylated  with  MNT25  and  are  part  of  a  methylator  phenotype  in  a  variety  of  tumour 
types.  However,  it  remains  unclear  what  the  biological  process  driving  this  concordance  is. 
It  is  possible  that  the  concordant  methylation  of  these  6  genes  reflects  a  difference  in 
methylation  propensity  or  a  selective  advantage  and  this  will  most  likely  affect  more  genes 
than  the  candidates  examined  here.  Genome  wide  screening  methods  in  ovarian  cancer 
(Wei  et  al.,  2002)  will  ultimately  identify  further  methylated  loci  which  have  potential  to 
be  defined  within  a  CINT  category.  This  may  aid  in  gathering  further  evidence  regarding 
whether  CHAP  exists  (1)  as  a  definitive  biological  lesion,  (2)  within  a  spectrum  of  multiple 
random  epigenetic  events  or  (3)  as  a  combination  of  both,  as  the  biological  significance  of 
the  CRv1P  remains  unknown. Catriona  Hardie,  2007 
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4  Identification  of  novel  DNA  methylation  markers 
of  acquired  chemoresistance  in  ovarian  cancer 
4.1  Analysis  of  a  CGI  library  to  identify  potential  novel 
chemoresistance  markers  in  ovarian  cancer 
The  initial  aim  of  this  part  of  the  project  was  to  identify  and  characterise  novel  DNA 
methylation  markers  for  acquired  chemoresistance  in  ovarian  cancer.  These  could  then 
potentially  help  identify  clinically  relevant  mechanisms  of  acquired  resistance  which 
would  impact  on  detection  of  relapsed,  chemoresistant  disease  in  patient  subgroups  and 
allow  stratification  of  chemotherapy  regimes  to  individual  patients.  In  a  collaborative  effort 
with  Dr.  Tim  H.  -M.  Huang  (Ohio  State  University,  Columbus,  Ohio)  and  Dr.  Jens 
Teodoridis  (University  of  Glasgow),  a  CGI  microarray  was  analysed  using  Differential 
Methylation  Hybridisation  (DMH)  for  DNA  sequences  whose  methylation  state 
discriminate  between  cisplatin-sensitive  and  cisplatin-resistant  ovarian  surface  epithelial 
cancer  cell  lines.  DMH  was  used  to  detect  genome  wide  changes  in  CGI  methylation  in 
DNA  from  16  well  characterised,  matched  ovarian  cancer  cell  line  models  including  the 
cisplatin-sensitive  parental  cell  line  A2780,5  cisplatin-sensitive  clonal  derivatives 
(A2780p3,  A2780p5,  A2780p6,  A2780p13  and  A2780pl4)  and  10  cisplatin-resistant  cell 
lines  (A2780cp7O,  MCPI-9).  The  resistant  cell  lines  were  generated  by  repeated  exposures 
of  the  A2780  cell  line  to  cisplatin  (Behrens  et  al.,  1987;  Brown  et  al.,  1997).  A  schematic 
description  of  this  method  is  given  in  chapter  2.14.  An  example  of  a  DMH  microarray 
experiment  and  a  dye-swap  for  the  A2780  cell  line  is  shown  below  in  Figure  16. Catriona  Hardie,  2007  105 
Figure  16  Example  of  a  DMH  microarray  experiment  for  the  cell  line  A2780.  left:  McrBC 
digested  DNA  was  labelled  green  (Cy3),  mock-digested  DNA  was  labelled  red  (Cy5);  right:  dye 
swap  experiment. 
Signal  intensities  were  corrected  for  background  intensity  and  after  removal  of  weak  (equal 
or  less  than  the  average  plus  two  standard  deviations  of  background  signals)  and  frequently 
missing  signals  from  each  sample  data  set,  Prediction  Analysis  for  Microarrays  (PAM) 
(Tibshirani  and  Efron,  2002)  was  applied  to  the  microarray  data  using  PAM  2.0  for  Excel. 
The  results  are  obtained  by  gradually  removing  those  sequences  which  are  creating  noise 
by  increasing  a  threshold  estimated  by  cross  validation.  PAM  identified  a  set  of  13 
sequences  whose  methylation  states  optimally  discriminate  between  cisplatin-sensitive  and 
cisplatin-resistant  cell  lines.  The  sequences  are  shown  below  in  Table  12  and  these 
included  119A6,66G6,41D9,5134  and  123D9  which  are  described  in  more  detail  later  in 
this  chapter.  Two  sequences  did  not  map  to  CGIs,  one  sequence  mapped  to  the  3'  region  of 
AH7VAK  and  two  sequences  could  not  be  aligned  to  the  genome.  CGIs  mapping  to  LMXIA 
and  SOX12  were  identified  independently  twice.  Therefore,  DMH  identified  putative 
methylation  of  CGIs  located  within  or  in  proximity  to  7  known  genes  as  shown  below  in 
Table  12.  Within  the  listed  sequences  below,  a  higher  rank  indicates  a  stronger 
discriminatory  sequence. Catriona  Hardie,  2007  106 
PAM 
Rank 
Resistant 
score 
Sensitive 
score 
Microarray 
ID'  Chromosome  CG12 
Distance 
from  TS3 
(bps) 
Gene 
symbol 
1  0.1739  -0.2675  119A6  6q21  Yes  0  NR2EI 
2  0.1708  -0.2627  66G6  9q22.32  Yes 
3  0.1141  -0.1756  42D9  no  alignment  - 
4  0.0919  -0.1415  41  D9  12qI3.12  Yes  +82  WNT1 
5  0.0872  -0.1342  5D4  Iq23.3  Yes  +2021  LlVlX1A 
6  0.0644  -0.0991  6134  4  1  q23.3  Yes  +2021  LIVIXIA 
7  0.0551  -0.0848  55F8  7q36.3  Yes 
8  0.0476  -0.0732  801-15  no  alignment 
9  0.0199  -0.0306  39EI  16p13.3  No  +6300 
10  0.0158  -0.0243  123D9  20p13  Yes  -1055  SOX12 
11  0.0115  -0.0177  109A6  I1qI2.3  Yes  +102006  AHNAK 
12  0.0027  -0.0042  122D95  20p13  Yes  -1055  SOX12 
13  0.0004  -0.0006  51  H8  3p14.2  No  -1033  ZNF312 
Table  12  Ranking  of  DNA  sequences  which  discriminate  cisplatin-sonsitive  and  cisplatin- 
resistant  cell  lines  Identified  by  Prediction  Analysis  for  Microarray  (PAM). 
lhftp:  //data.  microarrays.  ca/cpg/searchsingleclones.  htM  2  CpG  Islands  are  defined  as  "stretch  of 
DNA  of  at  least  200bp  long  with  at  least  50%  GC  content"  (hftp:  //data.  microarrays.  ca/cpg/faq.  htm) 
'TS:  Predicted  transcriptional  start  site  4  Sequence  identical  to  5D4.5Sequence  identical  to  123D9. Catriona  Hardie,  2007  107 
4.2  Validation  of  identified  sequences  using  MSP 
It  was  important  to  validate  the  results  of  the  DMH  analysis  using  an  independent  method 
to  detect  CGI  methylation.  The  methylation  states  of  these  sequences  in  the  cisplatin- 
sensitive  and  cisplatin-resistant  cell  lines  were  therefore  firstly  examined  using  MSP,  as 
described  previously  in  Chapter  3.  MSP  was  performed  on  the  sequences  within  or 
immediately  upstream  of  known  genes  for  the  top-ranking  sequences.  66G6  was  included 
because  PAM  analysis  identified  it  as  the  second-strongest  individual  discriminator 
between  cisplatin-sensitive  and  cisplatin-resistant  cell  lines  (Table  12).  The  results  which 
are  illustrated  in  Figure  17  clearly  show  that  no  methylation  was  detectable  for  either  of  the 
two  top-ranking  sequences,  119A6  or  66G6,  in  cisplatin-sensitive  cell  lines  but  in  contrast 
there  was  strong  methylation  in  cisplatin-resistant  cell  lines.  For  5D4  and  41D9,  weak 
methylation  signals  were  observed  in  some  of  the  cisplatin-sensitive  cell  lines  but  an 
overall  distinct  increase  was  still  observed  for  these  candidate  loci.  No  methylation  was 
detected  for  123D9  using  several  different  MSP  primer  sets  and  therefore  this  sequence 
was  removed  from  further  analysis  although  it  should  be  noted  that  this  was  in  keeping 
with  the  PAM  results  where  it  was  the  weakest  discriminator.  Although  no  methylation  for 
123D9  was  detected  using  MSP,  this  method  will  only  detect  methylation  within  the 
primer  binding  sites,  i.  e.  at  specific  CpG  sites,  and  there  may  still  be  changes  in 
methylation  in  other  regions  of  123D9  that  are  detected  by  DMH.  The  MSP  results  for 
11  9A6,66G6,5D4  and  41  D9  confirm  and  corroborate  the  PAM  analysis  of  the  DMH  data. 
In  addition  to  the  cell  lines  described  above,  a  further  6  cisplatin-resistant  cell  lines 
(Clcis6,  C2cis6,  C2E3,  c3cis6,  C5E4  and  C5E4(15))  were  included  in  the  MSP  validation 
(Figure  17)  which  were  derived  by  exposing  A2780  cells  to  a  single  high  dose  of  cisplatin 
(McLaughlin  et  al.,  1991).  Methylation  of  119A6,66G6,41D9  and  5D4  was  not  as 
frequent  in  these  cell  lines  compared  to  the  multiply  selected  cisplatin  resistant  cell  lines 
but  there  was  still  clear  evidence  of  acquisition  of  methylation  of  the  sequences  analysed 
by  MSP  following  a  single  cisplatin  exposure. Catriona  Hardie,  2007 
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Figure  17  MSP  validation  of  DMH  results.  Validation  using  MSP  of  11  9A6,66G6,41  D9,5D4  and 
123D9  in  the  cell  lines  analysed  by  DMH  as  well  as  6  additional  cisplatin  resistant  cell  lines, 
ClCis6-C5E4(15).  (M),  methylated  primer  set  and  (U),  unmethylated  primer  set.  H20,  reaction 
without  template  DNA;  IVM,  in  vitro  methylated  DNA;  PMN,  DNA  from  whole  male  blood. 
Amplification  of  bisulphite  modified  CALPONIN  promoter  used  as  a  control  for  successful  bisulphite 
modification,  as  described  previously. Catriona  Hardie,  2007  109 
4.3  Methylation  frequencies  of  identified  sequences  in 
epithelial  ovarian  tumours 
Methylation  of  119A6,66G6,5134  and  41139  showed  a  distinct  increase  in  chemoresistant 
versus  chemosensitive  cell  lines  as  shown  above  in  Figure  17.  The  methylation  status  of 
these  four  sequences  was  therefore  next  analysed  using  MSP  in  DNA  from  199  primary 
epithelial  ovarian  turnours  which  included  16  early  stage  (1111)  and  183  late  stage  (III/IV) 
turnours  to  identify  if  similar  changes  could  be  seen  in  in  vivo  as  in  vitro,  as  methylation 
events  in  tumours;  may  not  necessarily  mimic  those  seen  in  cell  lines.  The  turnours 
analysed  were  comprised  of  125  samples  from  the  prospective  DNA  Methylation  Study 
which  were  collected  frozen  from  chemonaive  turnours  undergoing  cytoreductive  surgery 
for  primary  ovarian  cancer,  and  74  samples  from  the  retrospective  study  described  in 
Chapter  3.119A6  and  5D4  were  methylated  in  12.6%  (25/199)  and  61.8%  (123/199)  of  the 
ovarian  turnour  samples  respectively  as  shown  below  in  Table  13.  Methylation  frequencies 
for  119A6  and  5D4  were  higher  for  early  versus  late  stage  disease  with  119A6  being 
methylated  in  18.8%  (3/16)  versus  12%  (22/183)  and  5D4  being  methylated  in  75% 
(12/16)  versus  60%  (111/183)  respectively.  In  contrast  no  methylation  was  identified  for 
66G6  and  41D9  in  55  of  the  primary  epithelial  ovarian  turnours,  as  shown  below  in  Figure 
18.  This  would  suggest  that  methylation  of  66G6  and  41D9  is  a  rare  event  in  primary 
ovarian  tumour  specimens.  66G6  and  41D9  were  therefore  removed  from  further  analysis 
as  rare  methylation  in  primary  ovarian  tumour  samples  would  reduce  their  potential 
usefulness  as  clinical  markers  of  this  disease,  although  it  can  not  be  excluded  that 
methylation  of  these  genes  could  be  selected  for  during  chemotherapy  since  only 
chemonaive  turnours  were  examined. Catriona  Hardie,  2007  110 
I 
Methylation  frequency  of  identified  sequences 
Samples  (N)  119A6  5134 
7 
66G6  41  D9 
Retrospective 
stage  I  and  11  18.8(3/16)  75(12/16) 
(16) 
Retrospective 
stage  III  and  10.3(6/58)  58.6  (34/58) 
IV  (58) 
Prospective 
stage  III  and  12.8  (16/125)  61.6  (77/125)  0(0/55)  0(0/55) 
IV  (125) 
Overall 
ovarian  12.6  (25/199)  61.8  (123/199)  0(0/55)  0(0/55) 
turnours 
(199) 
Table  13  Methylation  frequencies  of  identified  sequences  in  epithelial  ovarian  tumours. 
Methylation  frequency  %  (number  methylated/total  number  of  samples) 
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Figure  18  Examples  of  MSP  for  119A6,66G6,41139  and  5134  in  primary  epithelial  ovarian 
turnours.  Controls  included  as  per  Figure  11  including  50%  IVM,  dilution  of  1:  2  in  vitro  methylated 
DNA  into  PMN.  M,  methylated  primers  shown. Catriona  Hardie,  2007  ill 
Methylation  of  119A6  or  5D4  was  not  detected  in  4  normal  ovarian  surface  epithelium 
(nOSE  14)  DNA  samples.  In  addition,  for  the  3  immortalised  ovarian  surface  epithelial 
(iOSE  1-3)  samples  analysed,  no  methylation  was  detected  for  119A6  but  2  out  of  3  of  the 
samples  (iOSE  samples  I  and  3)  showed  methylation  at  5D4  as  shown  below  in  Figure  19. 
In  combination,  the  very  frequent  methylation  seen  in  primary  ovarian  epithelial  tumours 
(61.8%)  and  iOSE  (67%),  but  not  mortal  OSE,  may  suggest  that  methylation  of  5D4  is  an 
early  event  in  the  development  of  ovarian  cancer. 
H,  O  IVM  NM  nOSE  1-4  ý-iOSE  1-3 
5D4 
119A6 
Figure  19  MSP:  5134  and  119A6  in  ovarian  surface  epithelial  samples.  Controls  included  as 
above.  4  normal  mortal  ovarian  surface  epithelium  samples  (nOSE)  and  3  immortalised  ovarian 
surface  epithelial  samples  (iOSE)  shown.  Methylation  identified  in  iOSE  samples  I  and  3  for  51D4. 
As  described  above,  the  initial  DMH  study  identified  119A6  and  5134  as  being  sequences 
whose  methylation  states  could  discriminate  cisplatin-selected  from  parental  cell  lines.  In 
the  first  instance,  MSP  was  used  to  analyse  a  set  of  12  matched  pairs  of  ovarian  turnours 
biopsied  from  patients  both  before  and  after  platinum-based  chemotherapy  (samples  kindly 
provided  by  the  University  Medical  Centre  Groningen,  The  Netherlands).  Residual  tumour 
that  was  present  after  completion  of  chemotherapy  was  considered  to  be  indicative  of 
cisplatin-resistance  where  the  tumour  may  be  expected  to  be  enriched  for  resistant  cells 
and  analysis  of  this  allowed  a  direct  comparison  with  the  in  vitro  model  described  above  in 
the  validation  set.  Using  MSP,  methylation  of  119A6  was  increased  in  33%  (4/12)  of 
paired  tumours  post-chemotherapy  (Figure  20:  paired  samples  1,2,5  and  12)  which  is  in 
keeping  with  the  idea  of  119A6  being  a  marker  of  chemoresistance.  Histological  analysis 
showed  that  the  percentage  of  tumour  cells  in  all  paired  samples  were  almost  equal  (except 
paired  samples  4  and  5)  which  would  indicate  that  the  obvious  increase  in  methylation  seen 
in  I  19A6  post-chemotherapy  is  not  due  to  a  quantitative  increase  in  tumour  cells  following 
treatment  or  simply  enrichment  of  tumour  cells  after  chemotherapy.  In  contrast  to  119A6 
though,  there  was  no  consistent  change  in  methylation  of  5134  following  chemotherapy 
when  examined  with  MSP.  Frequent  methylation  was  seen  in  both  pre-  and  post- 
chemotherapy  samples  for  this  sequence  (Figure  20:  paired  samples  1,2,4,5,8,11  and Catriona  Hardie,  2007  112 
12).  This  is  in  keeping  with  the  overall  frequent  methylation  seen  previously  in  primary 
epithelial  ovarian  turnours  for  5D4  but  not  with  the  theory  that  5D4  may  be  a  marker  of 
chernoresistance  as  was  originally  hypothesised. 
0  Pair  1  Pair  2  Pair  3  Pair  4  Pair  5  Pair6  Pair7  PairS  Pair9  Pairl  Pairll  Pair12 
cli  >  LO  Z 
119A6 
5D4 
%Tumour 
Figure  20  Methylation  changes  in  chemonaive  versus  residual  disease.  Methylation  of  119A6 
can  increase  in  residual  disease  after  chemotherapy(*)  compared  to  chemona*fve(*)  tumours 
whereas  methylation  of  51D4  is  similar  in  both.  Tumour  percentage  by  histological  analysis  is  shown 
(%  Tumour). 
However,  it  was  important  to  quantitatively  analyse  the  methylation  differences  between 
the  paired  samples.  Pyrosequencing  technology  was  used  to  address  this  for  both  119A6 
and  5D4.  As  shown  below  in  Figure  21  and  22,7  and  5  individual  CpG  sites  within  the 
MSP  product  sequences  for  119A6  and  5134  respectively  were  analysed  using 
pyrosequencing  technology,  (for  method,  see  Chapter  2.16),  for  each  of  the  12  paired 
samples.  Background  CpG  methylation  was  determined  by  pyrosequencing  of  DNA  from 
male  whole  blood,  as  shown  in  Figures  21B  and  22B  (dotted  line).  This  allowed 
non-nalisation  of  each  result  to  this  background  level  of  methylation  seen  in  whole  male 
blood  (unmethylated  control)  and  eliminated  any  "noise".  For  119A6  and  5134,  there  was  a 
background  "noise"  level  of  3%  and  10.3%  respectively.  119A6  pyrosequencing  showed  a 
quantitative  strong  increase  in  methylation  over  the  7  CpG  sites  in  4/12  (33.3%)  paired 
samples  following  chemotherapy  (pairs  1,3,4  and  5)  as  shown  in  Figure  21.5134 
pyrosequencing  showed  a  quantitative  strong  increase  in  methylation  over  the  5  CpG  sites 
in  3/12  (25%)  paired  samples  following  chemotherapy  (pairs  4,5  and  10)  as  shown  in 
Figure  22.  The  quantitative  increase  in  methylation  seen  for  each  of  the  CpG  sites  which 
were  pyrosequenced  for  119A6  and  5134  are  tabulated  below  in  Table  14. Catriona  Hardie,  2007  113 
(A)  119A6:  %  CpG 
methylation  at  each  CpG  I  CpG  2  CpG  3  CpG  4  CpG  5  CpG  6  G7 
loci 
Chemonaive  0  10.1  7.9  3.3  0  2.4  0 
Pair  I 
Residual  12.5  50.2  20.2  17.5  17.4  2.1  56.2 
disease 
Chemonaive  0  0  3.9  0  0  0  0 
Pair  3 
Residual  8.2  36.5  38.6  3.5  30.1  25.1  45.9 
disease 
Chemonaive  0  22.4  6.8  13.6  13.6  0  0.5 
Pair  4 
Residual  16.8  41.7  28.3  24  3  30.1  14.3  24 
disease  . 
Chemonaive  0  7.4  2.3  2  0  0  7.3 
Pair  5 
Residual  27  42.8  36.4  31.1  33.9  23.6  45.4 
disease  II 
(B)  5134:  %  CpG 
methyl  ion  at  each  loci  CpG  I  CpG  2  CpG  3  CpG  4  CpG  5 
Chemonaive  12.7  11.7  7.1  15.6  37.8 
Pair  4 
Residual  19  9  11.8  5  0  30.9  76.4 
disease  .  . 
Chemonaive  6.6  10.7  6.3  12.3  15.7 
Pair  5 
Residual 
disease  52.1  50.9  43.7  53.2  63.2 
Chemonalve  4.1  9.1  3.1  8.4  17.9 
Pair  10 
Residual 
disease 
7 
19.3  27.7  6.2  23.2  41.8 
11 
Table  14  Pyrosequencing  CpG  methylation  percentage  at  each  Individual  CpG  site.  Paired 
samples  which  showed  a  quantitative  overall  increase  in  methylation  in  residual  disease  compared 
to  chemonaive  tumours  for  (A)  II  9A6  and  (B)  5D4.  Values  for  each  individual  CpG  site  are  shown. Catriona  Hardie,  2007 
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Figure  21  Pyrosequencing  analysis  of  119A6  in  12  paired  chemonaive  turnours  (green)  and 
residual  disease  following  chemotherapy  (red).  (A)  Methylation  average  (%)  of  7  individual  CpG 
sites  from  at  least  2  independent  experiments.  Grey  scale  depicts  %  of  methylation.  (B)  Average 
CpG  methylation  over  7  sites  for  each  matched  pair.  Dotted  line  indicates  background  methylation 
in  DNA  from  whole  male  blood  of  3%.  *Increase  in  methylation  seen  in  residual  disease  samples  1, 
3,4  and  5.  (C)  Examples  of  pyrograms  from  pyrosequencing  analysis  of  matched  Pair  1  of 
chemonaive  (left)  and  residual  disease  (right)  ovarian  turnours. Catriona  Hardie,  2007 
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Figure  22  Pyrosequencing  analysis  of  5134  in  12  paired  chemonaive  turnours  (green)  and 
residual  disease  following  chemotherapy  (red).  (A)  Methylation  average  (%)  of  5  individual  CpG 
sites  from  at  least  2  independent  experiments.  Grey  scale  depicts  %  of  methylation.  (B)  Average 
CpG  methylation  over  5  sites  for  each  matched  pair.  Dotted  line  indicates  background  methylation 
in  DNA  from  whole  male  blood  of  10.3%.  *Increase  in  methylation  seen  in  residual  disease 
samples  4,5  and  10.  (C)  Examples  of  programs  from  pyrosequencing  analysis  of  matched  Pair  5 
of  chemonaive  (left)  and  residual  disease  (right)  ovarian  tumours. Catriona  Hardie,  2007  116 
In  summary,  the  findings  above  would  suggest  that  119A6  and  5D4  may  be  important 
novel  DNA  methylation  markers  of  acquired  chemoresistance  due  to  the  acquisition  of 
methylation  in  both  the  paired  residual  tumours  and  cell  lines.  In  addition,  the  5D4  locus  is 
very  frequently  methylated  in  chemonaive  primary  ovarian  tumours  and  iOSE  specimens, 
and  therefore  in  addition  to  its  potential  role  as  a  marker  of  acquired  resistance,  it  may  also 
be  a  marker  for  the  early  detection  of  ovarian  cancer.  To  further  strengthen  their  potential 
role  as  biomarkers,  methylation  of  5D4  or  119A6  is  not  observed  in  nOSE  and  this 
suggests  that  these  sequences  are  preferentially  methylated  in  tumour  compared  to  non- 
turnour  ovarian  surface  epithelium.  This  is  a  crucial  finding  when  considering  a  methylated 
locus  as  a  potential  clinical  marker. Catriona  Hardie,  2007 
4.4  Bisulphite  sequencing  of  119A6,5D4  and  LMXlA 
117 
As  discussed  in  Chapter  3.1,  MSP  is  not  an  assay  which  can  be  used  to  quantitatively 
measure  density  of  CGI  methylation.  For  this  reason,  bisulphite  sequencing  was  used  to 
compare  the  differences  in  methylation  density  between  the  cisplatin-sensitive  and 
cisplatin-resistant  cell  lines,  and  corroborate  the  MSP  findings.  The  identification  of 
specific  regions  which  showed  quantitative  differences  in  methylation  could  then  be  used 
to  identify  specific  CpG  sites  for  Pyrosequencing  analysis  in  the  matched  tumour  samples. 
119A6  maps  to  the  Ist  exon  /transcriptional  start  site  of  the  human  gene  encoding  for 
NR2EI,  a  nuclear  receptor,  and  it  is  located  within  a  CGI  (Figure  23).  5D4  is  2kB 
downstream  of  the  transcriptional  start  site  of  the  human  gene  which  encodes  for  LAff]A, 
a  LIM  box  transcription  factor,  but  importantly  it  maps  to  a  CGI  that  extends  into  the 
promoter  region  of  LAMIA,  as  shown  below  in  Figure  23. 
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Figure  23  Genomic  positions  of  119A6  and  5D4.  The  positions  of  119A6  and  51D4  in  relation  to 
the  predicted  transcriptional  start  sites  of  NR2E1  and  LMX1A,  respectively. 
Sodium  bisulphite  sequencing  of  5  cell  lines  (A2780,  A2780p6,  MCPI,  MCP6  and  MCP9) 
described  in  the  MSP  validation  experiment  above  was  performed  to  quantify  the  DNA 
methylation  status  of  3  regions:  119A6  (within  the  CpG  island  of  NR2EI),  5134  and  the 
region  which  overlaps  the  transcriptional  start  site  of  LMXIA.  The  latter  region  was 
analysed  to  see  if  the  methylation  status  at  5134  is  associated  with  the  methylation  status  of 
the  DNA  region  around  the  predicted  transcriptional  start  site  of  LMXIA.  The  cell  lines 
examined  were  2  cisplatin-sensitive  cell  lines  (A2780  and  A2780p6)  and  3  cisplatin- 
resistant  cell  lines  (MCPI,  MCP6  and  MCP9).  119A6  was  sequenced  from  797bp Catriona  Hardie,  2007  118 
upstream  of  the  predicted  transcription  start  site  of  NR2EI  (sequence  length  1494bp)  and 
quantified  the  methylation  status  of  102  CpGs  in  this  region.  LMXIA  was  sequenced  from 
595bp  upstream  of  its  predicted  transcription  start  site  (sequence  length  971bp)  and 
quantified  methylation  of  82  CpGs.  The  region  surrounding  5134  was  also  examined  which 
was  2021bp  downstream  of  the  predicted  transcription  start  site  of  LMXIA  (sequence 
length  610bp)  and  included  36  CpGs. 
As  described  in  Chapter  2.15,  successful  transformants  (white  colonies)  were  selected  by 
genetic  selection  using  blue:  white  colony  screening  as  shown  in  Figure  24  and  submitted 
for  sequencing.  Complete  sequencing  of  >I  0  colonies  was  included  for  each  region  and  the 
methylation  density  of  each  individual  CpG  was  rounded  to  the  nearest  increment  of  10%. 
Figure  24  Blue;  white  colony  screening  for  sodium  bisulphite  sequencing.  This  screening 
method  relies  on  disruption  of  the  LacZa  gene  resulting  in  uncleaved  X-Gal  and  white  colony 
formation  in  successful  transformants.  Left  plate  (-ve  control  plate):  only  blue  colonies  grown.  Right 
plate:  both  blue  and  white  colonies  grown. 
The  bisulphite  sequencing  results  of  the  3  loci  examined  are  shown  below  in  Figure  25. 
Bisulphite  sequencing  showed  distinct  changes  in  the  overall  methylation  density  of  all  3 
loci  when  comparing  cisplatin-sensitive  versus  cisplatin-resistant  cell  lines  which  further 
confirms  the  DMH  and  MSP  results.  Sequencing  of  NR2EI  confirmed  the  differences 
observed  in  the  validation  MSP  experiment  (Chapter  4.2).  There  was  dense  methylation  of 
CpG  sites  in  the  cisplatin-resistant  cell  lines  compared  to  low  levels  of  methylation  in  the Catriona  Hardie,  2007  119 
cisplatin-sensitive  cell  lines  but  the  bisulphite  sequencing  results  showed  that  the  density  of 
methylation  was  not  distributed  evenly  throughout  the  DNA  regions  examined.  The 
methylation  differences  were  more  pronounced  in  the  region  flanking  the  predicted 
transcriptional  start  site  of  NR2E1.  The  methylation  differences  were  even  more  apparent 
downstream  of  the  transcriptional  start  site  of  NR2E1  where  methylation  increased  in  the 
cisplatin-resistant  cell  lines.  Average  methylation  densities  of  119A6  were  5.6%  in  the 
cisplatin-sensitive  cell  lines  which  increased  to  53.7%  in  the  cisplatin  resistant  cell  lines.  In 
both  the  5D4  and  LAMA  sequences,  these  differences  were  certainly  not  as  obvious.  For 
LAMA,  stronger  methylation  was  seen  in  the  cisplatin-resistant  versus  cisplatin-sensitive 
cell  lines  although  there  was  a  region  downstream  of  the  transcriptional  start  site  (CpG  52- 
82)  where  the  differences  in  methylation  density  were  less  pronounced.  5D4  showed 
similar  results  in  that  although  more  methylation  was  seen  in  resistant  cell  lines,  there  were 
not  the  same  distinctive  differences  as  seen  in  the  NR2E1  sequence.  Average  methylation 
densities  of  5D4  and  the  region  overlapping  the  predicted  transcriptional  start  site  of 
LAMA  were  18.1%  and  14.1%  respectively  in  the  cisplatin-sensitive  cell  lines  which 
increased  to  59.1%  and  33.5%  in  the  cisplatin  resistant  cell  lines  respectively. Catriona  Hardie,  2007  120 
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Figure  25  Bisulphite  sequencing  in  ovarian  cancer  cell  lines.  Sodium  bisulphite  genomic 
sequencing  of  A2780,  A2780p6,  MCP1,  MCP6  and  MCP9  to  quantitatively  assess  methylation 
densities  of  the  loci  119A6  (top  panel),  the  region  which  overlaps  the  transcriptional  start  site  of 
LMX1A  (middle  panel)  and  5ID4  (bottom  panel).  Grey  scale  depicts  %  of  methylation. 
Transcriptional  start  site  of  NR2EI  and  LMX1A  shown  by  arrows.  DMH  locus  shown  in  blue. Catriona  Hardie,  2007  121 
4.5  Expression  profiling  of  NR2E1  and  LMXIA 
CGI  methylation  within  promoter  regions  of  genes  has  been  shown  to  be  associated  with 
transcriptional  repression  of  the  reciprocal  gene  (Bird  and  Wolffe,  1999).  The  RNA 
expression  levels  of  LMXIA  and  NR2EI  were  quantified  in  the  cisplatin-sensitive  cell  lines 
A2780  and  A2780p6,  and  the  cisplatin-resistant  cell  lines  MCPI,  MCP6  and  MCP9  using 
qRT-PCR  (see  Chapter  2.20),  in  collaboration  with  Dr.  Jens  Teodoridis.  As  shown  below 
in  Figure  26,  increased  methylation  of  119A6  (mapping  to  NR2EI)  and  5D4  (mapping  to 
LAMA)  in  cisplatin-resistant  cell  lines  (MCPI,  MCP6  and  MCP9)  compared  to  cisplatin- 
sensitive  lines  (A2780  and  A2780p6)  was  associated  with  reduced  expression  levels  of 
both  NR2EI  and  LAMA,  respectively.  qRT-PCR  was  used  to  quantitatively  examine  the 
expression  levels  by  measuring  mRNA  levels  in  the  five  cell  lines  for  both  NR2EI  and 
LAMA  before  and  after  treatment  with  the  demethylating  agent  decitabine  (DAC).  This 
was  calculated  successively  in  three  individual  experiments  to  verify  values  obtained,  as 
shown  in  the  graphs  on  Figure  26. 
Figure  26  shows  that  treatment  of  MCPI,  MCP6  and  MCP9  with  the  demethylating  agent 
DAC  led  to  re-expression  of  NR2EI  and  LAMA  in  these  cell  lines.  qRT-PCR  confirmed 
that  NR2EI  mRNA  levels  in  the  cisplatin-resistant  cell  lines  (MCPI,  MCP6  and  MCP9) 
were  reduced  by  at  least  92%  in  comparison  to  the  mRNA  level  of  NR2EI  in  the  cisplatin- 
sensitive  cell  line,  A2780.  This  suggested  that  methylation  of  NR2EI  was  associated  with 
reduced  mRNA  expression  in  cisplatin-resistant  cell  lines.  The  differences  in  the 
expression  levels  of  LWIA  following  treatment  with  decitabine  are  less  pronounced  if 
comparing  the  cell  lines  A2780  and  A2780p6  with  MCPI,  MCP6  and  MCP9.  This  may  be 
because  5D4  and  the  region  which  flanks  the  predicted  transcriptional  start  site  of  LAMIA 
already  show  methylation  even  in  the  cisplatin  sensitive  cell  lines.  However,  after 
treatment  with  decitabine,  an  obvious  increase  in  expression  of  LAMA  is  observed. Catriona  Hardie,  2007 
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Figure  26  Quantitative  RT-PCR  values  for  NR2E1  and  LMX1A.  qRT-PCR  was  performed  with 
primers  amplifying  NR2E1  (left)  and  LMX1A  (right)  cDNA.  GAPDH  qRT-PCR  was  used  for 
normalisation  and  values  are  from  3  independent  experiments.  Values  represent  averages 
standard  deviation.  Filled  bars:  untreated  cells,  open  bars:  DAC-treated  cells.  (DAC  =  Decitabine) Catriona  Hardie,  2007 
4.6  Discussion 
123 
Successful  treatment  of  patients  with  advanced  ovarian  malignancy  lies  not  only  in  the 
surgical  and  medical  management  of  the  initial  presenting  tumour  mass,  but  also  in  the 
management  of  acquired  drug  resistance  in  the  relapsed  patient  (Vasey,  2005).  Identifying 
markers  of  chemoresistance  will  enable  clinicians  to  optimise  chemotherapeutic  regimes  to 
individual  patients  and  personalise  therapy.  Further  to  this,  identification  of  novel  CGI 
methylation  markers  may  allow  enrichment  for  patients  who  will  benefit  greatly  from 
epigenetic  treatments  that  lead  to  reversal  of  chemoresistance  (Lyko  and  Brown,  2005). 
DMH  was  used  as  a  discovery  approach  to  identify  genome-wide  differences  in  CGI 
methylation  in  a  panel  of  6  cisplatin-sensitive  and  10  cisplatin-resistant  well  characterised, 
matched,  human  ovarian  cancer  cell  lines.  PAM  (Tibshirani  and  Efron,  2002)  identified  13 
sequences  whose  methylation  states  optimally  discriminate  between  cisplatin-sensitive  and 
cisplatin-resistant  cell  lines,  and  the  validation  using  MSP  which  was  carried  out  on  five  of 
these  sequences  (119A6,66G6,41D9,5D4  and  123D9)  agreed  with  the  PAM  analysis. 
119A6  and  66G6  showed  a  strong  methylation  signal  in  cisplatin-resistant  versus  cisplatin- 
sensitive  cell  lines.  41D9  and  5D4  showed  weak  methylation  signals  in  some  of  the 
cisplatin-sensitive  cell  lines  but  an  overall  increase  was  still  observed  in  the  resistant  lines. 
Methylation  of  123D9  could  not  be  detected  and  this  may  reflect  differences  in  the  DMH 
and  MSP  methodologies.  However,  this  sequence  has  little  discriminatory  power  according 
to  PAM  analysis.  In  the  validation  work,  41D9  and  66G6  showed  no  methylation  signal  in 
primary  ovarian  turnours.  Therefore,  the  resulting  work  in  Chapter  4  focussed  on  5D4  and 
I  19A6  as  potential  markers  of  cisplatin  resistance. 
5D4  was  methylated  in  61.8%  of  primary  ovarian  turnours  overall,  and  interestingly, 
frequent  methylation  was  observed  in  both  early  (75%)  and  late  stage  (60%)  disease.  This 
not  only  indicates  that  5D4  is  frequently  methylated  in  ovarian  cancer  but  also  it  can  be 
detected  frequently  in  early  stage  carcinogenesis  (stage  I  and  II),  which  has  implications 
for  its  use  in  early  detection,  as  applied  and  discussed  in  Chapter  5.  The  high  methylation 
frequency  was  further  emphasised  when  comparing  results  with  those  of  Chapter  3.  In  this 
previous  study,  MSP  identified  aberrant  methylation  changes  of  24  candidate  CGI  loci  in  a 
group  of  epithelial  ovarian  tumours.  It  was  important  to  use  the  same  stringent  acceptance 
criteria  for  the  MSP  method  in  order  to  directly  compare  both  studies.  5D4  methylation 
frequency  in  Stage  I-IV  disease  was  higher  than  that  of  OPCML  (37.4%)  (Teodoridis  et  al., 
2005),  and  is  comparable  to  one  of  the  highest  reported  methylation  frequencies  in  the 
literature  for  ovarian  cancer  (Sellar  et  al.,  2003).  In  agreement  with  the  above  findings, Catriona  Hardie,  2007  124 
frequent  methylation  of  the  CGI  of  LAMIA  has  been  observed  by  others.  LAMIA  has  been 
shown  to  be  differentially  methylated  in  HCT116  wild-type  versus  DNMTI/DNTN4T3b 
knockout  (DKO)  cells  (Hu  et  al.,  2005;  Paz  et  al.,  2003).  Colorectal  adenoma  and 
carcinoma  showed  methylation  of  this  CGI  (42%  and  55%  respectively)  (Paz  et  al.,  2003) 
and  a  potential  role  for  CGI  methylation  of  LAMIA  in  turnourigenesis  was  suggested,  but 
not  in  drug  resistance.  Methylation  of  this  CGI  has  also  been  reported  in  myeloid 
leukaemic  cell  lines  using  a  novel  profiling  method  (Gebhard  et  al.,  2006)  which  is  one  of 
the  largest  published  lists  of  potentially  methylated  genes.  Encouragingly,  there  was  no 
methylation  identified  in  mortal  ovarian  surface  epithelium  samples  but  interestingly, 
methylation  was  seen  in  66.7%  of  immortalised  ovarian  surface  epithelium  samples.  This 
further  emphasises  that  5134  may  play  a  role  as  an  early  event  in  the  initiation  of  ovarian 
cancer  due  to  these  changes  which  are  seen  in  immortalised  cells.  Methylation  of  LAMIA 
was  also  shown  to  be  associated  with  transcript  loss  (Paz  et  al.,  2003).  This  is  in  keeping 
with  the  qRT-PCR  results  here  where  methylation  of  5D4  is  associated  with  transcriptional 
silencing. 
5D4  maps  to  a  CGI  which  extends  into  the  promoter  region  of  a  human  gene  known  as 
LAMIA.  This  gene  encodes  a  LIM-box  transcription  factor  involved  in  roof  plate  formation 
and  brain  development  during  murine  development  (Millonig  et  al.,  2000).  In  chick 
developing  spinal  cord,  LMXIA  has  been  shown  to  induce  expression  of  Wntl  (Chizhikov 
and  Millen,  2004).  This  is  interesting  because  in  the  DMH  screen,  methylation  of  41D9, 
mapping  to  a  CGI  located  at  the  917VTI  promoter,  was  identified  in  the  cisplatin-resistant 
cell  lines.  Alterations  in  the  canonical  Writ  signalling  pathway  have  been  implicated  in  the 
pathogenesis  of  a  variety  of  tumour  types  (Duan  et  al.,  2006;  Simon  et  al.,  2005). 
Overexpression  of  P-catenin  has  been  suggested  to  play  a  role  in  ovarian  cancer  (Rask  et 
al.,  2003;  Wang  et  al.,  2006a)  although  the  specific  molecular  alterations  of  the  Writ 
pathway  which  are  involved  remain  to  be  elucidated.  Epigenetic  silencing  of  LAMIA  could 
be  an  early  event  which  may  influence  other  epigenetic  and  genetic  pathways,  causing  a 
tumour  to  addict  itself  to  the  oncogenic  Wnt  pathway  (Baylin  and  Ohm,  2006;  Weinstein, 
2002).  The  methylation  changes  seen  in  drug-resistant  cell  lines  also  suggest  that 
alterations  of  the  Wnt  pathway  may  play  a  role  in  drug  resistance  mechanisms.  Normally, 
Wnti  overexpression  favours  tumour  development,  but  the  results  of  this  thesis  suggest 
that  lack  of  methylation  of  LAff1A  and  WWI  are  associated  with  chemosensitivity.  A 
similar  situation  exists  in  the  BRCAI  pathway,  where  inactivation  of  its  components 
(BRCAI,  FANCF)  favour  turnourigenesis  but  are  associated  with  increased 
chemosensitivity  (Taniguchi  et  al.,  2003).  It  may  be  that  LMXIA  may  be  sufficient  but  not 
necessary  for  Wntl  expression  (i.  e.  overexpression  of  LMXIA  will  lead  to  an  increase  in Catriona  Hardie,  2007  125 
Wntl  expression,  but  a  reduction  in  expression  of  LMXIA  through  epigenetic  mechanisms 
will  not  reduce  Wntl  expression).  Potentially,  it  could  be  envisioned  that  other 
transcription  factors  compensate  for  the  loss  of  LMXlA  at  the  WNTI  promoter  and 
maintain  its  expression,  contributing  to  tumour  development  and/or  chemoresistance. 
Epigenetic  silencing  of  LAMIA  could  then  be  involved  in  turnourigenesis  and  factors 
relating  to  chemoresistance  via  a  Wntl  independent  mechanism.  LMXlA  also  induces 
MSX1,  which  in  turn  interacts  with  the  p53  turnour  suppressor  and  inhibits  turnour  growth 
by  induction  of  apoptotic  mechanisms  (Park  et  al.,  2005).  It  has  been  shown  that 
overexpression  of  MSX1  in  OVCAR3  ovarian  tumour  cells  inhibits  cell  proliferation  by 
increasing  the  length  of  the  G1  phase  of  the  cell  cycle  (Park  et  al.,  2001).  This  further 
emphasises  the  potential  of  this  pathway  to  suppress  growth  of  ovarian  tumour  cells  and  its 
role  in  chemotherapy  induced  apoptosis. 
119A6  maps  to  a  CGI  overlapping  the  first  exon  of  the  human  NR2EI  gene  which  encodes 
an  orphan  nuclear  receptor  and  was  methylated  in  12.6%  of  primary  ovarian  turnours.  This 
gene  is  the  human  homologue  of  murine  TLX,  mapping  to  a  region  of  common  deletion  in 
human  lymphoid  leukaemia  on  chromosome  6q2I  and  may  function  as  a  tumour 
suppressor  gene  (Jackson  et  al.,  1998).  The  results  above  show  that  methylation  of  the 
119A6  locus  is  associated  with  transcriptional  repression  of  the  associated  gene.  This  is  the 
first  report  of  an  epigenetic  mechanism  regulating  the  transcriptional  status  of  this  nuclear 
receptor  although  methylation  of  other  nuclear  receptors  including  retinoic  acid  receptor 
alpha2  and  IL2  have  been  reported  previously  (Farias  et  al.,  2002;  Misawa  et  al.,  2005). 
5D4  and  119A6  represent  potential  novel  loci  for  the  study  of  chemoresistance  markers  in 
ovarian  cancer.  5D4  and  119A6  showed  an  increase  in  methylation  of  25%  (3/12)  and 
33.3%  (4/12)  respectively  when  comparing  post-chemotherapy  to  chernonaive  tumour 
samples.  This  makes  them  promising  epigenetic  markers  of  cisplatin-resistance  in  relapsed 
disease.  This  increase  in  methylation  at  the  time  of  relapse  has  also  been  reported  for  other 
markers  such  as  OEM  (Gifford  et  al.,  2004). 
The  relationship  between  the  abnormal  expression  of  transcription  factors  and  drug 
resistance  has  been  the  focus  of  various  studies  and  emerging  evidence  suggests  that  drug 
resistance  in  cancer  can  arise  from  elaborate  gene  expression  of  multiple  transcription 
factors.  For  example,  inhibition  of  PAX2  (which  is  frequently  overexpressed  in  renal 
carcinoma)  with  antisense-cDNA  can  enhance  cisplatin-induced  apoptosis  in  renal 
carcinoma  cells  (Hueber  et  al.,  2006),  activation  of  NFKB  can  mediate  paclitaxel  resistance 
in  ovarian  cancer  cell  lines  (Mabuchi  et  al.,  2004),  overexpression  of  Ets-1  results  in Catriona  Hardie,  2007  126 
increased  cisplatin  resistance  in  the  ovarian  cancer  cell  line  2008  (Wilson  et  al.,  2004)  and 
overexpression  of  BARX2  leads  to  increased  sensitivity  against  cisplatin  in  the  ovarian 
cancer  cell  line  PEOI  (Sellar  et  al.,  2002).  Currently  though,  the  relevance  of  these 
mechanisms  to  the  development  of  drug  resistance  in  patients  remains  unclear. 
TLX,  the  murine  homolog  of  NR2EI,  is  an  upstream  regulator  of  PAX2  (Yu  et  al.,  2000) 
and  suppresses  PAX2  expression  in  mice.  This  is  intriguing  because,  firstly,  the  human 
neuronal  apoptosis  inhibitory  protein  (NAIP)  gene  promoter  has  been  shown  to  be  a 
downstream  target  of  PAX2  which  then  suppresses  apoptosis  in  the  developing  kidney 
(Dziarmaga  et  al.,  2006).  In  addition,  downregulation  of  PAX2  can  enhance  cisplatin 
sensitivity  (Hueber  et  al.,  2006),  and  therefore  methylation  and  silencing  of  NR2EI  may 
increase  chemoresistance  by  increasing  PAX2  expression  in  tumours  and  inhibiting 
cisplatin-induced  apoptosis  through  binding  to  NAIP.  PAX2  has  also  been  shown  to 
activate  W7VT4  gene  expression  (Torban  et  al.,  2006),  and  therefore  could  also  be 
potentially  involved  in  regulatory  mechanisms  of  the  Wnt  signalling  pathway  in 
carcinogenesis,  although  any  involvement  in  drug  resistance  mechanisms  remains  to  be 
investigated.  TLX  can  also  regulate  PTEN  and  other  genes  involved  in  signalling 
pathways,  including  TGFP  and  MAPK  signalling  in  the  mouse  retina  (Zhang  et  al.,  2006). 
TLX  is  required  for  development  of  the  retina  (Yu  et  al.,  2000;  Zhang  et  al.,  2006)  and 
brain  including  the  dentate  gyrus  (Monaghan  et  al.,  1997)  and  the  subventricular  zone  (Shi 
et  al.,  2004).  Stem  cells  are  located  in  these  regions  and  indeed  TLX-positive  neuronal 
cells  show  stem  cell-like  properties  in  their  ability  to  self-renew  and  are  multipotent  (Shi  et 
al.,  2004). 
It  has  previously  been  proposed  that  acquired  drug  resistance  following  chemotherapy  can 
be  due  to  either  the  survival  and  growth  of  chemoresistant  subpopulations  initially  present 
in  heterogeneous  chemonaive  turnours,  or  may  be  due  to  cancer  stem  cells  repopulating  the 
tumour  environment  (Agarwal  and  Kaye,  2003).  Both  of  these  are  possibilities  in  acquired 
resistance  mechanisms,  either  singularly  or  in  combination.  NR2E1  seems  to  induce 
cisplatin-induced  apoptosis  (Dziannaga  et  al.,  2006;  Hueber  et  al.,  2006),  and  cisplatin- 
based  chemotherapy  may  select  pre-existing  subpopulations  with  epigenetically  silenced 
NR2E1.  Alternatively,  there  is  increasing  interest  in  the  suggestion  that  epigenetic 
alterations  in  stem  cells  may  be  inherently  linked  to  many  properties  seen  in  turnours,  such 
as  drug  resistance  (Feinberg  et  al.,  2006),  and  that  survival  of  cancer  stem  cells  may 
provide  them  with  a  role  in  acquired  drug  resistance  following  chemotherapy  (Dean  et  al., 
2005).  In  addition,  stem  cells  have  been  reported  to  contribute  to  the  aggressive  behaviour 
of  EOC  (Bapat  et  al.,  2005).  NR2E1  and  LAMA  are  both  expressed  in  stem  or  progenitor Catriona  Hardie,  2007  127 
cells  and  are  implicated  in  stem  cell  maintenance,  cell  fate  determination  and 
differentiation  (Burbach  and  Smidt,  2006;  Shi  et  al.,  2004).  These  stem  cells  may  only 
comprise  a  very  small  proportion  of  the  cells  within  a  tumour  and  be  relatively  quiescent 
therefore  avoiding  the  toxicity  of  the  chemotherapy  regime  which  will  target  rapidly 
dividing  cells.  Therefore,  the  acquisition  of  methylation  post-chemotherapy  could 
represent  survival,  growth  and  differentiation  of  cancer  stem  cells  which  were  present  in 
the  original  tumour  prior  to  treatment  with  chemotherapy.  However,  from  the  results 
described,  it  is  not  possible  to  distinguish  if  drug  resistant  subpopulations  or  stem  cells 
contribute  to  the  resistance  seen.  Considering  that  both  of  the  genes  examined  here  were 
firstly  detected  in  a  cell  culture-based  search  for  methylation  markers  of  chemoresistance, 
it  seems  unlikely  that  stem  cell-related  processes  should  occur  in  such  an  in  vitro  system. 
However,  other  groups  have  reported  the  presence  of  side  populations  of  tumourigenic 
stem-like  cells  in  cell  lines  cultured  in  vitro  for  several  years  (Kondo  et  al.,  2004; 
Patrawala  et  al.,  2005).  Therefore,  the  presence  of  stem  cell  populations  and  consequently 
a  role  for  them  in  acquired  drug  resistance  in  these  cell  cultures  cannot  be  excluded. 
The  above  findings  represent  novel  diagnostic  and  therapeutic  challenges  in  ovarian 
cancer.  The  clinical  implications  of  these  are  discussed  in  Chapter  S. Catriona  Hardie,  2007 
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Clinical  application  of  aberrant  DNA  methylation 
markers  in  ovarian  cancer 
5.1  Early  detection  biornarkers:  identification  of  CGI 
methylation  in  plasma 
Ovarian  cancer  remains  difficult  to  detect  at  an  early  stage  with  currently  available 
screening  methods.  Results  described  in  Chapters  3  and  4  showed  that  CGI  methylation 
can  be  frequently  identified  in  early  stage  EOC.  5D4  (2kB  downstream  of  the  predicted 
transcription  start  site  of  the  transcription  factor,  LAMA),  OPCML,  RASSFIA  and  HICI 
were  frequently  methylated  in  early  stage  ovarian  turnours  (75%,  53%,  31%  and  22% 
respectively).  87.5%  of  the  early  stage  tumours  examined  were  methylated  in  at  least  one 
of  these  4  genes.  Therefore,  a  combination  of  these  methylation  markers  could  potentially 
impact  on  the  current  poor  sensitivity  levels  of  detecting  early  stage  disease  and  therefore 
improve  poor  survival  rates  for  patients  presenting  with  ovarian  cancer.  However,  CGI 
methylation  will  only  be  acceptable  as  a  clinical  marker  of  early  detection  if  we  can 
identify  the  changes  described  above  in  easily  accessible  body  fluids,  such  as  plasma 
extracted  from  whole  blood. 
Matched  plasma  and  PBMC  DNA  samples  were  examined  from  patients  in  the  prospective 
DNA  methylation  study  undergoing  cytoreductive  surgery  for  ovarian  cancer.  This  was  to 
see  if  the  same  epigenetic  changes  could  be  detected  in  plasma  as  were  seen  in 
corresponding  tumour.  In  an  initial  feasibility  study,  thirty  matched  blood  and  chemonaive 
epithelial  ovarian  tumour  samples  were  analysed  and  compared  for  methylation  of  the  four 
loci  which  were  frequently  methylated  in  early  stage  disease  (5D4,  OPCAE,  RASSFIA  and 
HICI)  with  the  aim  of  correlating  these  with  MSP  data  from  the  corresponding  tumour 
sample.  A  gene  which  was  negative  for  hypermethylation  in  the  tumour  DNA  was  always 
negative  in  the  matched  plasma  DNA.  The  converse  was  also  true,  in  that  when  a  gene  was 
methylated  in  plasma,  it  was  also  methylated  in  matched  tumour  DNA,  representing  a 
specificity  of  100%.  The  plasma-positive  cases  were  all  sampled  from  patients  with  late 
stage  III/IV  EOC.  However,  because  only  1/30  samples  was  from  a  Stage  I  ovarian 
tumour,  more  early  stage  samples  will  require  analysis  for  conclusions  to  be  drawn 
regarding  CGI  methylation  frequencies  in  these  early  stage  cancers.  Methylation  of  at  least 
one  of  the  four  genes  analysed  was  found  in  100%  of  the  30  ovarian  tumour  samples,  with 
individual  methylation  frequencies  of  90%,  50%,  33.3%  and  20%  for  5D4,  OPCML,  HICI Catriona  Hardie,  2007  130 
and  RASSFIA  respectively.  Individually,  methylation  of  5D4,  OPCML,  and  RASSFIA  was 
observed  in  43.3%  (13/30),  20%  (6/30)  and  6.7%  (2/30)  of  the  plasma  samples 
respectively.  No  methylation  signal  was  detected  for  HICI  in  any  of  the  plasma  samples 
examined.  The  sensitivity  of  detecting  methylation  of  5134  alone  in  plasma  from  patients 
whose  tumour  was  methylated  at  this  locus  was  48.2%.  Overall,  the  sensitivity  of  detecting 
methylation  of  at  least  one  of  the  four  genes  examined  was  53.3%  (16/30)  in  the  matched 
plasma  samples  (i.  e.  14  patients  showed  no  methylation  in  plasma  DNA  despite  showing 
methylation  in  tumour).  Encouragingly,  10%  (3/30)  and  3.3%  (1/30)  of  plasma  samples 
were  co-methylated  in  at  least  2  or  3  genes  respectively.  Table  15  shows  the  methylation 
status  of  all  loci  for  matched  plasma  and  tumour  samples. 
GENE  ANALYSED  IN  MATCHE  TUMOUR  (T)  OR  LASMA  (P  ) 
5134  OPCM  L  RAS  SFIA  HI  CI 
PATIENT  T  p  T  p  T  p  T  p 
I  m  u  u  u  m  u  u  u 
2  m  m  u  u  u  u  u  u 
3  m  m  u  u  u  u  u  u 
4  m  u  u  u  m  m  m  u 
5  m  m  m  u  m  u  u  u 
6  u  u  u  u  m  u  u  u 
7  m  u  m  u  m  u  m  u 
8  m  m  u  u  u  u  m  u 
9  m  m  m  m  u  u  m  u 
lo  m  m  u  u  u  u  u  u 
11  m  u  u  u  u  u  u  u 
12  m  u  m  m  u  u  u  u 
13  M  u  u  u  u  u  u  u 
14  M  u  u  u  u  u  u  u 
15  m  u  u  u  u  u  u  u 
16  m  m  m  m  u  u  u  u 
17  m  m  m  m  m  m  u  u 
18  m  m  u  u  u  u  u  u 
19  u  u  m  u  u  u  m  u 
u  u  u  u  u  u  m  u 
21  m  m  u  u  u  u  u  u 
22  m  u  m  u  u  u  m  u 
23  M  m  m  u  u  u  u  u 
24  m  u  m  u  u  u  u  u 
25  m  m  m  u  u  u  u  u 
26  m  m  m  m  u  u  m  u 
27  m  u  u  u  u  u  u  u 
28  m  u  m  u  u  u  m  u 
29  m  u  m  m  u  u  m  u 
m  u  m  u  u  u  u  u 
90%  43.30%  50%  20%  20%  6.70%  33.30%  0% 
Table  15  Methylation  status  of  matched  tumour  and  plasma.  Tabulation  of  methylation  status 
of  the  loci  (51D4,  OPCML,  RASSF1A  and  HIC1)  for  30  matched  tumour  (T)  and  plasma  (P)  patient 
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5.2  Predictive  biornarkers  in  ovarian  cancer 
The  majority  of  the  24  genes  examined  in  Chapter  3  have  previously  been  shown  in 
experimental  models  to  be  associated  with  cellular  sensitivity/response  to  DNA  damage 
(Teodoridis  et  al.,  2005).  In  order  to  identify  potentially  useful  predictive  markers  of 
disease  response  to  treatment  at  initial  presentation,  patterns  of  methylation  were  examined 
in  the  group  of  retrospective  late  stage  III/IV  ovarian  turnours  to  see  if  there  was  any 
correlation  with  chemotherapy  response.  This  work  was  done  in  collaboration  with  Dr. 
Jacqueline  Hall.  All  of  the  patients  had  been  treated  with  platinum-based  chemotherapy 
(100%),  either  cisplatin  or  carboplatin,  and  the  majority  had  received  a  course  of  taxoid 
chemotherapy  (69%).  Only  70  of  the  106  patients  were  suitable  for  assessment  of  their 
response  to  chemotherapy.  For  the  purpose  of  this  analysis,  complete  and  partial  clinical 
response  were  combined  and  compared  to  stable  and  progressive  disease.  The  CGIs  were 
grouped  according  to  the  biological  role  of  a  specific  gene,  as  shown  below  in  Table  16, 
and  examined  for  associations  with  clinical  response  to  chemotherapy.  It  was  hypothesised 
that  disruption  of  a  biological  pathway  at  any  specific  point  had  the  potential  to  affect  the 
functioning  of  that  cellular  response.  In  addition,  grouping  genes  together  also  reduced 
problems  of  multiple  statistical  analyses.  A  group  was  considered  methylated  if  at  least  one 
CGI  examined  was  methylated.  Correlation  between  methylation  and  response  was 
assessed  by  the  e  test  unless  the  smallest  expected  value  was  less  than  5,  and  then  Fisher's 
Exact  Test  was  used  (Chapter  2.21.1).  All  statistical  analysis  in  Chapter  5  was  performed 
using  the  SPSS  v12.01  software  package  (SPSS  Inc.,  Chicago,  USA). 
BIOLOGICAL  FUNCTION  GENE  GROUPS 
APOPTOSIS  APAFI,  CASP8,  DAPK,  DCRI,  Fas,  MLHI,  P14,  P73 
RASSFIA,  Survivin,  TMSI 
OVARIAN  TUMOUR 
SUPPRESSOR 
OPCML 
PROLIFERATION  PTEN,  SFRP1,  SOCS3 
DNA  REPAIR  /  DRUG 
DETOXIFICATION 
BRCA1,  FANCF,  MGMT,  GSTPI 
CELL  CYCLE  P16,  P21 
OTHER  /  UNKNOWN  BLU,  HICI,  MINT25 
Table  16  Genes  grouped  according  to  specific  biological  function. Catriona  Hardie,  2007  132 
Methylation  of  any  one  of  the  24  CGIs  examined  compared  to  no  gene  methylated  did  not 
associate  with  response  to  treatment  (p=0.51,  n--64).  Methylation  of  the  group  of  genes 
involved  in  regulation  of  apoptosis  (APAF-1,  CASP8,  DAPK,  DCRI,  FAS,  MM,  P14, 
P73,  RASSFIA,  SURVIVIN  and  TMSI)  was  not  significantly  associated  with  response  to 
chemotherapy  in  those  patients  that  were  evaluable  (p=0.74).  MLH1  was  included  in  the 
group  of  apoptosis-related  genes,  rather  than  the  DNA  repair  set,  because  a  lack  of  MM 
has  been  shown  to  lead  to  DNA  damage  tolerance  due  to  loss  of  engagement  of  an 
apoptotic  response  (Luo  et  al.,  2004).  Methylation  of  the  groups  of  genes  involved  in  cell 
cycle  control  and  proliferation  (P16,  P21,  PTEN,  SFRPI,  SOCS-3)  did  not  significantly 
correlate  with  response  (p=0.999).  However,  methylation  of  at  least  one  of  the  group  of 
genes  involved  in  DNA  repair  and  drug  detoxification  (BRCA],  GSTP1,  MGAfl)  was 
significantly  associated  with  increased  response  to  chemotherapy  (p=0.013,  n--70).  In  the 
patient  group  that  showed  methylation  of  BRCAI,  GSTPI  or  MGMT,  response  rate  to 
chemotherapy  was  100%  compared  to  a  response  rate  of  62.7%  for  patients  not  showing 
methylation  of  any  one  of  these  genes.  The  majority  of  the  ovarian  tumours  examined  in 
the  DNA  repair  group  showed  methylation  of  BRCA1  (85%),  but  methylation  of  BRCAI 
alone  showed  only  borderline  significance  for  association  with  response  to  treatment 
(p=0.049,  n--70). 
The  patterns  of  CGI  methylation,  which  are  described  above  may  have  the  potential  to 
predict  clinical  outcome  but  adequate  power  and  careful  validation  of  results  is  important. 
The  validation  study  of  the  hypotheses  generated  here  are  described  below  in  Chapter  5.3. Catriona  Hardie,  2007 
5.3  Validation  of  predictive  biomarkers 
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The  retrospectively  collected  ovarian  tumour  samples  which  have  been  discussed  in 
previous  chapters  were  obtained  from  a  heterogeneous  population  of  patients  who  did  not 
always  receive  comparable  chemotherapeutic  regimes  following  cytoreductive  surgery.  It 
was  important  to  confinn  and  validate  the  observations  and  hypotheses  generated  in 
Chapter  5.2  in  a  prospective  collection  of  tumours  from  patients  who  all  received  standard 
first-line  platinum  based  chemotherapy  (+/-  taxane)  following  surgery.  To  achieve  this 
aim,  the  "DNA  Methylation  Study"  was  set  up  to  collect  primary  epithelial  ovarian 
tumours  from  a  more  defined  homogenous  patient  population.  Samples  were  collected  at 
the  time  of  cytoreductive  surgery  prior  to  chemotherapy.  The  precise  number  of  samples 
which  were  required  depended  on  the  exact  details  of  recruitment  rate  and  the  minimum 
follow-up  period  of  this  study.  It  was  assumed  that  50%  more  patients  than  events  were 
required,  which  meant  having  approximately  a  minimum  of  I  year  follow-up  for  the  vast 
majority  of  patients.  The  sample  size  calculations  were  based  on  the  primary  end-point  of 
PFS.  Assuming  a  power  of  90%,  between  131  and  258  patients  were  required  for  this  study 
(hazard  ratio  2.0). 
The  statistical  analysis  of  the  MSP  results  in  Chapter  5.2  showed  that  methylation  of  at 
least  one  of  the  group  of  genes  involved  in  DNA  repair  and  drug  detoxification  (BRCA], 
FANCF,  GSTPI,  MGAM  was  significantly  associated  with  increased  response  to 
chemotherapy  (p=0.013,  n=70).  We  tested  this  in  an  independent  data  set  using  samples 
from  the  prospective  collected  ovarian  turnours. 
The  initial  MSP  analysis  of  BRCA  1,  FANCF,  GSTP1  and  MGMT  was  performed  in  125 
ovarian  turnours  which  were  collected  prospectively  although,  as  shown  below,  not  all  of 
these  samples  were  included  in  statistical  analysis.  Methylation  of  BRCAI  (n=13,10.4%) 
and  FANCF  (n--I,  0.8%)  were  observed  but  no  methylation  was  seen  for  either  MGMT  or 
GSTPL  These  methylation  frequencies  observed  are  comparable  to  those  obtained  in  the 
retrospective  study,  as  shown  in  Table  10,  Chapter  3.1. 
77  of  the  125  tumours  analysed  had  collected  clinical  information.  19  of  these  samples 
were  removed  from  further  statistical  analysis  because  3  turnours  were  found  to  be  non- 
epithelial.  derived  ovarian  tumour  samples  and  16  tumours  were  of  an  earlier  stage  (<Stage 
III)  than  those  examined  in  Chapter  5.2.58  tumour  samples  were  therefore  available  for 
further  analysis.  Of  these  58  patients,  28  patients  had  unevaluable  disease  (Le  had  no 
measurable  tumour  volume  following  cytoreductive  surgery)  and  11  patients  had  some Catriona  Hardie,  2007  134 
missing  or  incomplete  clinical  data  and  therefore  were  excluded  which  reduced  the  number 
to  19  suitable  patients.  Clearly  these  numbers  are  small  and  the  study  is  underpowered  to 
validate  the  original  findings.  However,  due  to  time  constraints  it  was  not  possible  to 
prospectively  accrue  sufficient  samples,  so  the  data  was  analysed  as  it  was. 
For  the  purpose  of  this  analysis,  complete  and  partial  clinical  response  were  again 
combined  and  compared  to  stable  and  progressive  disease.  Those  patients  with  evaluable 
response  data  included  12  patients  who  responded  to  chemotherapy  and  7  patients  who  did 
not  respond.  These  results  are  illustrated  below  in  Table  17. 
Outcome  DNA  Repair 
Unmethylated 
DNA  Repair 
Methylated  Total 
No  response 
_ 
7 
, 
0  7 
Response  9  3  12 
Total  (both)  16  3 
Table  17  Cross  tabulation  of  response  to  chemotherapy  In  the  prospective  validation  set. 
For  several  reasons,  the  19  patient  samples  which  were  evaluable  for  response  were 
underpowered  for  any  further  statistical  interpretation.  Firstly,  there  were  28  patients  with 
missing  response  endpoints  due  to  unevaluable  disease  prior  to  chemotherapy.  There  was 
also  insufficiently  mature  response  data  for  II  patients.  In  addition  to  these  issues,  there 
were  also  a  low  number  of  methylation  events  in  the  DNA  repair  set  of  genes  which  made 
it  difficult  to  assess  the  data  statistically  with  such  small  numbers.  However,  it  should  be 
noted  that  a  trend  was  observed  in  Table  17  which  showed  that  there  were  more 
methylation  events  in  the  DNA  repair  set  in  responders  versus  non-responders  (3  versus  0), 
in  keeping  with  the  statistically  significant  findings  in  the  retrospective  group. Catriona  Hardie,  2007  135 
5.4  Identifying  novel  markers  of  acquired  resistance  in 
ovarian  cancer 
The  potential  to  uncover  novel  DNA  methylation  markers  of  acquired  chemoresistance  in 
ovarian  cancer  was  investigated  in  Chapter  4.  Two  novel  markers,  5D4  and  119A6,  were 
identified  which  could  potentially  improve  detection  in  the  relapsed  patient  and 
individualise  treatment  in  subgroups  of  patients.  199  patient  samples  were  analysed  for 
methylation  of  these  2  markers.  126  of  these  had  sufficient  clinical  information  for 
associations  with  clinical  characteristics  to  be  sought  and  had  been  treated  with  platinum 
+/-  taxane  therapy  as  a  first  line  treatment  regime.  Where  it  was  appropriate,  Pearson  Xý  or 
Fisher's  Exact  Test  were  used  to  examine  associations  between  methylation  frequency  and 
stage,  grade  and  histology  (details  as  shown  in  Table  18).  The  Mann  Whitney  U  Test  was 
applied  to  test  associations  between  methylation  and  age.  This  uses  a  range  of  frequencies 
rather  than  specific  categories.  Methylation  of  119A6  and  5D4  was  independent  of  age 
(I  19A6:  p=0.87  and  5D4:  p=0.34,  N=125),  stage  (early  vs.  late  stage,  119A6:  p=0.23  and 
5D4:  p=0.99,  N=126)  and  grade  (well/moderately  vs.  poorly/undifferentiated,  119A6: 
p=0.65  and  5D4:  p=0.13,  N=93).  Stage  was  categorised  into  early  versus  late  because  the 
numbers  for  each  individual  stage  were  low.  In  spite  of  the  small  numbers,  for  119A6, 
there  was  a  slight  trend  of  a  reduction  in  methylation  with  advancing  tumour  although  this 
was  not  statistically  significant  (p=0.23).  Removal  of  cases  with  unknown  histology 
showed  that  the  proportion  of  cases  methylated  for  119A6  and  5D4  was  not  significantly 
different  between  serous  and  non-serous  histological  subtypes  (I  19A6:  p=0.68  and  5D4: 
p=0.75,  N=94). Catriona  Hardie,  2007  136 
119A6  5D4  Total  (n) 
HISTOLOGICAL 
Serous  6(13%)  29(64%)  45 
Endometrioid  3(33%)  6(67%)  9 
Clear  Cell  2(25%)  5(63%)  8 
Mucinous  1(17%)  3(50%)  6 
Other  0  1(50%)  2 
Adenocarcinoma  2(8%)  15(63%)  24 
Unknown  3(9%)  17(53%)  32 
TOTAL  17  76  126 
TUMOUR  STAGE 
Early  4(25%)  10(63%)  16 
Late  13(12%)  66(60%)  110 
TOTAL  17  76  126 
TUMOUR  GRADE 
Well  1(17%)  2(33%)  6 
Moderate  4(17%)  14(61%)  23 
Poor/Undifferentiated  4(6%)  39(61%)  64 
TOTAL  9  55  93 
PATIENT  RESPONSE 
Response  6(13%)  28(62%)  45 
No  Response  2(8%)  13(54%)  24 
TOTAL  8  41  69 
Table  18  Details  of  clinicopathological  data  of  126  tumours  examined  for  methylation  of 
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Kaplan  Meier  survival  curves  and  log  rank  tests  were  used  to  assess  associations  with  PFS 
(defined  as  from  presentation  to  first  progression)  or  OS.  Methylation  of  either  119A6  or 
5134  was  not  associated  with  PFS  or  OS  (PFS/I  19A6:  p=0.34,  PFS/5D4:  p=0.47; 
OS/I  19A6:  p=0.86,  OS/5134:  p=0.93).  The  Kaplan  Meier  curves  are  illustrated  below  in 
Figure  27. 
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Figure  27  Kaplan  Meier  survival  curves  to  assess  association  of  119A6/SD4  methylation  with 
PFS  or  OS.  Methylation  of  either  marker  does  not  associate  with  PFS/OS.  Green  line 
metýiyýate!.  Blue  line  =  unmethylated. Catriona  Hardie,  2007  138 
Response  information  was  only  available  for  69  patients  as  shown  below  in  Table  19.24 
patients  were  classified  as  non-responders  and  45  were  responders.  No  association  was 
shown  between  response  to  chemotherapy  and  methylation  of  119A6  or  5D4  (P=0.54  and 
p=0.52  respectively).  The  cross  tabulation  of  this  is  shown  in  Table  19. 
5D4 
(Methylat  d) 
119A6 
(Methylated)  Total 
Response  28(62%)  6(13%)  45 
No  response  13(54%)  2(8%)  24 
69 
Table  19  Cross  tabulation  of  response  to  chemotherapy  for  methylated  loci  I  19A6  and  5D4. Catriona  Hardie,  2007 
5.5  Discussion 
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The  results  in  Chapters  3  and  4  illustrate  that  aberrant  CGI  methylation  is  detected  at  all 
stages  of  EOC.  It  is  accepted  that  this  can  potentially  be  used  as  a  diagnostic  tool  to  detect 
cancer  (Esteller,  2003),  and  the  results  here  show  that  different  groups  of  methylated  CGIs 
may  specifically  be  useful  for  early  disease  detection,  prediction  of  response  to 
chemotherapy  and  as  markers  of  relapsed  disease.  It  is  feasible  that  as  a  cancer  cell 
accumulates  an  increasing  number  of  methylation  events  over  time,  these  may  then 
potentially  impact  on  the  phenotype  of  the  tumour  and  subsequently  affect  its  ability  to 
respond  to  chemotherapy.  It  is  also  worth  considering  that  heterogeneous  turnours  may 
exhibit  differing  methylation  patterns,  therefore  examining  groups  of  potentially 
methylated  markers  may  increase  the  sensitivity  and  specificity  of  a  biomarker  (Levenson, 
2004).  In  order  to  use  CGI  methylation  as  a  clinical  biomarker,  it  firstly  has  to  be  readily 
detectable  in  easily  accessible  surrogate  body  sources  such  as  plasma.  It  has  already  been 
shown  that  CGI  methylation  can  be  detected  in  plasma  with  the  same  characteristic 
changes  as  are  found  in  the  corresponding  turnour  (Esteller  et  al.,  1999b;  Gifford  et  al., 
2004;  Ibanez  de  Caceres  et  al.,  2004;  Weaver  et  al.,  2006).  Encouragingly,  this  is  highly 
specific  for  ovarian  cancer  (Chang  et  al.,  2002).  Methylation  analysis  is  particularly  suited 
to  plasma  DNA  because  highly  sensitive  PCR-based  assays  such  as  fluorescent-MSP  only 
require  small  amounts  of  DNA.  These  types  of  MSP-based  assays  will  potentially  be  very 
useful  in  the  clinic  to  detect  changes  since  hypermethylation  of  a  given  gene  tends  to  occur 
at  the  same  location  (i.  e.  close  to  the  promoter),  meaning  that  one  PCR  primer  set  can  be 
used  in  most  patients  (Baylin  et  al.,  2000),  avoiding  the  need  for  multiple  different 
analyses.  This  is  in  sharp  contrast  to  DNA  mutations  in  genes  such  as  p53  (Fliss  et  al., 
2000)  which  can  often  involve  numerous  base  alterations  at  a  multitude  of  positions  and 
therefore  are  not  easily  analysed  in  a  high  throughput  manner.  In  addition,  aberrant  CGI 
methylation  which  is  frequently  identified  in  tumours  is  not  observed  in  normal  tissues 
(Bird, 1986),  including  peripheral  blood  mononuclear  cells  (PBMCs)  and  these  can  be  used 
as  a  negative  control  in  comparison  to  tumour  DNA  in  plasma  samples  (Toyota  et  al., 
2001).  DNA  is  also  more  stable  than  mRNA  which  reduces  the  technical  problems  of 
handling  potentially  unstable  RNA  when  processing  tissue  and  blood  samples. 
The  potential  for  early  detection  methylation  biomarkers 
The  efficacy  of  screening  methods  in  ovarian  cancer  remain  unproven  (Rosenthal  et  al., 
2006)  and  to  date  there  has  been  no  cost-effective  screening  strategy  available  for  this Catriona  Hardie,  2007  140 
disease  (www.  figo.  org).  However,  a  reliable  screening  protocol  which  would  specifically 
identify  early  stage  lesions  could  improve  the  dismal  survival  rates  associated  with  this 
clinically  silent  disease  (Hickey  et  al.,  1999).  The  results  in  Chapter  5.1  have  identified 
CGI  methylation  as  a  promising  molecular  strategy  for  early  detection  of  ovarian  cancer 
that  may  be  independent  of  its  functional  implications.  There  have  been  many  groups  who 
have  identified  tumour-specific  hypermethylation  in  surrogate  body  fluids  matched  to 
several  early  stage  tumour  types.  These  include  methylation  changes  in  serum  from 
patients  with  breast  cancer  (Dulaimi  et  al.,  2004),  urine  from  patients  with  kidney  turnours 
(Cairns,  2004)  and  sputum  from  patients  with  lung  cancer  or  with  a  smoking-related  risk  of 
this  disease  (Belinsky  et  al.,  2006;  Wang  et  al.,  2006b).  However,  the  results  in  this  thesis 
are  one  of  the  first  descriptions  of  these  epigenetic  changes  in  matched  early  stage  ovarian 
tumours  and  plasma.  Only  one  previous  study  which  investigated  methylation  as  a  frequent 
early  event  in  ovarian  turnours  and  matched  serum,  plasma  and  peritoneal  fluid  could  be 
identified  (Ibanez  de  Caceres  et  al.,  2004).  Frequent  CGI  methylation  of  5D4  (LMXIA), 
OPCML,  RASSFIA  and  HICI  were  observed  in  early  stage  epithelial  ovarian  tumours 
(75%,  53%,  3  1%  and  22%  respectively)  as  shown  in  Chapters  3  and  4.87.5%  of  the  early 
stage  tumours  examined  were  methylated  in  at  least  one  of  these  genes.  These  methylated 
loci  were  then  further  investigated  in  matched  plasma  and  tumour  from  patients 
undergoing  cytoreductive  surgery  for  EOC.  In  this  initial  feasibility  study,  methylation  of 
at  least  one  of  these  four  genes  (5D4,  OPCML,  RASSFIA  or  HICI)  was  observed  in  16/30 
of  the  plasma  samples,  giving  a  sensitivity  of  53.3%.  When  methylation  was  detected  in 
plasma,  it  was  always  detectable  in  the  corresponding  tumour,  representing  a  specificity  of 
100%.  This  suggests  a  mechanism  by  which  tumour  DNA  is  either  directly  shed  into  the 
circulation  or  may  be  due  to  DNA  released  following  apoptosis  in  neoplastic  cells 
(Sidransky,  2002),  either  of  which  would  then  lead  to  the  identical  methylation  changes 
seen.  Hypermethylation  of  any  gene  may  not  have  been  detected  in  46.6%  (14/30)  plasma 
samples  due  to  low  levels  of  neoplastic  DNA  in  some  patients  which  are  not  detectable  by 
Fluorescent-MSP  as  described  in  previous  work  (Ibanez  de  Caceres  et  al.,  2004). 
Additionally,  previous  work  in  ovarian  cancer  has  shown  that  there  is  only  a  73% 
concordance  between  turnour  and  plasma  methylation  (Hickey  et  al.,  1999).  Heterogeneity 
is  seen  both  in  individual  ovarian  tumours  and  between  samples,  meaning  that  CGI 
hypermethylation  will  vary  in  tumours  (Rathi  et  al.,  2002;  Strathdee  et  al.,  200  1),  as  shown 
above.  Future  studies  will  require  analysis  of  a  panel  of  markers  which  could  include  5D4, 
OPCML,  RASSFIA  and  HICL  This  will  inevitably  lead  to  marker  redundancy,  but  will 
increase  diagnostic  coverage  and  the  sensitivity  of  a  screening  test.  The  sensitivity  will 
require  to  reach  at  least  75%  in  order  to  achieve  a  positive  predictive  value  of  10%  (Bast Catriona  Hardie,  2007  141 
2003).  The  specificity  of  this  study  is  100%  since  methylation  in  plasma  was  only 
observed  when  methylation  could  be  detected  in  the  matched  tumour,  which  is  in  keeping 
with  requirements  for  the  specificity  of  such  a  test  to  be  at  least  99.6%  (Jacobs  and  Menon, 
2004).  In  addition,  the  specificity  of  diagnosis  will  also  benefit  from  screening  a  larger 
number  of  methylation  markers,  such  as  one  of  those  described  by  Ibanez  de  Caceres  et  aL 
(R,  4SSFIA,  BRCAI,  APC,  pMAu,  p16N"'  or  DAPK)  and  this  will  potentially  reduce  the 
probability  of  detecting  false  positives.  Although  this  thesis  did  not  identify  many  of  these 
genes  as  being  hypermethylated  in  ovarian  cancer,  tumour  heterogeneity  may  mean  that 
methylation  of  these  markers  will  occur  in  larger  sample  sets  examined.  However,  from  the 
results  of  this  feasibility  study  in  the  plasma  sample  collection,  if  this  can  be  confirmed  in 
larger  groups  of  patients,  these  methylated  markers  may  have  potential  as  a  foundation  for 
a  larger  set  of  early  diagnostic  epigenetic  markers  in  EOC. 
In  an  attempt  to  identify  relevant  early  detection  biomarkers,  it  is  important  to  firstly 
understand  the  epigenetic  mechanisms  which  may  be  implicated  in  the  initiation  event(s) 
responsible  for  development  of  an  ovarian  neoplasm.  Currently,  it  would  suffice  to  say  that 
we  know  more  details  about  the  maintenance  of  methylation  in  tumour  suppressor  genes 
rather  than  the  initiating  events  themselves.  There  have  been  some  recent  studies 
examining  the  role  of  methylation  in  the  potential  malignant  transformation  of  benign  and 
low  malignant  potential  ovarian  tumours  to  invasive  cancers  (Makarla  et  al.,  2005;  Wiley 
et  al.,  2006).  In  addition,  other  groups  have  suggested  that  epigenetic  events  most 
frequently  occur  during  the  earliest  stages  of  neoplasia,  including  the  development  of 
precancerous  lesions  (Feinberg  and  Tycko,  2004;  Yamada  et  al.,  2005).  In  addition  to 
tumour  suppressor  genes  being  epigenetically  inactivated  in  the  initiation  events  of  a 
cancer,  there  may  also  be  an  epigenetic  "switch"  in  gene-imprinting  status  which  could 
contribute  to  the  early  stages  of  many  turnours,  which  has  been  suggested  for  colorectal 
cancer  (Cui  et  al.,  2003;  Holm  et  al.,  2005;  Sakatani  et  al.,  2005).  Recent  promising  work 
has  shown  the  use  of  cultured  mouse  ovarian  surface  epithelium  in  identifying  sequential 
molecular  changes,  including  the  epigenetic  silencing  of  tumour  suppressor  genes,  during 
the  development  of  ovarian  cancer  from  an  initial  premalignant  model  (Roberts  et  al., 
2005).  Using  this  novel  model,  it  may  be  possible  to  identify  other  epigenetic  events,  in 
addition  to  the  potential  markers  described  in  this  thesis,  which  can  initiate  an  EOC  and  be 
used,  in  the  long  term,  as  early  diagnostic  markers  of  this  disease.  In  addition,  there  may 
be  specific  events  which  can  be  seen  in  the  adjacent  normal  tissue  which  then  put  a  patient 
"at  risk7'  of  developing  an  overt  tumour.  Certainly,  results  described  in  Chapter  3  for  non- 
tumour  adjacent  tissue  showed  that  methylation  of  specific  genes  (HIC1,  DCRI,  APAF-1, 
OPCAff,  and  RASSFIA)  were  seen  in  these  samples,  and  in  some  cases  this  was  a  frequent Catriona  Hardie,  2007  142 
event.  Perhaps  cancer  progresses  in  a  step-wise  fashion  as  epigenetic  and  genetic  control  of 
homeostasis  is  lost  as  described  for  HICI  (Chen  et  al.,  2005a).  Interestingly,  methylation 
of  HICI  in  non-tumour  adjacent  tissue  was  frequently  seen  in  Chapter  3  and  may  represent 
a  very  early  event  in  ovarian  carcinogenesis.  This  type  of  homeostatic  loss  of  control  could 
lead  to  the  disease  progressing  through  phases  including  metaplasia,  dysplasia,  early  stage 
and  metastatic  disease.  If  this  is  an  early  event,  it  is  curious  that  this  epigenetic  event  was 
not  detected  in  the  plasma  DNA  of  ovarian  cancer  patients.  It  may  be  that  increasing  the 
number  of  samples  analysed  will  show  methylation  of  this  gene  in  some  patients.  Overall, 
understanding  the  molecular  components  which  initiate  epigenetic  change  and  gene 
silencing  could  provide  the  much  needed  answers  as  to  what  markers  may  be  important  for 
risk  assessment  and  early  detection  in  many  cancers,  including  ovarian.  This  concept  will 
be  discussed  further  in  Chapter  6  examining  future  outlooks  which  may  lead  on  from  this 
project. 
The  use  of  predictive  biomarkers 
Predictive  biomarkers  can  potentially  predict  a  response  to  a  specific  chemotherapy  and 
therefore  provide  information  that  will  lead  to  a  decision  regarding  treatment.  Ultimately, 
these  markers  have  the  potential  to  translate  into  individualised  treatment  options  for 
patients.  Having  investigated  the  CGI  methylation  of  genes,  the  results  obtained  were 
assessed  with  statistical  methods  to  interpret  if  this  biological  process  was  linked  with  the 
clinical  outcome  of  ovarian  cancer  patients.  Recently,  large  genome-wide  studies  have 
focussed  on  ovarian  cancer  and  have  shown  that  methylation  of  groups  of  CGIs  could 
provide  important  predictive  or  prognostic  signatures  in  assessing  and  managing  cancer 
(Wei  et  al.,  2006;  Wei  et  al.,  2002).  In  addition,  it  has  also  been  suggested  that  the  CIMP 
may  have  associations  with  clinical  outcome  in  cancers  including  neuroblastoma  (Abe  et 
al.,  2005;  Abe  et  al.,  2006)  and  colorectal  cancer  (Van  Rijnsoever  et  al.,  2003),  although 
there  have  yet  to  be  any  studies  such  as  these  which  suggest  a  link  of  the  CIMP  with 
outcome  in  ovarian  cancer. 
The  predictive  potential  of  the  candidate  CGI  methylation  data  in  106  late  stage  turnours 
from  the  retrospective  study  (Chapter  3)  were  first  examined  statistically.  Genes  were 
grouped  according  to  biological  function  although  categorising  the  genes  in  this  way  is 
admittedly  oversimplifying  the  biological  process  involved  here.  Methylation  of  at  least 
one  gene  involved  in  DNA  repair  or  drug  detoxification  (BRCA  I,  GSTPI  or  MGAfl)  was 
associated  with  improved  response  to  chemotherapy  (p=0.013).  These  genes  have 
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types.  MGMT  (06  -methylguanine-  DNA  methyltransferase)  is  a  DNA  repair  enzyme 
which  removes  methyl  groups  as  well  as  larger  adducts  from  the  06  position  of  guanine. 
The  alkylation  of  DNA  at  the  06  position  of  guanine  is  associated  with  the  formation  of 
mutations  in  DNA  (Gerson,  2004).  Methylation  of  MGMT  has  been  reported  in  a  variety  of 
cancers  including  granulosa  cell  turnours  of  ovarian  origin,  head  and  neck  carcinoma  and 
colorectal  cancer  (Dhillon  et  al.,  2004b;  Esteller  et  al.,  1999a;  Esteller  et  al.,  2000d). 
MGW  activity  has  been  shown  to  be  a  major  mechanism  causing  resistance  to  alkylating 
agents  by  rapid  reversal  of  adducts  formed  at  the  06  position  of  guanine  by  such 
chemotherapeutics  (Esteller  and  Herman,  2004).  In  concordance  with  the  results  above, 
methylation  of  a  CGI  in  the  MGMT  promoter  has  been  shown  to  be  an  independent 
predictive  marker  of  longer  survival  for  glioblastoma  patients  treated  with  temozolomide 
(Hegi  et  al.,  2004)  and  hypermethylation  of  the  MGMT  promoter  also  correlated  with 
increased  survival  of  patients  with  diffuse  large  B-cell  lymphoma  after  chemotherapy 
(Esteller  et  al.,  2002).  The  Glutathione-S-Transferases  (GST)  are  a  family  of  metabolic 
enzymes  which  detoxify  potentially  carcinogenic  agents  by  catalysing  the  conjugation  of 
glutathione  to  a  variety  of  electrophilic  intermediates.  This  prevents  the  accumulation  of 
compounds  that  can  lead  to  damaged  DNA  (Hayes  and  Strange,  2000).  GSTs  might 
detoxify  chemotherapeutic  drugs  within  cancer  cells  which  would  contribute  to 
chemoresistance,  and  this  is  well  established  in  cell  culture  models  (Perquin  et  al.,  2001). 
Tberefore,  silencing  of  GSTPI  could  increase  sensitivity  to  chemotherapy.  GSTPI  is  the 
most  frequently  methylated  gene  in  prostate  cancer  (Perry  et  al.,  2006),  although  to  date, 
there  have  still  been  no  studies  examining  CGI  methylation  of  GSTPI  and  clinical 
chemosensitivity.  BRCA1  aids  in  the  maintenance  of  genomic  integrity  and  participates  in 
double  strand  break  repair  by  homologous  recombination  (Tutt  and  Ashworth,  2002). 
Several  in  vitro  studies  show  that  the  integrity  of  the  BRCA1  pathway  is  important  for 
turnour  response  to  chemotherapy.  It  has  been  shown  that  BRCAI  deficiency  is  linked  to 
sensitivity  to  cisplatin  and  other  DNA  damaging  agents  (Sgagias  et  al.,  2004;  Tassone  et 
al.,  2003),  although  the  need  for  further  clinical  studies  of  BRCA1  and  response  to 
chemotherapy  has  recently  been  highlighted  (Kennedy  et  al.,  2004).  It  has  been  reported 
that  promoter  hypermethylation  of  BRCAI  is  a  frequent  event  in  sporadic  ovarian  tumours 
(Esteller  et  al.,  2000b;  Ibanez  de  Caceres  et  al.,  2004)  and  mechanistically,  methylation  of 
BRCAI  could  inhibit  cells  from  repairing  the  damage  caused  by  chemotherapeutic  agents 
leading  to  an  apoptotic  response  in  these  damaged  cells. 
As  shown,  multiple  biological  pathways  are  affected  by  methylation  in  individual  patients 
and  this  will  lead  to  complex  patterns  in  patients  with  the  same  phenotype.  However,  some 
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which  methylation  events  were  important  and  influenced  the  biological  phenotype,  a  larger 
homogeneous  study  was  required.  The  results  above  were  taken  from  a  retrospective  study 
which  was  excellent  for  the  hypothesis-generating  observations  above  but  tumours  varied 
in  histological  type  and  had  been  exposed  to  various  chemotherapies.  Therefore,  the 
validation  of  these  results  was  examined  in  an  independent  set  of  epithelial  ovarian  tumour 
samples  from  a  more  defined  patient  population  in  the  prospective  "DNA  Methlyation 
Study",  funded  through  the  Scottish  Gynaecological  Cancer  Trials  Group.  The  validation 
result  for  the  potential  predictive  markers  BRCAIIGSTPIIMGMT  was  not  statistically 
significant.  However,  there  was  a  trend  in  keeping  with  the  previous  results.  One  reason 
why  these  results  may  not  have  been  significant  was  because  the  validation  set  was 
significantly  underpowered  and  there  had  not  been  enough  time  for  a  number  of  clinical 
events  to  occur.  To  address  this  question,  the  study  will  require  further  analysis  at  a  later 
date  after  allowing  more  events  to  accumulate  for  analysis. 
Ultimately,  the  results  described  within  this  subchapter  suggest  that  methylation  profiling 
may  be  useful  to  identify  individual  patients  who  may  benefit  from  specific  current 
therapies  to  improve  clinical  outcome.  Also  though,  and  perhaps  more  importantly,  these 
types  of  studies  may  identify  those  patients  who  are  eligible  to  enter  clinical  trials 
investigating  novel  epigenetic  therapies  depending  on  their  methylation  profile. 
The  potential  to  identify  markers  of  relapsed  disease 
Biomarkers  which  identify  patients  with  chemoresistant  tumours  have  the  potential  to 
significantly  contribute  to  the  optimisation  of  second-line  chemotherapies  in  the  treatment 
of  ovarian  cancer.  Identification  of  these  markers  remains  the  elusive  goal  in  successfully 
identifying  and  treating  the  patient  with  relapsed  disease.  Ultimately,  this  may  lead  to  the 
ability  to  recognise  patients  who  can  undergo  reversal  of  chemoresistance  with  novel 
epigenetic  therapies  (Lyko  and  Brown,  2005).  Methylation  of  the  novel  markers,  119A6 
and  5D4,  were  shown  to  be  selected  for  during  platinum-based  chemotherapy  in  Chapter  4. 
Despite  this  selection  during  chemotherapy,  methylation  of  119A6  or  5D4  in  chemonalfve 
ovarian  tumours  taken  at  presentation  was  not  shown  to  be  associated  with  response  to 
chemotherapy,  progression  free  survival  or  overall  survival.  Again,  a  lack  of  a  significant 
association  between  methylation  patterns  and  clinical  outcome  is  not  evidence  for  its 
absence  here.  There  may  not  have  been  adequate  statistical  power  here  to  detect  small 
effects  or  the  examination  of  these  two  novel  loci  in  isolation  may  not  be  sufficiently 
sensitive.  Indeed,  an  increase  in  sensitivity  may  be  achieved  by  measuring  these  markers  as 
part  of  a  larger  methylation  profile  (Glasspool  et  al.,  2006).  The  lack  of  statistical  findings Catriona  Hardie,  2007  145 
may  have  been  due  to  the  fact  that  the  samples  examined  were  heterogeneous  chemonaive 
tumours,  and  to  understand  the  biology  of  chemoresistance,  ovarian  tumours/plasma 
samples  from  the  relapsed  patient  may  be  required  for  this  type  of  analysis.  These  types  of 
relapse  samples  have  previously  been  the  focus  of  a  study  which  successfully  identified 
that  acquired  methylation  of  the  DNA  mismatch  repair  gene,  hMLHI,  is  associated  with 
patient  survival,  rather  than  the  methylation  status  at  presentation  (Gifford  et  al.,  2004). 
Potentially,  one  could  hypothesis  that  a  combination  of  hMLHI,  5D4  and  119A6  may  be  a 
useful  set  of  methylation  markers  for  acquired  chemoresistance  but  this  will  need  further 
assessment  with  appropriate  samples. Catriona  Hardie,  2007 
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6  Summary  and  future  outlook  of  this  project 
6.1  Summary  of  findings 
This  project  aimed  to  identify  novel  methylation  patterns  associated  with  early  disease 
detection,  prediction  of  disease  response  to  chemotherapeutics  and  chemoresistance 
markers  in  ovarian  cancer.  CGI  methylation  was  a  frequent  event  at  all  stages  of  EOC.  In 
early  stage  chemonaive  turnours,  a  set  of  3  candidate  loci  (CGIs  linked  to  the  OPCML, 
RASSFIA  and  HICI  genes)  were  methylated  for  at  least  one  locus  in  64%  of  turnours. 
Further  results  revealed  that  methylation  of  5D4,  mapping  to  the  novel  gene  LAMA,  was  a 
potential  novel  epigenetic  marker  which  was  very  frequently  methylated  in  75%  of  early 
stage  ovarian  turnours.  In  combination,  87.5%  of  the  early  stage  tumours  examined  were 
methylated  in  at  least  one  of  these  4  loci.  The  clinical  application  of  this  was  investigated 
by  examining  matched  plasma  from  chemonaive  patients  with  ovarian  cancer  with  the  aim 
of  identifying  methylation  changes  in  a  relatively  non-invasive  blood  test.  Detection  of 
LMX1A  (5D4)  methylation  in  plasma  was  found  to  have  a  sensitivity  of  48.2%  and  a 
specificity  of  100%.  The  sensitivity  may  increase  by  examining  a  larger  panel  of  markers. 
In  late  stage  chemonaive  ovarian  tumours,  the  MSP  data  was  examined  to  identify  if 
methylation  of  groups  of  markers  could  be  correlated  with  response  to  chemotherapy. 
Methylation  of  CGIs  associated  with  either  BRCA  I,  GSTPI  or  MGMT,  which  are  involved 
in  DNA  repair  and  drug  detoxification,  were  correlated  with  an  improved  response  to 
chemotherapy  (p=0.013).  The  validation  of  these  results  has  not  been  completed  due  to  the 
immaturity  of  clinical  response  data  but  it  will  be  important  to  assess  if  these  relationships 
can  be  validated  in  an  independent  set  of  ovarian  tumours.  Also,  in  this  group  of  late  stage 
turnours,  a  non-random  pattern  of  DNA  was  seen.  This  demonstrated  that  there  is  an 
underlying  biological  mechanism  which  leads  to  co-methylation  of  specific  genes  but  the 
cause  of  this  remains  unidentified. 
Two  novel  sequences  (5D4  and  119A6)  were  identified  in  a  genome-wide  CGI  screen 
whose  methylation  status  can  discriminate  cisplatin  sensitive  and  resistance  cell  lines,  and 
who  are  also  abberantly  methylated  in  ovarian  turnours.  These  novel  loci  may  represent 
newly  discovered  epigenetic  biomarkers  in  ovarian  cancer  which  are  selected  for  during 
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6.2  The  challenge  of  identifying  early  epigenetic  markers 
The  evidence  has  shown  that  ovarian  cancer  is  only  curable  if  detected  at  an  early  stage. 
The  results  in  this  thesis  have  indicated  that  epigenetic  methylation  events  are  ubiquitous 
in  early  stage  ovarian  neoplasia  and  can  also  be  detected  in  matched  non-tumour  adjacent 
tissue.  A  promising  novel  marker,  5D4,  has  been  described  which  has  one  of  the  highest 
reported  methylation  frequencies  in  ovarian  cancer  and  potential  in  early  diagnosis.  Future 
research  should  be  targeted  at  detecting  which  additional  epigenetic  events  are  potential 
initiating  factors  in  premalignant  and  early  stage  cancers.  If  methylation  abnormalities 
arise  early  in  normal  tissues,  then  comparison  between  histologically  normal  ovarian 
surface  epithelium  from  early  stage  cancer  patients  and  healthy  controls  may  identify 
methylated  markers  which  are  useful  in  assessing  risk,  and  ultimately  developing  a 
screening  test.  A  single  tumour  may  contain  important  histological  components  which 
could  be  involved  in  carcinogenesis  and  should  be  examined  including  inclusion  cysts, 
cortical  invaginations  of  the  surface  epithelium  and  stromal  abnormalities  (Cvetkovic, 
2003).  These  possible  precursor  lesions  may  create  a  turnour-promoting  microenvironment 
and  it  would  be  interesting  to  examine  the  role  of  epigenetic  change  in  these  lesions. 
Potential  issues  will  include  the  difficulty  which  histopathologists  have  in  identifying  these 
precursor  lesions,  the  fact  that  normal  ovaries  are  rarely  removed  due  to  the  current  climate 
of  more  non-invasive  treatment  modalities  and  the  rarity  of  identifying  an  early  stage 
ovarian  turnour  itself.  Examination  of  adjacent  tissues  next  to  a  matched  early  stage  tumour 
provide  some  much  needed  answers  regarding  the  epigenetic  events  which  initiate  an 
ovarian  neoplasm  such  as  those  described  here.  Comparison  between  tumour  and 
equivalent  histologically  "normal"  non-tumour  tissue  from  the  same  patient  may  be 
possible  using  technologies  such  as  DMH  to  detect  differences.  Alternatively,  the  use  of 
the  mouse  ovarian  surface  epithelium  (Roberts  et  al.,  2005)  may  provide  an  excellent 
model  to  identify  early  epigenetic  events. 
Identification  of  a  panel  of  early  epigenetic  markers,  including  methylation  of  5D4, 
OPCML,  RASSFIA  and  HICI  could  alert  the  clinician  that  the  patient  is  at  risk  of  ovarian 
cancer  and  lead  to  the  implementation  of  appropriate  treatment  at  an  earlier  stage.  What 
will  be  the  appropriate  treatment  though  and  when  will  it  be  best  implemented? 
Admittedly,  the  difficulty  will  be  when  epigenetic  changes  are  identified  but  existing 
technologies  used,  such  as  CT  scanning,  classify  the  patient  as  "disease  free".  The  role  of 
methylation,  and  examining  if  it  has  a  higher  sensitivity  than  existing  methods,  will  only  be 
determined  in  longitudinal  studies  in  which  patients  are  followed  up  to  see  if  they  do Catriona  Hardie,  2007  149 
indeed  develop  a  recognised  malignancy.  This  could  potentially  involve  patients  being 
recruited  to  trials  and  followed  up  for  many  years  which  may  be  technically  unfeasible.  It 
could  be  that  ultimately  treatment  of  "at  risk7'  lesions  which  show  identical  epigenetic 
changes  to  an  occult  neoplasm  should  receive  similar  management.  This  could  then 
potentially  impact  on  improving  survival  from  this  disease.  The  caveat,  though,  is  that 
there  is  a  recognised  high  morbidity  associated  with  complex  pelvic  surgery  and  the  use  of 
this  procedure  in  women  with  "at  risk"  lesions  rather  than  definitive  cancers  may  lead  to 
surgical-related  complications  in  women,  some  of  whom  may  have  false-positive  screening 
results  (Jacobs  and  Menon,  2004).  This  may  then  reduce  the  benefits  of  early  detection  and 
treatment  in  women  with  true-positive  results. 
Earlier  results  in  this  thesis  have  shown  that  the  use  of  a  non-invasive  blood  test  will  be  an 
important  tool  in  future  studies  examining  methylation  as  an  early  diagnostic  marker  in 
ovarian  cancer.  It  should  be  noted  that  this  is  a  very  early  study  but  the  sensitivity  achieved 
is  encouraging  for  future  larger  screening  studies.  There  are,  however,  some  potential 
considerations  when  applying  this  type  of  test  to  early  stage  ovarian  neoplasia.  It  has 
previously  been  thought  that  the  early  detection  of  lung  cancer  may  be  hindered  by  the  fact 
that  DNA  from  early  stage  lesions  may  not  be  efficiently  released  into  the  plasma  due  to 
reduced  vascularisation  of  this  stage  of  lung  turnour  (Belinsky,  2004).  The  same  may  be 
said  for  premalignant/early  stage  changes  in  the  ovary  which  would  then  reduce  the 
sensitivity  of  a  blood  test  considerably.  However,  encouragingly,  other  groups  have  shown 
that  a  detectable  amount  of  DNA  from  stage  Ia  ovarian  cancer  (ie  confined  to  one  ovary)  is 
released  into  the  bloodstream  (Hickey  et  al.,  1999).  There  are  also  issues  with  the 
specificity  of  such  a  test.  Can  we  be  sure  of  an  ovarian  origin  for  specific  methylation 
changes  seen  in  plasma?  Again,  one  could  hypothesis  that  a  larger  panel  of  markers  may 
increase  the  specificity  of  the  test  but  this  would  have  to  be  specific  for  ovarian  cancer  if 
used  for  diagnosis. 
The  identification  of  methylation  in  bodily  fluids  also  has  implications,  not  only  in 
detection  of  disease  at  an  early  stage,  but  also  in  how  an  ovarian  neoplasm  is  staged.  It  has 
previously  been  proposed  that  DNA  is  released  directly  into  the  plasma  from  early  stage  Ia 
ovarian  tumours  (Hickey  et  al.,  1999).  However,  another  pathway  may  be  that  DNA  from 
tumour  cells  shed  into  the  peritoneal  cavity  could  enter  the  bloodstream  through  the 
lymphatics  (Hickey  et  al.,  1999).  Hickey  et  al  have  suggested  that  there  is  potential  to 
"molecularly  upstage"  an  ovarian  cancer  if  turnour  DNA  was  detected  in  peritoneal  fluid. 
This  is  an  interesting  point  if  we  consider  our  methylation  analysis  results.  Currently, 
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histopathological  diagnosis  of  an  ovarian  tumour  to  accurately  stage  a  tumour  using  FIGO 
(International  Federation  of  Gynaecology  and  Obstetrics)  criteria.  Currently,  and  still  under 
debate  by  some  groups,  adjuvant  platinum  based  chemotherapy  is  used  in  patients  with  ?: 
Stage  Ic  disease  or  in  those  with  high  grade  earlier  stage  turnours  (Trimbos  et  al.,  2003). 
Potentially  though,  if  ovarian  cancer  was  molecularly  upstaged  by  detection  of  methylation 
in  peritoneal  fluid,  this  would  perhaps  not  only  increase  the  use  of  adjuvant  therapy  in 
early  stage  disease,  but  also  introduce  the  use  of  novel  epigenetic  therapies  to  target  these 
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6.3  Translating  identified  epigenetic  markers  into  routine 
clinical  use 
This  thesis  has  shown  that  epigenetic  biomarkers  can  be  used  to  stratify  both  current 
chernotherapeutics  and  potentially  novel  epigenetic  therapies  to  individual  patients 
depending  on  their  methylation  status.  The  major  challenge  still  remains  though  that  well- 
designed  prospective  clinical  trials  are  required  to  obtain  samples  at  crucial  stages  of 
treatment  and  relapse.  These  trials  need  to  be  carefully  designed  with  well-defined 
objectives  and  clinical  endpoints.  There  is  a  need  for  new  objective  measures  of  clinical 
outcome.  Studies  vary  in  their  use  of  endpoints  and  how  they  define  these.  To  explain, 
survival  encompasses  other  factors  which  may  influence  the  direct  survival  of  the  patient. 
PFS  and  OS  do  not  explain  the  underlying  biological  mechanism  of  cell  death  following 
chemotherapy.  The  endpoint  of  response  is  used  with  the  aim  of  encompassing  information 
on  chemoresistance  but  is  not  quantitative.  New  quantitative  and  objective  measures  of 
response  to  chemotherapy  may  help  uncover  new  biologically  relevant  markers. 
Identification  of  these  markers  will  require  genome-wide  analysis,  such  as  the  microarray 
experiment  described  in  Chapter  4,  to  obtain  complex  data  concerning  the  ovarian  cancer 
epigenome.  The  difficulties  and  complexities  in  statistically  analysing  the  tremendous 
amount  of  data  obtained  from  these  types  of  experiments  will  also  have  to  be  addressed. 
Validation  of  the  hypothesis-generating  studies  described  will  be  required  and  this  thesis 
has  illustrated  that  this  can  only  occur  after  a  sufficient  number  of  events  have  been 
allowed  to  accumulate.  It  is  worth  noting  that  the  vast  majority  of  published  biomarker 
studies  to  date  have  not  been  validated  and  this  will  be  a  crucial  component  in  the  future. 
Tumour  biopsies  from  relapsed  patients  with  ovarian  cancer  are  rarely  used  in  studies  due 
to  the  difficulties  in  procuring  such  samples.  However,  in  order  to  test  the  hypothesis,  that 
methylation  of  5D4  and  119A6  are  selected  for  during  chemotherapy  and  are  markers  of 
relapse  in  ovarian  cancer,  these  are  the  types  of  samples  will  be  necessary  for  analysis.  If  it 
is  true  that  chemotherapy  positively  selects  for  resistant  subpopulations  of  cells  (Agarwal 
and  Kaye,  2003),  methylation  analysis  of  tumour  biopsies  at  relapse  may  shed  some  light 
on  the  methylation  status  of  these  subpopulations  and  their  potential  role  in  acquired 
resistance.  Acquired  methylation  will  be  magnified  in  post-chemotherapy  samples  due  to 
selective  pressure.  To  avoid  the  problems  of  inter-patient  heterogeneity,  matched  samples 
pre-  and  post-chemotherapy  will  need  to  be  examined  and  correlated.  One  of  the  problems 
in  acquiring  these  samples  lies  in  the  fact  that  secondary  cytoreductive  surgery  is  rarely 
performed  in  the  relapsed  patient  and  its  use  remains  controversial  (Benedetti  Panici  et  al., Catriona  Hardie,  2007  152 
2007).  To  date,  there  has  been  no  randomised  trial  comparing  secondary  cytoreductive 
surgery  with  second-line  chemotherapy  in  relapsed  ovarian  cancer  and  therefore  these 
samples  are  not  readily  available  as  patients  most  commonly  undergo  treatments  with  a 
secondary  cytotoxic  agent.  Admittedly,  surgery  for  recurrent  disease  is  technically 
challenging  with  associated  risks  of  organ  damage  such  as  bowel  or  bladder,  and  therefore 
it  remains  ethically  unconsiderable  to  perform  a  second  laparotomy  in  order  to  obtain 
biopsied  tumour  from  this  type  of  patient.  An  alternative  consideration  may  be  biopsy  of 
relapsed  tumour  via  laparoscopy,  however,  this  will  require  careful  ethical  consideration  in 
setting  up  a  clinical  trial  and  appropriate  patient  consent  explaining  the  risks  of  the 
procedure.  Otherwise,  the  collection  of  plasma  at  relapse  and/or  ascitic  fluid  remains  the 
most  likely  source  of  this  type  of  material  following  chemotherapy.  The  less  invasive 
techniques  involved  would  most  likely  increase  the  number  of  patients  consenting  to  trials 
and  could  also  allow  investigation  of  selective  mechanisms  controlling  methylation  at 
different  timepoints  during  treatment.  The  caveat  is  that  the  concentration  of  DNA  in  these 
samples  may  be  low  therefore  reducing  the  sensitivity  of  the  test.  However,  if  a  greater 
number  of  patients  are  consented  to  this  more  non-invasive  sampling  method,  the  power  of 
the  test  may  increase. 
The  functionality  of  the  novel  genes  relating  to  chemoresistance  described  in  Chapter  4, 
LAMA  (5D4)  and  NR2E1  (119A6),  and  their  potential  roles  in  ovarian  turnourigenesis 
will  require  further  investigation.  In  addition  to  examining  the  mRNA  expression  levels  of 
LAMIA  and  NR2E1  shown,  it  will  be  important  to  attempt  to  correlate  these  results  with 
protein  expression  levels  in  the  cisplatin-sensitive  and  cisplatin-resistant  cell  lines.  This 
will  involve  the  use  of  Western  Blotting  and  Immunohistochernistry  techniques.  Potential 
functional  studies  could  involve  the  overexpression  and  knockdown  of  these  genes  in  vitro 
to  allow  determination  of  their  effects  on  colony  formation  (LMXIA)  and  drug  sensitivity 
(LAMA  and  NR2E]).  Additionally,  it  was  hypothesised  in  the  discussion  section  of 
Chapter  4  that  methylation-related  transcriptional  repression  of  NR2E1  may  influence 
chemoresistance  mechanisms  by  increasing  the  expression  of  the  transcription  factor, 
PAX2,  in  turnours.  It  would  be  intriguing  to  examine  the  expression  of  PAX2  using  RT- 
PCR  in  both  chemoresistant  cells  which  show  methylation  of  NR2E1,  and  in  relapsed 
tumours  following  chemotherapy.  Increased  expression  of  PAX2  should  reduce  cisplatin- 
induced  apoptosis  and  lead  to  chemoresistance.  The  Wnt  signalling  pathway  and  its 
involvement  in  the  pathogenesis  of  ovarian  cancer  remains  unclear,  but  methylation  of 
LAMA  and  NR2E1  could  potentially  affect  this  pathway  in  cancer.  It  would  be  interesting 
to  look  at  this  pathway  in  ovarian  tumours  using  a  candidate  gene  approach  to  determine 
the  influence  which  methylation  may  have  on  associated  Wnt-signalling  genes.  Both  of Catriona  Hardie,  2007  153 
these  novel  markers  are  involved  in  stem  cell  maintenance  and  differentiation  and  a 
potential  link  between  epigenetic  changes  of  these  genes  in  stem  cell  compartments  could 
be  investigated  using  tissue  microarray-based  approaches  (TMAs).  Are  these  eventual 
markers  of  chemoresistance  methylated  in  stem  cells  and  then  selected  for  during 
chemotherapy?  Finally,  it  could  be  considered  if  selection  of  methylation  of  these  novel 
markers  has  a  role  to  play  in  the  chemoresistant  phenotype  of  other  turnours. 
The  hypothesis-generating  results  obtained  from  the  work  described  in  this  thesis  do 
require  further  validation,  but  the  identification  of  these  predictive  and  chemoresistance 
markers  may  influence  future  translational  studies.  Potentially,  these  results  could  lead  to 
the  rational  use  of  epigenetic  therapies,  such  as  those  described  in  Chapter  1,  which  will 
improve  sensitivity  to  current  chernotherapeutics  and  improve  the  dismal  survival  rates 
associated  with  this  disease.  Well-designed  large  prospective  trials  are  still  required  though 
to  identify  those  key  genes  silenced  by  epigenetic  mechanisms  among  the  multiple 
potential  candidates  that  can  help  a  clinician  make  real-time  treatment  decisions  in  respect 
to  a  particular  regimen  depending  on  a  patient's  epigenetic  profile. 154 
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